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Summary
Sum m ary
1. Peptide hormones, once available only through extraction from animal tissue, are 
now increasingly manufactured synthetically. However, the route of administration 
is usually by injection due to the low oral bioavailability of the hormones, as a 
consequence of proteolytic degradation in the small intestine, poor penetration of 
the intestinal mucosa, and clearance from the portal vein by the hepatocytes of the 
liver.
2. Since bile acids are efficiently absorbed by an active carrier system in the ileum, the 
present study investigated the degree to which transport of ileally-administered 
tetragastrin, a peptide composed of four amino acid residues, could be enhanced by 
coupling with cholic acid. Conjugation with cholic acid was at the position where
- glycine and taurine attach naturally in the formation of conjugated bile salts.
3. In the fasted anaesthetised rat, gastric acid secretion was measured at 15 min 
intervals as a bioassay for the levels of tetragastrin in the blood stream. In all 
experiments, intravenous administration of tetragastrin or the tetragastrin-cholic 
acid conjugate (G-CA) was adopted as the first and final procedure, in order to 
demonstrate the continued viability of the animal preparation.
4. Intravenously administered tetragastrin (minimum effective dose, most commonly 
15pg kg'b as a first procedure was shown to evoke a mean peak increase in gastric 
acid levels of 0.50 ± 0.06pmol ISminb Over a period of one hour following 
injection, a mean cumulative increase in gastric acid output of 1.07 ± 0.39pmol hr"^  
was demonstrated (n=31). G-CA (15pg kg'^ also demonstrated biological activity 
when administered intravenously: a mean peak increase in gastric acid levels of 
0.50 ± O.lSpmol 15min"\ and a mean cumulative increase of 0.91 ± 0.47pmol hr'  ^
were obtained (n=32). In both cases, a broadly comparable increase in gastric acid 
secretion was also obtained in response to a second intravenous injection, 
indicating that the animal preparation was neither fatigued, nor that earlier 
procedures had resulted in potentiation of the response.
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Summary
5. Intra-intestinal administration of tetragastrin (2500|ig kg ^  was shown not to 
produce a measurable increase in gastric acid levels. By contrast, the present study 
demonstrated unequivocally that infusion of G-CA (600pg kg'b into the ileum 
resulted in the stimulation of increased levels of gastric HCl secretion (means of 
small samples were weighted to give a true mean increase of 1.84 ± 1.22pmol 
ISOmin'b-
6. Simultaneous infusion of tetragastrin and glycocholic acid (in a ratio of 3:2, total 
dose of 600p,g kg'^ into the ileum did not elicit any measurable increases in gastric 
acid secretion, despite the solution being biologically active, as confirmed by a 
measurable increase in gastric acid secretion following intravenous injection (1.09 
± 0.58pmol hr"% P=0.033; n=5).
7. Surprisingly, instillation of tetragastrin (2500pg kg'^ into the ileum did evoke a 
significantly marked increase in gastric acid secretion (3.05 ± 1.89pmol 180min'\ 
P=0.006; n=7), though only when tetragastrin was preceded by ileally-administered 
G-CA (600pg kg'b- This indicated that a possible lasting permeability change in 
the ileal mucosa was caused by ileal G-CA, thus permitting the permeation of the 
intestinal wall by tetragastrin. Nevertheless, the results of light microscopic 
analysis revealed little evidence of a pathological alteration to the intestinal 
mucosa.
8. The transmucosal movement of G-CA appeared to be specific to the ileum, as 
there was no evidence of transport across the jejunal mucosa following intra­
luminal instillation of G-CA (600|ig kg'^ Subsequent administration of G-CA 
(600pg kg'b in the ileum of the same rat produced a significant increase in gastric 
acid secretion.
9. The results of the present study are indicative of utilisation of the bile salt active 
transporter by G-CA. This is very encouraging in terms of a successfiil approach 
to address the facilitation of permeation of otherwise poorly absorbed 
oligopeptides across the intestinal mucosa and into the systemic circulation.
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Intro du c tio n
The self-evident drawback of drug delivery by injection reinforces the preference for 
the oral route for the administration of therapeutic drugs. However, oral delivery of 
various drugs, particularly peptides, very often results in a relatively poor 
bioavailability (the proportion of the intact biologically active compound that 
eventually reaches the systemic circulation from the site of administration), as a result 
of degradation by proteolytic enzymes both in the gastrointestinal lumen and during 
absorption through the intestinal epithelium, poor penetration of the intestinal mucosa 
and extensive first-pass metabolism by the liver (Doherty and Pang, 1997).
1.1 Overview of protein digestion and absorption
In order to understand the difficulties involved in achieving success in oral delivery of 
peptide drugs, it is important to provide a general review of protein digestion and 
absorption. A more detailed account can be found by referring to the chapters by 
Alpers (1994) and Ganapathy, Brandsch and Leibach (1994).
1.1.1 Pepsin
Protein digestion within the gastrointestinal tract begins in the stomach. Pepsin, the 
active protease, is thought to be secreted mainly by the chief cells in its inactive form, 
pepsinogen. The presence of hydrochloric acid converts pepsinogen to pepsin, and 
also provides an optimal pH of 1.5 to 3.5 for the activity of the enzyme. Pepsin then, 
by the process of autocatalysis, carries the conversion of pepsinogen to pepsin to 
completion (chapter by Bell, Emslie-Smith and Paterson, 1976). Proteins most 
susceptible to pepsin-catalysed hydrolysis are those that contain peptide bonds formed 
by amino acid residues (of L-configuration) containing aromatic side chains (Mahler 
and Cordes, 1969a). Pepsin is referred to as an endopeptidase since it hydrolyses 
peptide bonds in the interior of polypeptide chains (Mahler and Cordes, 1969a). The 
action of pepsin breaks proteins down into a mixture of peptides of vaiying chain 
lengths (referred to as peptones in older texts).
Introduction
1.1.2 Pancreatic proteases
The next stage of protein hydrolysis occurs in the duodenum and small intestine, and 
involves the pancreatic proteases, namely trypsin, a-chymotrypsin, elastase and 
carboxypeptidases A and B (Lee and Amidon, 1995). The actions of the pancreatic 
endopeptidases, trypsin, a-chymotrypsin and elastase are complementary in that they 
catalyse the hydrolysis of almost all of the internal peptide linkages likely to be 
encountered in proteins and peptides. Trypsin cleaves peptide bonds at basic amino 
acids such as lysine and arginine; a-chymotrypsin cleaves peptide bonds at 
hydrophobic amino acids such as leucine, methionine, phenylalanine, tryptophan and 
tyrosine; elastase acts on the peptide bonds of amino acid residues with smaller, 
unbranched, non-aromatic structures such as alanine, glycine, isoleucine, serine and 
valine. Carboxypeptidases are exopeptidases which act on substrates with a free 
terminal carboxyl group and a C-terminal amino acid of L-configuration (Lee, 1988). 
The summed actions of these enzymes results in the production of approximately 40% 
free amino acids and 60% peptides with two to six amino acids (Alpers, 1994), 
although the extent of luminal degradation of proteins and peptides is determined by 
both the size of the protein molecule and the amino acid composition of these 
compounds. Adibi and Morse (1977) demonstrated that, within the human jejunal 
lumen, di- and triglycines were not hydrolysed; however, tetra- to hexaglycines did 
undergo degradation. Further, Adibi (1971) also found that although di- and 
triglycines were not hydrolysed in the human small intestine, di- and trileucines were.
1.1.3 Brush border and intracellular peptidases
The most important peptide-hydrolysing agents appear to exist at the brush border 
membrane and within the cytosol of the enterocytes. Listings of the known brush 
border and intracellular peptidases, to date, may be found in a review by Alpers 
(1994), while, a simplified version is reproduced in Tables 1-la and 1-lb. There may 
also be further degradative activity as a result of pancreatic proteases such as trypsin 
and chymotrypsin, adsorbed from the luminal fluid on to the enterocyte brush border 
(Goldberg, Campbell and Roy, 1968; 1971). The brush border peptidases are capable 
of hydrolysing peptides of up to ten amino acid residues, but have a preference for 
tripeptides rather than dipeptides (Matthews and Payne, 1980).
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Table 1-la: Intestinal brush border peptidases
Enzyme Substrate
Neutral endopeptidase 
Aminopeptidase N 
Aminopeptidase A 
Aminopeptidase P 
Aminopeptidase W 
Dipeptidyl aminopeptidase IV 
Dipeptidyl carboxypeptidase (ACE) 
Carboxypeptidase M 
y-Glutamyl transpeptidase 
Carboxypeptidase P 
Folate conjugase 
Membrane Gly-Leu peptidase 
Zinc-stable Asp-Leu dipeptidase 
Membrane peptidase
Hydrophobic internal amino acids 
Oligopeptides C2-C6 with neutral AA-X- 
Oligopeptides C2-C6 with Asp/Glu-X- 
Oligopeptide with X-Pro- 
Oligopeptide with Glu-Trp- 
Oligopeptides with Pro-X- or Ala-X- 
Angiotensinogen or -X-Pro- 
Peptides with -X-Lys- or -X-Arg- 
Peptides with y-glutamyl bonds 
-X-Pro-
Polyglutamyl folates 
Dipeptides, especially Gly-Leu 
Dipeptides, especially Asp-Leu 
Dipeptides and glutathione conjugates
(AA, amino acids; -X-, next amino acid in sequence; ACE, angiotensin converting enzyme; Asp, 
aspartate; Gin, glutamate; Pro, proline; Trp, tryptophan; Ala, alanine; Lys, lysine; Leu, leucine)
Table 1-lb: Intestinal intracellular peptidases
Enzyme Substrate
Amino tripeptidase 
Amino dipeptidase 
Prodipeptidase 
Arg-selective endoproteinase
Tripeptides 
Dipeptides 
X-Pro dipeptides 
Presomatostatin -Arg-X-
(-X-, next amino acid in sequence; Pro, proline; Arg, arginine)
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1.2 Intestinal transport of amino acids and peptides
The intestinal epithelium has efficient transport mechanisms to absorb not only free 
amino acids from the gastrointestinal lumen, but also di- and tripeptides. Free amino 
acids are absorbed into the enterocyte across the brush border membrane via group- 
specific amino acid transport systems. Di- and tripeptides are transported intact 
across the brush border membrane via specific peptide transport systems (Newey and 
Smyth, 1960; Newey and Smyth, 1962). These peptides undergo rapid hydrolysis by 
cytosolic peptidases to produce free amino acids (see Table 1-lb). The egress of 
amino acids from the enterocyte is via amino acid transport systems, although a very 
small proportion of intact peptides may also enter the portal circulation (Ganapathy, 
Brandsch and Leibach, 1994).
It is worth mentioning at this point that the small intestine of the neonatal mammal 
dififers from the adult small intestine in its increased capacity to take up and transport 
proteins (Walker, 1979). This process appears to be initiated by the adsorption of 
large molecules, for example, immunoglobulins on to the microvillous membrane of 
enterocytes. Once in sufficient concentration, invagination of the membrane occurs 
and small vesicles within the cytoplasm are formed. After a period of time, when 
intestinal immunological and non-immunological host defences have developed, the 
rate of uptake of macromolecules diminishes. This is the process known as “closure”, 
and is the result of morphological and functional maturation of the small intestinal 
epithelial cells. In rats, closure occurs 20 days after birth. In man the process is more 
subtle, although it is now well established that the intake of human milk by the new­
born facilitates the maturation of the intestine, leading to “closure” (Walker, 1979).
It is clear, therefore, that in order to increase the bioavailability of orally administered 
peptide drugs, the enzymatic barrier must be by-passed in some way. Reducing 
proteolytic degradation may be achieved by a number of strategies, for example, by 
modification of the peptide structure, by use of protease inhibitors, or by using the 
formulation approach to protect the peptide against proteolytic attack. These ideas 
will be discussed later in more detail.
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1.3 Anatomical barriers to intact peptide absorption
The wall of the gastrointestinal tract acts as a physical barrier to the absorption of 
intact peptide drugs, and is a major factor to be taken into consideration if a method 
of oral administration is to be achieved.
The stomach is of little significance in terms of absorption; the small intestine, the 
major site of food and drug absorption, is far more important, and its anatomical 
structure will thus be described. For a more detailed account, reviews by Carr and 
Toner (1984), Kararli (1989) and Madara and Trier (1994) should be consulted.
The intestine may be considered as a complex biological membrane, composed 
essentially of mucosal epithelial cells, tight junctions and intercellular spaces, the 
glycocalyx at the luminal face of the epithelial apical membrane, and the unstirred 
layer of water and mucus immediately adjacent to the luminal face of the glycocalyx. 
Permeation of drug molecules, therefore, requires the passage across these barriers.
1.3.1 Unstirred water laver
As a solute passes from the bulk phase in the intestinal lumen into the cytosol of the 
enterocyte (or through the tight junctions of the cells), it first encounters, and must 
pass through, the unstirred water layer (UWL). In humans, the UWL is 
approximately 500pm in thickness (Thomson and Dietschy, 1984), and is unaffected 
by forced convection in the bulk phase. Passage of an uncharged solute across the 
UWL occurs by simple diffusion and is determined by three factors: (i) effective 
thickness of the UWL (ii) effective surface area (iii) difhjsion coefficient of the 
substrate (Dietschy and Westergaard, 1975).
I = (Cl - Cz) D A where J = flux rate
d Cl = solute conc. at luminal bulk phase
C2 = solute conc. at aqueous-lipid interface
D = free diffusion coefficient
d = thickness of UWL
A - area being considered
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It would be expected that the UWL limits the absorption of lipophilic substrates such 
as long chain fatty acids, and steroids such as bile acids, cholesterol and steroid 
hormones. Since present-day drugs administered orally are generally fat soluble, their 
flux across the UWL will also be affected (Csaky, 1984a).
1.3.2 Mucous layer and glycocalyx
A layer of watery mucus covers the epithelial cells of the entire intestine. This layer is 
composed of water and electrolytes, together with mucopolysaccharides, proteins and 
nucleic acids which are bound to the brush border membrane by the glycocalyx (Van 
Hoogdalem, De Boer and Breimer, 1989). The glycocalyx is made up of 
glycoproteins and, in humans, is between 100 and SOOnm thick over the epithelial 
cells, but somewhat thinner over the goblet cells (Thomson and Dietschy, 1984). The 
glycocalyx (or fuzzy coat) is covalently linked to lipids and proteins of the apical cell 
membrane (Van Hoogdalem, De Boer and Breimer, 1989). However, on the basis of 
diffusion studies, it has been suggested that the intestinal mucus and glycocalyx do 
not impair the permeation of solutes significantly, and are not contributing factors to 
the barrier to diffusion of the UWL (Sallee and Dietschy, 1973; Lukie, Westergaard 
and Dietschy, 1974). However, the binding of drugs to mucus has been described in 
several studies (Barry and Braybrooks, 1975; Nimmerfall and Rosenthaler, 1980; 
Shurgers, De Blaey and Crommelin, 1985; Niibuchi, Aramaki and Tsuchiya, 1986), 
and this may reduce the extent of drug absorption.
1.3.3 Small intestinal wall
Making up the wall of the small intestine are four distinct layers; mucosa, submucosa, 
muscularis and serosa, going fi*om the luminal side outwards. These are common 
characteristics of the gastrointestinal tract from the stomach to the large intestine. In 
the small intestine, the luminal surface is covered by a layer, one cell thick, of mainly 
columnar epithelial cells and goblet cells with some endocrine cells; these stand on 
the basement membrane. This layer of cells presents the most important anatomical 
barrier against solute absorption.
Introduction
1.3.3(i) Apical cell membrane
The apical membrane of the enterocyte comprises densely packed microvilli, which 
results in a greater surface area for absorption, and the enterocytes are interconnected 
by tight junctions. It is, therefore, obvious that for solute absorption to occur, it must 
be as a result of either transcellular permeation (across the epithelial cell) or 
paracellular permeation (between the enterocytes via tight junctions into the 
intercellular space). The apical membrane is thicker than the lateral and basal 
membranes (lO.Snm against 7.5nm) (Carr and Toner, 1984), and consists of a 
phospholipid bilayer into which polysaccharide and proteins are incorporated. The 
incorporated proteins may span the entire thickness of the membrane, perhaps 
representing pores and carrier mechanisms involved in the selective permeability of 
the membrane, or they may protrude from one surface only, for example, those 
proteins involved in cellular metabolism (Carr and Toner, 1984). The extent of 
passive diffusion of molecules across the apical cell membrane depends very much 
upon their lipid-water partition coefficient (Diamond and Wright, 1969). It follows 
that molecules with a high hydrophilic nature, for example, certain antibiotics and 
peptides, will have restricted absorption, due to ionisation. After crossing the brush 
border, compounds then pass into the cytosolic compartment of the cell. As has 
already been discussed, a notable barrier to the complete absorption of intact peptide 
drugs is the presence of cytosolic peptidases (reviewed by Alpers, 1994).
1.3.3(ii) Basal and lateral cell membranes
The compounds must then cross the basal and the lateral membrane, 7.5nm in 
thickness, and enter into the interstitial fluid and intercellular cleft, respectively. The 
barrier function of the basolateral membrane is probably not as great as that of the 
apical membrane, partly because the lipid fluidity of the former exceeds that of the 
latter (Dudeja, Brasitus, Dahiya, Brown, Thomas and Lau, 1987), perhaps because of 
the lower content of glycospliingolipids (Van Meer, 1988).
1.3.3 (iii) Tight junctions
The tight junctions (zonulae occludentes) are regions of close contact between the 
apical ends of the epithelial cells, and act to separate the contents of the intestinal 
lumen from the lateral intercellular spaces. The tight junctions consist of a network of
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strands, with the number of strands determining the tight junction permeability: the 
fewer the number of strands, the greater the permeability (Van Hoogdalem, De Boer 
and Breimer, 1989). The tight junctions are not as impervious as the name implies. A 
study by Fromter and Diamond (1972) demonstrated that a large fraction of salt and 
water transport across the epithelial wall occurs via the tight junctions and 
intercellular spaces. However, large molecules are excluded from traversing the 
epithelium via the paracellular route, under normal circumstances. The tight 
junctions, therefore, act as a passive selective barrier. The leakiness of tight junctions 
may be increased by the use of certain adjuvants and hyperosmolar solutions by 
causing some irreversible or reversible degree of damage or alteration to the 
membrane structure. Examples of these are salicylates, EDTA, methylxanthines and 
ionic surface active agents (Kararli, 1989). Experimental studies carried out using a 
variety of such compounds will be discussed later.
1.3.3 (iv) Basement membrane
Solutes crossing the gut wall by both the paracellular and transcellular routes will 
subsequently have to permeate the basement membrane and cross into the lamina 
propria. In rat jejunum, the basement structure has been found to contain abundant 
fenestrations of between 0.5 and 5p,m in diameter (Komuro, 1985). The basement 
membrane is not considered to provide a major barrier to drug absorption (Csaky, 
1984b).
1.3.3 (v) Capillary wall
After reaching the lamina propria, the drug molecule enters either the blood or 
lymphatic circulations, or both. The endothelium of the capillaries is fenestrated, and 
is not considered to act as a barrier to the passage of molecules with sizes of 3nm or 
less (Kingham and Loehry, 1976; Kingham, Whorwell and Loehry, 1976). The 
lymphatic circulation would appear to be less important as a route for solute 
transport, except perhaps for highly lipophilic compounds. The flow of lymph in the 
intestine is slower than the flow of blood (l-2ml min"^  and 2000ml min'  ^ in humans, 
respectively), and this probably contributes to the lesser part played by the lymphatics 
(Kararli, 1989). Drugs absorbed by the lymphatics do, however, by-pass the liver
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with a consequent reduction in their metabolism, thereby leading to increased overall 
blood plasma levels.
1,4 routes and mechanisms of absorption of intact peptides and proteins
As has been previously stated, there are two potential routes of transport across the 
intestinal wall: transcellular and paracellular. The paracellular route refers to the 
passage of molecules through tight junctions between the enterocytes, whereas the 
transcellular route refers to movement across the apical membrane by carrier mediated 
transport, endocytosis, or diffusion through the aqueous channels or the lipid parts of 
the membrane into the cytosol and, thence, through the basolateral membrane into the 
interstitial fluid.
1.4.1 Paracellular pathway
Evidence in favour of the substantial transport of macromolecules by the paracellular 
route is limited. Nonetheless, paracellular movement of iodized oil (Lipiodol), 
contained in polyalkylcyanoacrylate capsules of 100 to 200nm in diameter, was traced 
after being administered directly into the jejunal lumen of the anaesthetised dog 
(Aprahamian, Michel, Humbert, Devissaguet and Damgé, 1987). Scanning electron 
microscopy at different elapsed times demonstrated the presence of intact capsules 
first in the intestinal lumen close to the mucous layer, then in the intercellular spaces 
and finally in the lamina propria and blood capillaries.
Preparation of these nanocapsules was undertaken in the presence of 0.5% Pluronic 
F68, a surfactant reported to cause gastric mucosal damage, at a concentration of 
approximately 1.0% (Nadai, Kondo, Tatematsu and Sezaki, 1972). However, 
concern regarding the occurrence of adverse structural changes may be unfounded 
since a separate study by Ohsumi and colleagues determined that a 10-fbld increase in 
Pluronic F68 concentration (5.0%) induced no discernible morphological or 
functional change in the intestinal mucosa of the rat, even after exposure over a 
period of 3 months (Ohsumi, Yonezawa, Aizawa et a/, 1980).
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1.4.2 Transcellular pathway
On the whole, evidence that, in the mature intestine, the transport of at least small 
amounts of intact macromolecules has occurred by the transcellular route is 
widespread. Morphocytochemical studies have revealed the adsorption of luminally 
administered horseradish peroxidase (HRP) (Cornell, Walker and Isselbacher, 1971) 
and of labelled-insulin (150U, in combination with aprotinin, a proteinase inhibitor, 
and sodium cholate, a permeation enhancer) (Bendayan, Ziv, Ben-Sasson, Bar-On and 
Kidron, 1990) onto the apical surface membranes of rat small intestinal enterocytes, 
prior to detection within vesicular and vacuolar structures within the cytosol. 
Subsequent appearance of these macromolecules at the basolateral membrane and in 
the extracellular spaces led the authors to conclude that absorption occurred 
transcellularly, and by an endocytotic process. The retained bioactivity of insulin was 
confirmed by an observed drop in blood glucose levels, which reached its lowest level, 
30 minutes after administration. From this, Bendayan and colleagues estimated the 
peak absorption of insulin to be 0.5U, an amount not attributable to structural 
damage, as demonstrated by the retained structural integrity of the intestinal mucosa 
observed with morphological examination.
Hence, it would appear that the most likely route for the passage of many 
macromolecules is via the transcellular route. Further evidence for this comes jfrom 
the view that increasing the lipophilicity of the protein or peptide will facilitate the 
absorption of the substance (Lee, 1988), and the fact that microemulsions such as 
liposomes and mixed micelles can enhance absorption (Patel and Ryman, 1977; Fukui, 
Murakami, Yoshikawa, Takada and Muranishi, 1987; Schilling and Mitra, 1990). 
Moreover, a review by O’Hagan (1990) states that, in healthy tissue at least, there is 
little reliable evidence to suggest that macromolecules use the paracellular route. 
However, absorption does appear to be very much related to the concentration of 
ingested protein (Walker and Isselbacher, 1974), since sufficient amounts of protein 
must escape degradation within the intestinal lumen in order for uptake to occur. 
Also, the amount of protein must exceed the lysosomal digestive capacity to allow the 
protein molecules to be transported out of the enterocyte and into the circulation.
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1.4.3 Intestinal location providing the optimal site for absorption of intact 
macromolecules
Since the cellular morphology and enzymatic make-up of the small intestinal mucosa 
varies as one moves from proximal to distal regions, studies investigating the sites 
where macromolecular absorption would be optimal are very useful when developing 
successful oral delivery formulations.
Experiments carried out using rat intestinal loops, both in vitro and in vivo, have 
revealed the ileum as the optimal location for intestinal absorption of macromolecules 
(Schilling and Mitra, 1990; Michel, Aprahamian, Defontaine, Couvreur and Damgé, 
1991; Morishita, Morishita, Takayama, Machida and Nagai, 1993). Ileal 
administration, in vitro, of insulin in doses up to 0.5mg ml"^  resulted in the transport 
of only very small amounts of insulin in its intact form (less than 0.2% of initial dose); 
however, this was significantly greater than that absorbed by the duodenum (Schilling 
and Mitra, 1990). The authors reasoned that in these experiments, insulin was 
restricted by the additional barrier presented by the serosal tissue which would not be 
the case in vivo. They further stated that hydrolysis of insulin is not a contributory 
factor; the absorption differences are, on the whole, a consequence of moiphological 
differences of the cells or tight junctions.
Michel and co-workers (1991) agreed that the ileum was the optimal site of 
absorption; however, they showed that the administration of encapsulated insulin 
(lOOU kg'^) to other parts of the small intestine, in vivo, also evoked a significant 
reduction in glycaemia (51% of the normal value at the duodenum, 53% at the 
jejunum, and 65% at the ileum) compared with the effects of non-encapsulated 
insulin, in streptozotocin-induced diabetic rats. This suggests that, in actual fact, 
proteolytic degradation is a major factor in the limitation of intact peptide absorption.
1.4 .4 Morphology of the distal small intestine - M cells
The increase in macromolecular absorption across the ileum compared to more 
proximal regions of the small intestine may be due to differences in its morphology, as 
has been previously stated. Peyer’s patches are located in the mucosal wall of the 
small intestine in mammals, and are particularly rich in the ileum close to the ileo- 
caecal junction (Owen and Jones, 1974; Owen, 1977). They are covered by a 
special type of cell, the M cell, or membranous epithelial cell, which extends between
11
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the adjacent enterocytes, forming a membrane separating lymphocytes in the mucosa 
from the intestinal lumen (Owen and Jones, 1974; Owen, 1977). M cells are 
significantly different from enterocytes as they possess irregular short and wide 
microvilli which are fewer in number than in enterocytes (Owen and Jones, 1974; 
Owen and Nemanic, 1978; Smith and Peacock, 1980). Also, vesicles are particularly 
abundant in the cytoplasm of M cells, reflecting endocytotic activity, and there 
appears to be fewer lysosomes and therefore a diminished rate of intracellular protein 
degradation. It has been shown that the rate of uptake of horseradish peroxidase 
(HRP) by M cells was greater than that of the enterocytes (Owen, 1977). However, a 
study by Ducroc and associates (Ducroc, Heyman, Beaufrere, Morgat and Desjeux, 
1983) stated that the rate of uptake of HRP by both the M cells and the enterocytes 
was similar. The rate of uptake by the M cells only appeared to be greater since the 
degradative activity is lower than in the enterocytes and, therefore, the net 
macromolecular passage is greater.
1.5 Facilitation of peptide and protein absorption across the gastrointestinal 
wall
One strategy to facilitate mucosal peptide and protein absorption across the intestinal 
wall is the co-administration of a peptide or protein with a penetration enhancer. This 
is usually a low molecular weight compound which increases drug absorption by one 
of several mechanisms e.g. increasing membrane hydrophilicity or expanding the 
pathway to solute transport through increased permeability of tight junctions (Lee,
1988). Examples of such enhancers are bile salts, chelating agents, surfactants and 
fatty acids.
However, the far from complete passage of peptides and proteins across the intestinal 
wall suggests there is at least one other barrier limiting absorption; this is the 
enzymatic barrier composed of exo- and endopeptidases (see Section 1.1). The 
enzymatic barrier is one of the most important of a series of barriers limiting peptide 
and protein absorption from the GI tract. In order to promote oral absorption of 
peptides and proteins from the GI tract, the components of the enzymatic barrier must 
be controlled. This can be achieved to some extent by the modification of protein and 
peptide structure, the use of protease inhibitors, and using the formulation approach. 
These strategies will now be reviewed in more detail.
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1.5.1 Protease inhibitors and penetration enhancers
In the stomach-perfiised rat, in vivo studies have shown that intraduodenally- 
administered tetragastrin (4 amino acid peptide) evoked only minor increases in 
gastric acid secretion (Jennewein, Waldeck and Konz, 1974). When the pancreatic 
duct was ligated, however, acid secretion increased 11-fold, an amount not dissimilar 
to that evoked after administration of tetragastrin to a jejunal or ileal loop. Porto- 
jugular anastomosis, resulting in by-pass of the liver, was also effective in increasing 
gastric acid secretion, although to a much lesser extent than in the ligated pancreatic 
duct preparation (3-fold increase). Taken together, the results of this study provide 
evidence to suggest the pancreatic proteases have an important role to play in the 
degradation of tetragastrin, with an additional small but significant part played by the 
hepatocytes.
Attempts to circumvent degradation of orally-administered peptides as big as insulin 
(51 amino acids) by co-administration with protease inhibitors have been met with a 
considerable degree of success, at least in the rat (Danforth and Moore, 1959; Kidron, 
Bar-On, Berry and Ziv, 1982; Takaori, Burton and Donowitz, 1986; Ziv, Lior and 
Kidron, 1987; Bendayan et al, 1990; Morishita et al, 1993), This is surprising since 
the application of one specific protease inhibitor would not be expected to lead to 
increased peptide bioavailability due to the continuing actions of the other proteases. 
The relative impermeability of the gastrointestinal wall provides a further barrier to 
the absorption of intact peptides. Indeed, studies have determined that potentiation of 
permeation may be achieved when peptides are administered in the presence of both 
protease inhibitors and absorption enhancing agents (Kidron et al, 1982; Ziv et al, 
1987; Bendayan et al, 1990). Permeation enhancers differ widely in their chemical 
composition; that they all have absorption-promoting capabilities appears to be the 
only common characteristic. Examples of such compounds are surfactants, bile salts 
and non-steroidal anti-inflammatory drugs. The natural occurrence of bile salts in the 
intestinal tract has brought about extensive application of these compounds in 
absorption-promoting studies as potentially safe permeation enhancers. Nonetheless, 
relatively low concentrations of some bile salts (0.2% sodium deoxycholate) causes 
considerable mucosal damage (Gaginella, Lewis and Phillips, 1977; Nadai, Kume, 
Tatematsu and Sezaki, 1975; Nakanishi, Masada and Nadai, 1983), whereas
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comparable concentrations of sodium taurocholate or sodium cholate did not 
(Miyamoto, Tsuji and Yamana, 1983). Of interest, then, is the report in a recent 
patent application (Cortecs Ltd., 1996), whereby the co-administration of carbonate 
ions (COs '^ ) or bicarbonate ions (HCO3 ) with bile salts in vivo enhanced the 
absorption of both insulin and salmon calcitonin (as reflected by a drop in plasma 
glucose levels, and in plasma Ca^  ^levels, respectively), without affecting cell viability 
(as observed in vitro). The mechanisms underlying the enhancement differ, depending 
on whether the applied bile acid is conjugated or not. In the presence of sufficient 
or HCO3 ions, the amount of conjugated bile acid required to increase mucosal 
permeability of the peptide hormone is reduced and, thus, mucosal permeability can 
be enhanced without concomitant adverse effects. In the case of unconjugated bile 
acids, rather than increase the degree of cell permeability, COs '^ or HCO3 ions reduce 
the toxic effect on cells after exposure to bile salts and, thus, greater concentrations of 
bile acids may be used to increase cell permeability. Additionally, the buffering effect 
of or HCO3' ions can increase the solubility of the bile acids, so that a higher 
local concentration of the bile salt will be attained, resulting in greater efficacy in 
enhancing intestinal permeation to bioactive compounds.
Table 1-2 summarises the outcome of a number of studies investigating the ability of 
protease inhibitors and permeation enhancers to enhance the absorption of insulin 
when administered to various regions of the small intestine. In addition to 
measurement of plasma insulin levels, evaluation of blood glucose levels was also 
carried out, thereby reflecting the absorption of biologically active insulin, as opposed 
to partially degraded fractions. The importance of this was demonstrated by Ziv et al 
(1987), who showed that a considerable amount of insulin-degraded fragments were 
of sufficient size to react with the added antibody during radioimmunoassay (RIA). 
Consequently, misleading results regarding the absorption of insulin may be reported 
if dependence was solely on RIA of plasma levels of insulin. Nonetheless, it is well 
established that intact insulin absorption is promoted in the presence of either protease 
inhibitors or absorption enhancers, such as bile salts. Furthermore, the effects are 
additive, with blood glucose levels dropping by as much as 66% of original levels in 
response to insulin dosage of between 100 and 150U ml'^  {c.f, maximum of 34% drop 
in blood glucose levels observed in response to insulin in the presence of either
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protease inhibitor or absorption enhancer (Ziv et al, 1987; Bendayan et al, 1990)). 
Nevertheless, the actual quantity of insulin absorbed across the rat ileum, in vivo, after 
30 minutes in the presence of both aprotinin and sodium cholate, was reported to be 
less than 1.0% of the initial amount (Ziv et al, 1987).
Thus, the promotion of absorption of large peptides, such as insulin, is very much 
dependent on the inhibition of proteolysis as well as enhancement of permeation using 
various absorption promoters. Nonetheless, establishment of the long-term effects of 
such permeation enhancers is required before this approach can be considered as a 
viable means of promoting oral drug delivery. Moreover, the very low oral 
bioavailability of therapeutic peptides (less than 1.0% of initial dose (Ziv et al, 1987)), 
even in the presence of both protease inhibitors and absorption promoters, suggests 
that to induce any beneficial effect, the dose administered must be immense.
1.5.2 Formulation approach
The formulation approach is another strategy designed to protect the peptide from 
contact with primarily luminal proteases, and to release the peptide only upon 
reaching an area favourable to its absorption. Several formulations have been devised 
eg. water-in-oil-in-water emulsions, liposomes, nanoparticles and soft gelatin capsules 
with polyacrylic polymers with pH dependent properties.
1.5.2(i) Liposomes
Liposomes are vesicles composed of a bilayer containing phospholipids and 
cholesterol, surrounding an aqueous compartment. In rats, oral administration of 
liposomally-encapsulated insulin caused a very much smaller hypoglycaemic effect 
compared with the same dose of intra-peritoneal insulin, delivered fi-ee or 
encapsulated (Patel and Ryman, 1976). Intra-luminal co-administration of 
encapsulated insulin and a protease inhibitor, however, did result in a significantly 
decreased plasma glucose level (Patel and Ryman, 1977). In the dog, liposomal 
insulin was demonstrated to have been transported across the duodenal wall but a 
subsequent fall in plasma glucose was absent. It was concluded that no more than 
1.0% of insulin had reached the circulation in an active form (Patel, Stevenson, 
Parsons and Ryman, 1982). Thus, it appears that although liposomes enhance 
absorption, they do not protect against proteolytic degradation.
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1.5.2(ii) Water-in-oil-in-water emulsions
Water-in-oil-in-water (W/OAV) emulsions have been used as a means of facilitating 
the gastrointestinal absorption of normally non-absorbed water-soluble polymers. Oil 
droplets containing their own dispersed phase of fine water droplets are suspended in 
an aqueous phase; contained within the internal aqueous phase is the therapeutic 
agent. Equivocal results have been reported as regards the effectiveness of W/OAV 
emulsions in promoting absorption of peptides, although it was suggested that insulin- 
containing emulsions may provide a possible means of protecting the peptide from 
proteolytic degradation and of facilitating absorption (Shichiri, Shimizu, Yoshida, 
Kawamori, Fukuchi, Shigeta and Abe, 1974). Indeed, Engel, Riggi and Fahrenbach 
(1968) previously demonstrated marked hypoglycaemia in the rat and gerbil, in 
response to intraduodenal administration of emulsified insulin.
1.5.2(iii) Nano/microspheres and nano/microcapsules
The containment of peptides within spherical structures made of various 
biodegradable polymers such as polyalkylcyanoacrylate or isobutylcyanoacrylate has 
been used in an attempt to minimise degradation of the peptide by proteolytic 
enzymes, and to facilitate permeation of the intestinal wall. On the whole, the results 
have been promising.
Polyalkylcyanoacrylate nanocapsules (100 - 200nm in diameter), loaded with iodized 
oil, were reported to enhance the rate of absorption of the entrapped substance from 
the intestinal lumen to the vasculature of the dog, as measured by increased levels of 
iodine in mesenteric venous plasma (Aprahamian et al, 1987). Further work 
demonstrated that, although relatively large in size compared with the enterocytes, 
significant amounts of radio-labelled polystyrene micro spheres, up to 300nm in 
diameter, were absorbed after feeding to rats (Jani, Halbert, Langridge and Florence,
1989).
Insulin (lOOU kg'^) entrapped in isobutylcyanoacrylate nanocapsules remains 
biologically active after ileal administration, as evidenced by a significant reduction in 
blood glucose levels of 65% in streptozotocin-induced diabetic rats (Michel et al,
1991). Hypoglycaemia was also evoked following intraduodenal or intrajejunal 
administration of insulin-containing capsules, although to a slightly lesser extent (52% 
of control levels). The authors suggested that the presence of M cells in the ileum
17
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may have enhanced absorption. In addition, the duration but not the intensity of the 
giycaemic response was dependent on the amount of nanocapsules administered; the 
response may last up to 6 or 20 days after a single oral administration of 12.5 or 5OU 
kg‘^  encapsulated insulin, respectively (Damgé, Michel, Aprahamian and Couvreur, 
1988).
Nanoparticies have also been used as mucoadhesive agents, allowing prolonged 
residence time of drugs in the gastrointestinal tract and, thus, increasing time for 
absorption of the entrapped therapeutic agent. In vitro studies in the rat have 
produced favourable results (Bridges, Woodley, Duncan and Kopecek, 1988; 
Pimienta, Lenaerts, Cadieux, Raymond, Juhasz, Simard and Jolicouer, 1990). For 
example, hydroxypropylmethacrylate (HPMA) nanoparticies have shovm a high level 
of adhesion to rat ileal intestinal mucosa; bonds appeared to develop very quickly 
since greater than 50% of the initially-administered nanoparticies remained even after 
immediate perfusion of the ileum (Pimienta et al, 1990).
Other formulations have been developed in order to enhance the bioavailability of 
orally administered peptide drugs. Perhaps one of the most promising results was 
obtained by Saflfran, Kumar, Savariar, Burnham, Williams and Neckers in 1986. 
Peptide drugs were coated with polymers cross-linked with azo-aromatic groups to 
form an impervious film in order to protect orally administered drugs fi'om digestion 
in the stomach and small intestine. When the azopolymer-coated drug reaches the 
large intestine (ileocecal junction), the azoreductase produced by the indigenous 
bacteria reduces the azo bonds, breaks the cross-links and degrades the polymer film. 
Thus, the drug is released into the lumen of the colon for local action or absorption. 
The ability of the azopolymer coating to protect peptide drugs was demonstrated in 
rats, with respect to the peptide hormones vasopressin and insulin; however, farther 
clarification is required as to whether the microbial proteases affect peptide integrity, 
and the extent to which faecal matter interferes with the absorption process.
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1.5.3 Chemical Modification
1.5.3(i) Peptides with improved resistance to proteases and enhanced lipophilic 
affinity
In addition to improving enzymatic stability, modification of the amino acid 
composition of peptides may also increase their lipophilicity, thereby facilitating 
permeation of the intestinal wall, and consequently minimising contact of the peptide 
with proteolytic enzymes at the site of absorption (Lee, 1988).
The replacement of naturally occurring L-amino acids of a peptide for unnatural 
amino acids (D-configurations) has been employed as a means of improving enzymatic 
stability. Table 1-3 illustrates this, by comparing the oral bioavailability of dipeptides 
with varying L- and D-configuration amino acid residues in rats, based on excretion of 
the administered dose (0.5mmol kg"‘ body weight) in urine over 240 minutes 
(Asatoor, Chadha, Milne and Prosser, 1973). Positive correlation existed between the 
rate of absorption and the rate of hydrolysis.
Table 1-3: Oral bioavailability of dipeptides in the rat
Peptide Isomer
Excretion 
(mmol mg‘^  of creatinine)
Ala-Phe LL 0.00
LD 0.00
DL 0.11
DD 35.00
Leu-Leu LL 0.00
LD 0.32
DL 0.25
DD 12.50
Gly-Trp LL 0.00
LD 17.0
(Ala, alanine; Phe, phenylalanine; Leu, leucine; Gly, glycine; Trp, tryptophan)
Chemical modification of arginine vasopressin (AVP), a nonapeptide, produced two 
analogues, 1 -deamino-8-O-arginine vasopressin (DDAVP) and l-deamino-2- 
tyrosine(o-ethyl)-oxytocin. The intestinal transport of these two analogues were 
subsequently compared in the rat jejunum, in vitro (Vilhardt and Lundin, 1986a).
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Detection by radioimmunoassay and quantitative high performance liquid 
chromatography determined that transport rates across the jejunal wall were greatest 
for DDAVP, and lowest for AVP, though the level of biological activity was not 
indicated. Nonetheless, previous reports demonstrated anti-diuresis in response to 
oral administration of DDAVP in both conscious dogs (Vilhardt and Bie, 1983) and 
human subjects (Vilhardt and Bie, 1984). This is likely to have occurred as a 
consequence of both increased resistance to proteases as well as increased lipophilic 
affinity. Despite this, radioimmunoassay of plasma DDAVP, after peroral 
administration to human volunteers, established that only between 0.7 and 1.0% of 
the initial dose actually appeared in the blood (Vilhardt and Lundin, 1986b).
1.5.3(ii) Carrier-mediated peptide transport
A more recent approach to the enhancement of oral bioavailability of therapeutic 
peptides has been the utilisation of carrier-mediated transport mechanisms. As has 
previously been discussed, poor permeation of the gastrointestinal wall is a major 
limitation to the successful oral administration of drugs. The means of overcoming 
this problem is by the use of absorption enhancers such as bile salts, chelating agents 
or surfactants. However, they may also have the undesirable effect of irreversible 
damage to or alteration of the epithelium. Utilisation of physiological carrier systems 
present in the gut, for example, the glucose or bile transporter, may therefore be a 
viable prospect in promoting oral drug delivery. Success in this field requires 
modification of the required peptide such that affinity with the carrier system is 
maintained or improved. Accordingly, a more extensive review is provided in the 
following sections.
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1.6 Facilitation of intestinal absorption by utilisation of carrier-mediated 
transport systems
1.6.1 Characteristics of carrier-mediated transport
Carrier-mediated transport involves the combination of the transported molecule with 
a specific site on the transport protein located in the cell membrane, and has a number 
of characteristic features, which are briefly summarised.
• Substrates transported by carrier-mediated transport are transported at a much 
more rapid rate than molecules of a similar molecular weight and lipophilic affinity, 
which cross the membrane by simple diffusion.
'max
Substrate concentration [S]
Fig. l-l:Graphical representation o f  saturation kinetics exhibited by carrier-mediated systems. 
(Jmax, maximal transport rate o f  substrate; K„„, concentî'ation o f  the transported substrate required 
for the transport rate to be half-maximal (Jmax/2).
# Since the number of binding sites is finite, saturation kinetics are demonstrated. As 
the concentration of the substrate is increased, the rate of transport increases until 
all the available sites are occupied, above which the transport rate increases no 
further (Figure 1-1). The rate of mediated-transport may be represented by the 
Michaelis-Menten equation:
, Jm. [S] where J is the rate of transport
Km +  [S] Jmax is the maximal rate o f transport
[S] is the concentration of the transported substrate in the
compartment from which it is being removed
Km is the substrate concentration required for half-masdmal
transport
21
Introduction
• Carrier-mediated systems show chemical specificity, so that only molecules with 
the requisite chemical structure are transported, although specificity is not usually 
absolute, since a particular transport system may be used by more than one 
substrate.
• Structurally related molecules may compete for transport. The amount of one 
substrate transported depends on its concentration relative to that of other 
substrates, in addition to the affinity of the binding site for the substrates present.
• Transport of a substrate may be inhibited by structurally unrelated compounds that 
bind to the transport protein and decrease the affinity of the system for the normal 
transport substrate. Carrier proteins, dependent on metabolic processes, are 
affected by metabohc inhibitors.
1.6.2 Intestinal glucose transport svstem
The active uptake of glucose and galactose by carriers located in the membrane of the 
epithelial cells of the gastrointestinal tract has been well documented (Stern and 
Jensen, 1966).
The glucose-carrier mediated transport system has been implicated in the transport of 
glucose- and galactose-conjugated compounds (yCl-naphthyl- and /?-nitrophenyl p-D - 
glucopyranoside, and y&naphthyl- and p-nitrophenyl P-D-galactopyranoside, 
respectively) in the rat everted jejunal sac (Mizuma, Ohta, Hayashi and Awazu,
1992). Evidence for this was presented by a significant diminution of the absorption 
clearance of these compounds in the presence of phloridzin, an inhibitor of the 
glucose transporter. Similarly, substitution of Na^ ions by K" ions in the incubation 
medium, producing a Na^ fi'ee medium, also showed marked attenuation of the 
absorption clearance in all cases. Despite this, it was subsequently demonstrated that 
approximately one-quarter of absorbed p-nitrophenyl p-D-galactopyranoside actually 
appeared on the serosal side as p-nitrophenyl glucuronide, which is evidence of a 
degree of hydrolysis of the substrate during absorption (Mizuma, Ohta, Hayashi and 
Awazu, 1993). The methodology behind these studies is, however, questionable, 
since replacement of Na^ ions with ions to produce an increase in extracellular 
concentration of to approximately 150mM, would result In the creation of 
conditions outside the normal physiological state.
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More recently, the potential for the glucose transport system to improve intestinal 
absorption of poorly absorbable drugs was investigated (Mizuma, Sakai and Awazu, 
1994). The coupling of mono- and disaccharides with a model tripeptide, 
tyrosylglycylglycine (TGG) markedly improved mucosal to serosal transport of this 
aminopeptidase-degradable peptide, in the rat everted jejunal sac, with little evidence 
of hydrolysis of the peptide. Both Na^-dependent and Na^-independent mechanisms 
were involved, indicating that, in addition to facilitating carrier-mediated transport of 
sugar-coupled TGG, susceptibility to proteolytic hydrolysis appears to be reduced. 
The applicability of such an approach in vivo using larger peptides requires 
elucidation, but preliminary results are encouraging.
1.6.3 Intestinal bile acid transport svstem
The approach taken in this study, with a view to enhancing the intestinal absorption of 
therapeutic peptides, was by way of exploitation of the bile acid transporters present 
in the plasma membrane of ileal enterocytes. A brief summary of the physiology of 
bile acid absorption and the enterohepatic circulation will first be presented, prior to a 
discussion of the current literature involving the use of bile acid transporters for 
intestinal drug delivery.
1 6.3(i) Chemical structure o f bile acids and bile salts
Evaluation of the current literature has been complicated by the fact that little 
distinction has been made between the terms “bile acid” and “bile salt”; generally, 
these terms have been used interchangeably. Strictly speaking, unionised forms 
should be referred to as bile acids, whereas ionised forms should be called bile salts, 
and as far as has been possible, this terminology has been adhered to. Further 
confijsion arises when no clear distinction is made between unconjugated and 
(taurine- or glycine-) conjugated forms.
Bile acids are produced as the end product of the metabolism of cholesterol by the 
liver, in which the cholesterol molecule is fijrther modified by the insertion of one or 
two hydroxyl groups at C-7 and/or C-12, in addition to the one present at position C- 
3, commonly in the a-configuration (Whiting, 1986). Further modification of 
cholesterol to produce the bile acids is the saturation of the double bond between C-5
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and C-6, the oxidative removal of C-25, C-26 and C-27 from the side chain, and the 
oxidation of C-24 to a carboxyl group. Bile acids which are synthesised from 
cholesterol in the liver are termed primary bile acids. These undergo fiirther 
conversion to secondary bile acids by the action of anaerobic bacteria in the distal 
intestine (see Section 1.6.3(ii)). In both man and the rat, cholic acid and 
chenodeoxycholic acid are the two most frequently encountered primary bile acids 
(Weiner and Lack, 1967). The structures of cholesterol, cholic acid and 
chenodeoxycholic acid are illustrated in Figure 1-2.
21 22
HO 64
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COOKCOOK
HOg "OH
chenodeoxychoiic acid
HO cholic acid
Fig. 1-2: Chemical structures o f  cholesterol, chenodeoxycholic acid, and cholic acid. The carbon 
atoms are numbered, and the carbon rings o f  the steroid nucleus are referred to as A, B, C and D.
Prior to secretion into the bile, bile acids are conjugated through a peptide linkage at 
C-24 to either glycine or taurine. In the rat, the relative amounts of glycine- and 
taurine-conjugated bile acids depends predominantly on the availability of these 
compounds, and their relative affinities for the coenzyme A derivatives which are 
involved in the conjugation (Weiner and Lack, 1967). The structures of glycocholic
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and taurocholic acid, formed as a result of conjugation of glycine and taurine, 
respectively, to cholic acid, are shown in Figure 1-3.
Consequently, the pKa of the bile acids and bile salts will depend on the unconjugated 
or conjugated state of the bile acid/salt. For example, unconjugated bile acids have a 
pKa of approximately 6.0, and thus, the ratio of salt.acid will vary depending on the
21 22
OH
C-NHCH.COOH
glycocholic acidOHHO
21 22
OHI121
taurocholic acidOHHO
Fig. 1-3: Chemical structures o f  glycocholic acid and taurocholic acid. The carbon atoms are 
numbered 1 to 24, and the carbon rings o f  the steroid nucleus are referred to as A, B, C and D.
pH of the medium. On the other hand, the pKa values for glycine and taurine 
conjugates are lower, at approximately 4.0 and 2.0, respectively, and as such, at 
physiological pH, they always occur as salts (Dietschy, 1968). The conjugation of 
bile acids with glycine or taurine is of functional relevance since not only does it 
prevent precipitation in the presence of acid or divalent cations (Whiting, 1986), but it 
also increases the active absorption of bile salts in the terminal ileum, since conjugated 
bile salts have a higher affinity for the ileal bile salt transporter than unconjugated bile 
acids (Gordon, Miner and Kern, 1971; Aldini, Roda, Lenzi, Ussia et al, 1992).
25
Introduction
Furthermore, conjugation reduces passive transport in the jejunum and proximal 
ileum, since the ionised state reduces lipophilic affinity, thereby making bile salts more 
available to participate in lipid digestion at these locations (see Section l,6.3(iii)).
1.6.3 (ii) The enterohepatic circulation
This exists as a highly efficient mechanism for the conservation and réutilisation of the 
bile salt pool. It has been estimated that in man, the liver secretes approximately 20 
to 30g bile salts daily, and of this, only about 0.8g appears in the faeces as bile salt 
excretory products per day (Bergstrom, 1959). Bile salts are synthesised and 
excreted by the hepatocytes of the liver into the bile canaliculi and are stored, and 
subsequently concentrated, in the gall bladder in the periods between meals. 
Contraction of the gall bladder, for example, in response to cholecystokinin (CCK), 
released by the duodenal mucosa in response to the presence of lipids in the 
duodenum, results in emptying of bile salts from the gall bladder into the duodenum 
(Ivy and Oldberg, 1928).
Bile salts are conserved through reabsorption across the small intestinal wall, and 
return to the liver primarily via the hepatic portal circulation. However, a small 
proportion of bile salts enter the colon; here, primary bile salts undergo conversion to 
secondary bile salts by anaerobic bacteria. Taurocholate and glycocholate are 
deconjugated and dehydroxylated to deoxycholic acid, and chenodeoxycholic acid 
becomes lithocholic acid. Up to one-half of deoxycholic acid is reabsorbed and taken 
up by the liver for reconjugation with glycine or taurine, whereas lithocholic acid is 
relatively insoluble and thus poorly absorbed (Whiting, 1986). A more detailed 
account of the processes involved in the enterohepatic circulation now follows.
1.6.3(iii) Physiology o f bile salt absorption
It was first established in 1878, by Tappeiner, that various sites of the small intestine 
differed in their ability to reabsorb bile salts, with bile salt reuptake being more rapid 
in the ileum than in more proximal regions. Confirmation of this came from the work 
of Frohlicher (1936), nearly 60 years later. Nevertheless, it was not until almost a 
century after Tappeiner’s first claims that substantial progress in this area was made. 
Equivocal evidence for the importance of the distal small intestine in the maintenance 
of the enterohepatic circulation in rat, guinea pig, hamster and human was reported
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(Baker and Searle, 1960; Borgstrom, Lundh and Hofmann, 1963; Lack and Weiner, 
1961; Playoust and Isselbacher, 1964; Holt, 1964). It was found that as one 
descended the rat small intestine, in vivo, the rate of sodium glycocholate and sodium 
taurocholate reabsorption increased in an exponential manner with distance (Baker 
and Searle, 1960). So, although absorption was evident over the entire length of the 
small intestine, there was indirect evidence that a specific system may exist in the 
mucosal epithelium of the ileum for the absorption of these bile salts.
Elucidation of this concept was first provided by Lack and Weiner (1961), who 
determined the transport mechanisms of the bile salts, taurocholate and glycocholate, 
in the everted gut sacs of the rat and guinea pig. Initially, the concentrations of the 
bile salt under consideration were equal in both the serosal and mucosal 
compartments. After a 90 minute incubation period, only those intestinal sacs 
prepared fi*om the distal quarter of the small intestine showed a mean serosal: mucosal 
ratio of much greater than 1.0. Thus, only the ileum appeared capable of transporting 
bile salts against a concentration gradient. Also, since the transmural potential 
difference of these sacs was, at most, only a few millivolts (Clarkson, Cross and 
Toole, 1961), transport could not be ascribed to a favourable electric gradient. 
Evidence for the presence of an active transport system in this region was further 
provided by inhibition of oxidative metabolism by replacement of the oxygen used to 
aerate the bathing medium, or addition of the oxidative metabolic inhibitors, 2,4 
dinitrophenol or sodium azide, resulting in the marked attenuation of bile salt 
transport. Finally, the transport activity of the distal segment reached a maximum 
with increasing concentrations of either glycocholate and taurocholate, indicative of a 
saturable process (see Section 1.6.1).
Subsequent experiments produced similar results in the hamster (Playoust and 
Isselbacher, 1964) and the rat (Playoust and Isselbacher, 1964; Holt, 1964), in that 
the ileal transport of bile salts against a concentration gradient was shown to obey 
Michaelis-Menten (saturation) kinetics. Further, the dependence of the transport 
system on Na^ ions was confirmed in both these studies by the marked inhibition of 
reuptake when Na^ ions were omitted from the incubation medium. Additionally, 
competitive inhibition of taurocholate uptake by the additional presence of cholate or 
glycocholate was evident, suggesting the existence of a common receptor site for the 
active transport of these bile salts in the ileum (Playoust and Isselbacher, 1964). Lack
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and Weiner (1966) expanded further on this evidence by showing that some synthetic 
bile salts, as well as naturally occurring bile salts, were able to utilise the bile salt 
carrier protein, in the guinea pig everted ileal sac. The presence of a negative charge 
on the bile salt side chain was a prerequisite. Nevertheless, because these experiments 
were carried out in vitro, and because no Km values (see Section 1.6,1) for the 
different bile salts were determined (serosal:mucosal ratios were typically measured at 
only one concentration), the results obtained should be considered with caution.
More recently, insight into the different mechanisms of the small intestine involved in 
the maintenance of the enterohepatic circulation has been provided. It is now well 
established that active transport and passive diffusion of bile salts exists from the 
ileum and jejunum, respectively, of several mammals such as the pig (Juste, Legrand- 
Defretin, Coning and Rerat, 1988), the rat (Yokote, 1994; Dakka, Dumoulin, 
Chayvialle and Cuber, 1995), the guinea pig (Amelsberg, Schteingart, Ton-Nu and 
Hofinann, 1996), and the rabbit (Aldini, Montagnard, Roda, Hrelia, Biagi and Roda, 
1996), as well as the fish (Honkanen and Patton, 1987). Passive dififijsion of bile salts 
from the jejunum of turkeys was also demonstrated (Sklan, 1980). More specifically, 
it was concluded that, in the rabbit, conjugated trihydroxy bile salts are actively 
absorbed from the ileum, conjugated dihydroxy bile salts share both active and passive 
ileal absorption, and unconjugated dihydroxy bile acids diflhjse passively across the 
entire length of the small intestine, according to their lipophilic affinity (Aldini et al, 
1996). Additionally, Amelsberg and colleagues (1996) proposed that the reuptake of 
conjugated bile acids occurs by at least two mechanisms: carrier-mediated transport 
of glycine and taurine-conjugates, and passive absorption in the protonated 
(uncharged) form of glycine conjugates. The latter, they suggest, may occur in the 
presence of the jejunal acidic microclimate, which exists close to the apical membrane 
of the jejunal enterocyte. In humans and rats, an acidic microclimate of between pH 
5.4 and 6.2 was measured with H  ^ ion sensitive microelectrodes (Lucas, Schneider, 
Haberich and Blair, 1975; Lucas, Blair, Cooper and Cooke, 1976; Lucas, 1983; 
M^Ewan, Daniel, Fett, Burgess and Lucas, 1988). However, at the lowest measured 
pH, only a very small fraction of glycine conjugates (~ 7%) would be in the 
protonated form, although in some pathological states, it is conceivable that passive 
absorption of protonated glycine conjugates plays an important role in bile acid/salt 
absorption.
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The presence of an active transport system for intestinal bile salt absorption, present 
only in the ileum, has thus led to the view that the distal small intestine is the major 
site of bile salt absorption within the enterohepatic circulation. However, NFClintock 
and Shiau (1983) suggested that this idea has arisen due to predominantly in vitro 
studies in which experimental concentrations of bile salts were below physiological 
levels (luminal bile salts in the fed rat are of the range: 10 to 12mM in the proximal 
jejunum; 18 to 20mM in the mid-intestine; 2-3mM in the terminal ileum (Dietschy, 
1968)). They showed that in the rat, in vitro, the uptake of low concentrations of 
taurocholate (0.5-1.0mM) from the jejunum was significantly less compared with that 
from the ileum. This is consistent with the earlier in vitro experiments. By contrast, 
jejunal and ileal uptake of taurocholate at concentrations above critical micellar 
concentration (4.0-15.OmM, depending upon the type of bile salt) was equal and 
linear with respect to concentration. However, in anaesthetised rats, approximately 
30% of luminally administered taurocholate was absorbed from the proximal jejunum 
over a 90 minute period, yet only approximately 1.0% was absorbed from more distal 
small intestinal regions. Furthermore, in the conscious fed animal, 60% of 
administered taurocholate was recovered in the bile before the bolus reached the distal 
ileum. The authors proposed that, because the luminal concentration of taurocholate 
is highest proximally, predominantly passive absorption contributes significantly to the 
maintenance of the enterohepatic circulation. Ileal active transport appeared to be 
most efficient at low concentrations, and may act to absorb the remaining 
taurocholate fiom the distal small intestine. This conflicts with the premise that, since 
intestinal transport of bile salts is dependent on both the luminal pH and the pKa of 
the bile salt, taurine-conjugated bile salts (pKa~2) would not be expected to cross the 
small intestinal wall rapidly by simple diffusion of the non-ionised form.
Further evidence for the re-evaluation of the role of the proximal small intestine in bile 
salt absorption comes from Juste et al (1988). In pigs, in vivo, the rate of bile salt 
reabsorption in the distal ileum and large intestine was only 20% that of the rate for 
the whole intestine (small and large intestine), implicating a sizeable contribution by 
the proximal intestine in the maintenance of the enterohepatic circulation.
Finally, it should also be recognised that a number of investigators have demonstrated 
jejunal expression of bile salt carrier proteins in both rats and humans following
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ileostomy, which presumably occurs as a consequence of jejunal cellular adaptation to 
transport requirements (review by Swaan, Szoka and 0ie, 1996),
1.6.3(iv) Ileal transcellular transport o f bile salts - a proposed model
The general consensus is that bile salts are transported across the ileal enterocytes by
way of an active, carrier-mediated, Na^ dependent, co-transport mechanism.
A model for the transcellular transport of bile salts in rat ileal enterocytes was 
proposed by Lin, Mullady and Wilson (1993), based on studies investigating the 
cloning and expression of the ileal bile salt carrier. The transport of bile salts across 
the brush border membrane is by a 99-kDa protein which constitutes a Na^ dependent 
active transport system. Within the cytosol of the enterocytes, bile salts bind either to 
actin (43-kDa protein) or 14- and 35-kDa cytosolic proteins, and are transported 
either to a microsomal 20-lcDa protein, or directly to the basolateral membrane. Bile 
salts may then be transferred to the basolateral membrane associated protein (59-kDa) 
before their egress from the cell via the 54-kDa integral basolateral membrane protein 
and an unidentified anion exchange mechanism (Figure 1-4).
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Fig. 1-4: Mechanism o f  ileal ti'anscellular transport o f  conjugated bile salts as proposed by Lin and 
associates (1993). Transport o f  bile salts at the ileal brush-border membrane occurs by way o f  a 
Na"^-dependent active co-transporter (99 k-Da). The bile salts are translocated through the cell by 
cytosolic proteins (14, 35 and 43 k-Da) to the basolateral membrane associated protein (59 k- 
Da),and exit the cell via a basolateral membrane bile salt/anion (X) counter-transporter (54 k-Da). 
An indirect pathway involving a microsomal protein (20 k-Da) (dashed arrows) may also contribute.
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1.6.3(v) Hepatic uptake o f bile salts and bile acids - a proposed model 
The review by Swaan et al (1996) has outlined the most recent findings regarding the 
mechanisms behind the uptake of bile salts and acids firom the sinusoidal blood supply 
and the excretion into the canaliculi of the liver. Two separate transport steps are 
involved: the uptake of bile salts and bile acids across the sinusoid-facing membrane 
of the hepatocyte, and transport of bile salts/acids across the canalicular membrane 
(Fig. 1-5).
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Fig. 1-5: Proposed model fo r the hepatic uptake o f  bile acids and bile salts, as reviewed by Swaan 
et al (1996). Conjugated bile salts (CBS) are transported at the sinusoid-facing membrane by a 
Na^-dependent active symporter (107-kDa), and are translocated intracellularly by cytosolic 
proteins (14-kDa, 33-kDa and 45~kDa). A t the sinusoid-facing membrane, unconjugated bile acids 
(UBA) are uptaken by a separate Na^-dependent transporter, and undergo conjugation to glycine or 
taurine within the cell by interaction o f  the enzymes, ligase (Li) and transferase (Tr). Conjugated 
bile salts are then exported across the canalicular membrane via a specific bile salt transporter 
(100-kDa) and a midti-specific organic anion transporter (MS).
Transport of conjugated bile salts across the sinusoid-facing membrane is thought to 
occur via a Na^-dependent carrier mediated symporter (107-kDa), and transport of 
unconjugated bile acids was suggested to occur via a different Na^-dependent carrier 
(Swaan et al, 1996). The conjugated bile acids undergo translocation through the cell 
to the canalicular membrane via the smooth endoplasmic reticulum (SER) and 
cytosolic bile salt-binding proteins, of which thiee have been identified in rat and 
human: glutathione S-transferase (45-50 kDa); Y’ bile salt binder (33-kDa); fatty 
acid-binding protein (14-kDa). Unconjugated bile acids are conjugated with glycine 
or taurine in the cytosol by interaction of a ligase and a transferase, prior to transport
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from the cell. Two separate transporters are involved in the export of bile salts across 
the canalicular membrane. Monovalent bile salts are carried by a specific bile salt 
transporter (100-kDa), whilst dihydroxy bile salts are transported by a multi-specific 
organic anion carrier.
Moreover, a comparison of cDNA coding regions and protein amino acid sequences 
of ileal and liver bile salt transporters in human, rat and hamster has revealed that, 
although similar regions in the carrier polypeptide chains exist, the hepatic and ileal 
bile salt transporters are not identical (Swaan et al, 1996).
1.6.3(vi) Use o f the ileal bile salt ti'ansporter for enhancing intestinal drug delivery 
Structural modifications of bile salts by coupling to poorly absorbable drugs may 
enable the enhancement of intestinal absorption of such molecules, since the bile salt 
is an endogenous chemical structure, recognised by the bile salt active transporter in 
the ileum. The initial interaction between the bile salt and the ileal transporter is 
reported to take place within a hydrophobic space of the enterocyte membrane, and 
involves three steps (Lack, 1979; Lack, Tantawi, Halevy and Rockett, 1984):
(1) interaction of a recognition site on the carrier protein with the steroid nucleus of 
the bile salt.
(2) an electrostatic interaction between the negative side chain of the bile salt and a 
cationic site of the carrier protein.
(3) an interaction of Na' with an anionic site on the carrier protein, located in close 
proximity to the cationic site of the carrier protein.
An account of the necessary characteristics required of modified bile salts in order to 
accomplish active uptake has been produced by Lack (1979); moreover, experimental 
confirmation of these criteria has been reported (reviewed by Kramer and Wess, 
1996).
They are as listed:
(1) at least one axial hydroxyl group (that is, -OH group extended in the direction 
perpendicular to the axis of steroid rings) at position C-3, C-7 or C-12 of the 
steroid nucleus.
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(2) a cis configuration of rings A and B of the steroid nucleus to ensure hydrophobic 
interaction with the transporter (see Figure 1-3 for position of A and B carbon 
rings).
(3) retention of an anionic side chain at position C-17 on the D-ring of the bile salt 
molecule required for electrostatic interaction with the cationic site of the 
transporter. Uptake of a bile salt/acid with a positively charged or neutral side 
chain is markedly attenuated.
The retention of the characteristics of naturally occurring bile salts when producing a 
drug-bile acid conjugate, as far as is possible, appears to be essential for successful 
targeting of such a system for drug delivery.
Ho (1987) carried out liver absorption and biliary excretion studies in situ, as well as 
intestinal perfusion experiments of the jejunum and ileum of the rat, and determined 
that 3-tosyl-cholate and 3-benzoyl-cholate, and 3-iodo-7a,12a-dihydroxycholan-24- 
oate were dealt with in the same way as naturally occurring bile salts. However, 
Kramer and Wess (1996) suggested that this was not unexpected since the 
compounds investigated were bile salt analogues with minor structural modifications, 
rather than drug-bile acid conjugates.
It has been reported that the Caco-2 cell line expresses the ileal bile transporter, and is 
able to transport bile acids unidirectionally from the apical to the basolateral 
membrane (Hidalgo and Borchardt, 1990). Coupling of cholic acid or taurocholic 
acid, at position C-3, with renin-inhibitory peptides (RIPs) resulted in a high affinity 
with the Caco-2 cell bile salt transporter, although bioavailability remained very low 
(Kim, Harrison, Ruwart, Wilkinson, Fisher, Hidalgo and Borchardt, 1993). 
Comparable results were also demonstrated in the perfiised rat ileum, in that the RIP- 
cholic acid conjugate went undetected in blood samples taken from the mesenteric 
vein (Kim et al, 1993). This would seem to indicate that either the translocation of 
the conjugate through the cell or its efflux fi-om the cell was impeded in some way. 
Recently, extensive work carried out by Kramer et al (1994), investigated the 
intestinal absorption of model peptides coupled to the 3-position of modified 3p-(m- 
aminoalkoxy)-7a,12a-dihydroxy~5P-cholan-24-oic acid in the anaesthetised rat. 
Coupling to the 3-position was deemed necessary since a previous study had
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demonstrated that drug-bile acid conjugates with attachment of the drug at this 
position were recognised as natural bile salts by the bile salt transport systems of the 
hepatocytes of the liver (Kramer et al, 1992; Wess et al, 1992). Furthermore, 
additional studies have shown that a negative charge in the side chain attached to C- 
17 of the bile salt molecule, and at least one hydroxyl group in positions 3, 7 or 12 of 
the steroid nucleus are essential for optimal recognition of a bile salt molecule by the 
bile salt carrier systems in the Uver and the ileum (Lack and Weiner, 1967; Anwer, 
O’Maille, Hofmann, Dipietro and Michelotti, 1985; Hardison, Heasley and 
Shellhamer, 1991; Kramer a/, 1993).
The model peptides constructed by Kramer and associates (1994) were composed of 
D-alanine and D-proline, and had 1, 2, 4, 8 or 10 amino acid residues (naturally 
occurring L-amino acids were replaced with D-amino acid residues to prevent 
enzymatic hydrolysis of the peptide backbone; see Section 1.5.3(i)), so that when 
conjugated with the bile acid at C-3, they created side chains of 1, 2, 4, 8 or 10 amino 
acid residues. The interaction between the peptide-bile acid conjugates and the ileal 
bile salt co-transport system was demonstrated by measuring competitive inhibition 
exerted by the conjugate on f  H] taurocholate uptake by rabbit ileal brush border 
membrane vesicles. Peptide-cholic acid conjugates with up to four amino acid 
residues in the peptide side chain were able to inhibit the uptake of [^H] taurocholate 
in a dose-dependent manner. Coupling of eight amino acid residues, however, 
resulted in a significant drop in the affinity for the ileal bile salt transporter, yet it 
remains unclear as to what the critical number of amino acid residues is as to cause 
this loss in affinity.
This study (Kramer et al, 1994) was taken a step further by investigating the ileal 
absorption of a tetrapeptide-bile acid conjugate, S3744, modified with an additional 
fluorescent labelling group in the rat, in vivo. The S3744 conjugate was found to be 
actively transported by the ileal bile salt transporter, while neither the parent peptide 
(SI037) nor its /-butylester (S4404) appeared in bile. The transport profile of S3744 
into bile was comparable to that of a natural bile salt. Additionally, competitive 
inhibition of uptake of ^ [Hjtaurocholate provided further evidence of the involvement 
of carrier-mediated transport.
The results of this extensive study demonstrated that targeting the intestinal bile salt 
carrier is a possible approach to facilitate the uptake of otherwise poorly absorbable
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molecules. The review by Kramer and Wess (1996) suggested that for successftil 
absorption of the drug-bile acid conjugate, the side chain at C-17 should remain 
untouched, and the drug moiety should be attached to the steroid nucleus, preferably 
at C-3. In addition, since the intact peptide-bile acid conjugate was excreted by the 
liver into bile (Kramer et al, 1994), it would appear that successful oral delivery of the 
intact peptide into the systemic circulation depends, at least in part, on the release of 
the peptide before it reaches the liver, perhaps by hydrolysis of the bond between the 
bile salt and the peptide, or by diminished affinity of the analogue for the hepatic bile 
salt transporter.
1,7 Objectives of the present study
The encouraging outcome of the study by Kramer and associates (1994), in which 
model peptides coupled with cholic acid demonstrated a high affinity for the ileal bile 
salt transporter with a similar transport profile to natural bile salts, demonstrates the 
practicability of this approach to the facilitation of peptide absorption. However, 
although conjugation with bile salts seemed to reduce the barrier to permeation, the 
work of Kramer et al (1994) did not involve the coupling of biologically-active 
peptides, and as such, there was little indication as to whether the peptide moiety 
would retain its bioactivity. Indeed, Km  et al (1993) reported the veiy low 
bioavailabilty of renin-inhibitory peptides coupled with cholic acid, even though a high 
affinity with the ileal bile acid transporter was demonstrated.
In the present study, we wished to expand on the work of Kamer and colleagues, by 
couphng of a biologically-active peptide with a bile acid, in an attempt to determine 
the viability of such a compound in oral drug delivery. While Kamer and Wess 
(1996) maintained that successful utilisation of the active bile salt carrier may only be 
achieved if the peptide moiety is attached to the steroid nucleus (preferably at C-3), 
and the bile acid side chain at C-17 remains unmodified, we were of the view that 
coupling of the peptide to the bile acid at the site where glycine or taurine naturally 
attach may be a viable alternative. Cholic acid (3a, la ,  12a-trihydroxy-5(3-cholan- 
24-oic acid) was selected as the bile acid since it has been established that, along with 
chenodeoxycholic acid, it is the most frequently encountered bile acid in man and the 
rat (Weiner and Lack, 1967). The peptide to be conjugated with cholic acid needed 
to be of relatively small size, at least for preliminary experiments, and measurable with
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a reliable assay. To this end, we decided upon tetragastrin, a peptide comprising the 
carboxy-terminal four amino acid residues (tryptophan-methionine-aspartate- 
phenylalanine amide) of gastrin. Using the stomach-perfused rat model, we were able 
to assess the ability of our “drug” in permeating the small intestinal wall and entering 
the systemic circulation by measurement of the increase in gastric acid secretion. A 
detailed review of the actions of gastrin on gastric acid secretion thus follows.
1.8 Gastric Acid Secretion
1.8.1 Regions of the stomach
The stomach may be divided into four distinct regions: the cardia; the ftindus; the 
body and the antrum (Fig. 1-6), although veiy often, for convenience of notation, a 
distinction is only made between the fundus and the antrum.
Oesophagus
Pylorus BodyDuodenal
bulb
Duodenum'
Fig. 1-6: The major anatomical subdivisions o f  the stomach
The gastric mucosa consists of a columnar epithelium with numerous pits (a recent 
description is provided by Kutchai, 1998). Opening into these are various types of 
glands depending on the region of the stomach in which they are located. Within the 
gastric mucosa of the cardia, mucous secreting cells open into each pit. The glands 
opening into the pits located in the fundus and body are, however, of a more complex 
nature (Fig. 1-7). Located here are the gastric glands which, in addition to mucous 
secreting cells, contain parietal (or oxyntic) cells involved in gastric acid secretion, 
and chief (or peptic) cells which secrete pepsinogens. Gastric glands are absent from 
the antrum; however, present in the antral pits are chief cells, and G cells which, in 
adult mammals, are involved in the release of the gastrointestinal hormone, gastrin. A
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general overview of the structure of the gastric mucosa can be found in Lloyd and 
Debas (1994).
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F[g. 1-7: Structure o f  the gastric gland, present in the fundus and body o f  the stomach. Solid 
symbols denote cell nuclei, and small open symbols denote vesicles.
1.8.2 Secretion of gastric acid - morphological changes
As has been previously stated, the parietal cells of the fundus and body of the stomach 
are involved in gastric acid secretion, the rate of which, in humans, ranges from 
between 1.0 and S.OmEq hf^ during basal secretion (Worrasley and Grossman, 1965) 
to between 6.0 and 40.0mEq hr'  ^at maximal stimulation (chapter by Kutchai, 1998). 
Discernible changes in the morphology of parietal cells accompanying gastric acid 
secretion were first observed by Camillo Golgi in 1895. More recent ultrastructural 
studies have shown that, at rest, the cell is characterised by numerous mitochondria, a 
network of tubovesicles, and an internalised intracellular canaliculus (Ito, 1987). 
Studies using electron microscopic radioautography have demonstrated that the 
canaliculi, as opposed to secretory granules, are the site of initiation of acid secretion 
(Sekiguchi, Nagaya, Satoh and Shino, 1992; Scott, Helander, Hersey and Sachs,
1993). Stimulation of the parietal cell results in the fiïsion of tubovesicles with the 
plasma membrane, by rearrangement of the cellular cytoskeleton, thereby opening the 
cell into the lumen of the gland (Ito, 1987). In humans, HCl is secreted into the 
gastric lumen in concentrations of up to 150mM, equivalent to a million fold 
concentration ofH  ions (Nordgren, 1963).
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1.8.3 Secretion of gastric acid - cellular mechanisms
The mechanism of acid secretion is well documented, the current view being as 
follows. The process depends primarily on the presence of an KT/K  ^ATPase located 
in the apical membrane of the parietal cell (Rabon and Reuben, 1990), and has an 
absolute dependence on oxygenation, as reflected by the large mitochondrial content 
of the cell; glycolysis is unable to support acid secretion (see Sachs (1994) for a 
review). The carrier protein extrudes fT ions fl"om the cytosol of the parietal cell into 
the canaliculus (and then into the lumen of the gastric gland) in exchange for the entry 
of ions. An intracellular build up of ions does not arise since the mucosal 
membrane is highly permeable to ions which permeate back into the lumen. The 
removal of HT ions from the cell by the FTfiC  ATPase results in an increase in HCO3" 
ions within the cytosol. In essence, the production of iT  and HCO3' ions arises from 
the dissociation of carbonic acid (H2CO3), formed by combination of CO2 and H2O; 
the reaction is catalysed by carbonic anhydrase (CA) which is closely associated with 
the canalicular membrane (Cross, 1970). Regulation of intracellular pH is achieved by 
a ClVHCOs" countertransporter located on the basolateral membrane, which removes 
HCO3" ions from the cell. Cf ions move into the cell, via the exchanger, down their 
electrochemical gradient, and subsequently pass into the lumen of the gland via an 
electrogenic anion channel situated on the apical membrane (general overview by 
Kutchai, 1998). The movement of Cl' ions thus preserves electroneutrality while the 
movement of water subsequent to ion transport preserves isosmolality. The result is a 
secretion of 150mM HCl solution. Intracellular pH is also maintained by the activity 
of a second exchange protein, the Na^/lC countertransporter, located on the 
basolateral membrane which normally ejects ions in exchange for entry of Na^ 
ions. The activity of this exchanger is diminished during stimulated gastric acid 
secretion. A summary of the main processes involved is illustrated in Figure 1-8.
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BASOLATERAL GASTRICMEMBRANE LUMEN
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Fig. 1-8: Simplified representation o f  the major ionic transport processes involved in the secretion 
o f  i f  and c r  o f  the parietal cells o f  the stomach. {CA denotes the enzyme, carbonic anhydrase; 
open circles denote facilitated transport; filled  circles (labelled ATP) denote energy dependent 
transport processes.)
1.8.4 Gastric bicarbonate secretion
The existence of a gastric alkaline secretion was documented in the 1950s when 
Grossman (1959) demonstrated the secretion of HCOs' ions from a canine antral 
pouch, in which parietal cells were absent. Hollander (1963) further described a 
similar secretion from the denervated fundal pouch of the dog, following instillation of 
acetylcholine or lodoacetamide. Although the results demonstrated that, on the 
whole, the concentration of secreted HCOs' ions was less than that of interstitial fluid, 
Hollander suggested that mixing with the parietal acid secretion would result in 
neutralisation and dilution of this secretion. In 1966, Makhlouf and McManus 
proposed a two-component model for gastric secretion, in which they referred to 
gastric acid secretion as the parietal component. In addition, another secretion was 
described, which had a composition similar to that of interstitial fluid with the 
exception that and HCO3" ions were higher in concentration. This was thouglit to 
arise from the chief cells and the mucous secreting cells of the gastric mucosa, giving 
rise to the non-parietal component. The rate of HCO3 secretion increases in the 
presence of acid in the gastric lumen (review by Flemstrom, 1994), such that the 
maximal rate of secretion is 10% that of maximal HCl secretion (Kutchai, 1998) and, 
furthermore, studies on the guinea pig stomach have demonstrated potentiation of 
HCO3 secretion by release of acetylcholine from the vagus nerves (Garner and 
Flemstrom, 1978).
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The release of bicarbonate, along with mucus secretion, is considered to act as a 
protective buffering mechanism against the potentially harmful effects of acid in the 
gastric lumen (Gamer and Flemstrom, 1978). However, this is a topic under debate; 
following studies on canine chief cells in culture (Sanders, Ayalon, Roll and Soil, 
1985), Machen and Paradiso (1987) proposed that protection arises predominantly 
from the low permeability of the apical membrane of epithelial cells to H^, rather than 
from buffering by an alkaline mucous barrier.
1.8.5 Control of gastric acid secretion
The three principal effectors of gastric acid secretion are gastrin, histamine and 
acetylcholine (as reviewed by Wood, 1987). Both gastrin and histamine act directly 
on specific receptors situated on the parietal cell to stimulate acid secretion but, in 
addition, studies on the dog (Chuang, Tanner, Chen, Davidson and Soli, 1992) and 
the rat (Lloyd, Raybould, Taché and Walsh, 1992) have demonstrated that gastrin 
may also exert its effect indirectly by stimulating the release of histamine. 
Acetylcholine, released fi-om vagal nerve varicosities, activates a specific receptor on 
the parietal cell to initiate the extrusion of H  ^ ions (described by Lloyd and Debas,
1994). Also, the release of another neurotransmitter, gastrin releasing peptide (GRP), 
from the vagi results in the stimulation of G cells to release gastrin (review by 
Bunnett, 1994). GRP, isolated fi-om the stomach and intestine of the pig (McDonald, 
Jornvall, Nilsson, Vagne, Ghatei, Bloom and Mutt, 1979), was discovered to have a 
remarkable similarity to the peptide, bombesin (discovered in extracts prepared from 
the skin of two European amphibians (genus Bombina) in 1970 by Erspamer, 
Erspamer and Inselvini). Bombesin, a peptide with 14 amino acid residues, shares 9 
out of 10 of its carboxy-terminal residues with GRP, which is now regarded as the 
mammalian counterpart of bombesin (as reviewed by Bunnett, 1994).
The role played by gastrin in the regulation of gastric acid secretion is of most 
relevance to this project and, thus, will be discussed in more detail.
1.9 Gastrin
The role of gastrin is summarised in most physiology textbooks, and an extensive 
account has been written by Walsh (1994). Gastrin is a gastrointestinal hormone 
secreted by the G cells of the antrum of the stomach. It was discovered in 1905 by
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Edkins, who proposed that digested food components caused the release of a 
substance which stimulated gastric acid secretion. However, the actions of gastrin 
were demonstrated unequivocally by Grossman, Robertson and Ivy only in 1948. 
They reported increased secretion, in the dog, of gastric acid from a transplanted 
frindal pouch in response to distension of a denervated antral pouch. So, the 
possibility of mediation by a neural mechanism was ruled out, and the existence of a 
circulating stimulant released from the gastric antrum was implicated. The outcome 
of this experiment, along with the results of a study by Komarov (1938), in which it 
was determined that a non-histaminergic substance of antral origin elicited gastric acid 
secretion when intravenously injected into cats, confirmed the existence of gastrin.
1.9.1 Chemical structure
Establishment of the amino acid sequence of gastrin (Gregory, Hardy, Jones, Kenner 
and Sheppard, 1964) followed the isolation and purification of gastrin from porcine 
gastric mucosa (Gregory and Tracy, 1964). A synthetic replicate of the peptide 
isolated from the gastric antrum (Anderson, Barton, Gregory, Hardy, Kenner, 
MacLeod, Preston, Sheppard and Moriey, 1964) was reported to have similar 
biological properties to the natural hormone (Gregory and Tracy, 1964; Moriey, 
Tracy and Gregory, 1965). Isolation of gastrins from many animal species has been 
achieved (review by Walsh, 1994); it has been established unequivocally that 
mammalian gastrins share in common the carboxy-terminal tetrapeptide amide 
sequence, tryptophan-methionine-aspartate-phenylalanine amide. This has been 
shown to be the active site of the peptide and is required for the full expression of the 
biological activity of gastrin (Moriey, Tracy and Gregory, 1965). For this reason, 
synthetic pentagastrin (containing the terminal 5 amino acid residues of gastrin) is 
often used in clinical tests, since it is easier to synthesise than the full molecule.
The application of radioimmunoassay (RIA) has allowed measurements of circulating 
gastrin levels to be recorded. This was first achieved for gastrin in 1968 by 
McGuigan and Trudeau who reported resting levels in fasted human subjects (with no 
known gastrointestinal disorder) of between 245 and 668pg mf^ of plasma. 
However, over the following two years, documented resting levels of gastrin have 
been much lower; one study reported levels of between 5 and 290pg mf^ (Hansky and 
Cain, 1969), and another suggested levels in control human subjects were no higher
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than 300pg (Yalow and Berson, 1970). Hansky and Cain proposed that the 
disparity between the initial report and their study could be accounted for by 
differences in vagal tone. Later, in the early 70s, reported levels fell further such that 
mean values of 71pg ml^ (McGuigan and Trudeau, 1973) and 44pg ml"^  (Straus, 
Gerson and Yalow, 1974) were announced. However, with advances in RIA enabling 
improved sensitivity, resting levels of gastrin greater than 20pg ml'^  are only 
considered to occur in approximately one quarter of subjects with no apparent 
gastrointestinal disease (reviewed by Straus, 1978).
Several forms of gastrin exist. Following the isolation of two heptadecapeptide 
gastrins (G17) (both composed of 17 amino acid residues but in which the tyrosine at 
position 6 was sulphated or non-sulphated) from porcine antral mucosa (Gregory and 
Tracy, 1964), further studies have established the existence of different forms of 
gastrin in a variety of species. The presence of gastrin heptadecapeptides and 
hexadecapeptides in a number of mammals such as the dog (Bonato, Eng, Hulmes, 
Miedel, Pan and Yalow, 1986), cat (Agarwal, Kenner and Sheppard, 1969), sheep 
and cow (Agarwal, Beacham, Bentley, Gregory, Kenner, Sheppard and Tracy, 1968), 
in addition to human (Bentley, Kenner and Sheppard, 1966) and rat (Reeve, Dimaline, 
Shively, Hawke, Chew and Walsh, 1981) has been documented (Fig. 1-9).
man Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe 
pig Glu-Gly-Pro-Trp-Met-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe 
cow Glu-Gly-Pro-Trp-VaLGlu-Glu-Glu-Glu-Ala-Ala-Tyr-Gly-Trp-Met-Asp-Phe 
rat Glu-Arg-PrO“Pro-Met-Glu-Glu-Glu-GlU“Glu~Ala-Tyr-Gly-Trp-Met-Asp-Phe 
dog Glu-Gly-Pro-T rp-Met-Glu-Glu-Ala-Glu-Glu-Ala-T yr-Gly-T rp-Met~ Asp-Phe
Fig. 1-9: Gastrin heptadecapeptide (G17) structures in man, pig, cow, rat and dog. Amino acid 
residues are indicated by conventional three letter codes. Amino acid residues in bold denote 
structural differences compared with human G17. Phe (phenylalanine) is present as amide. (Taken 
fi'om Andersen, 1985).
Sequences were subsequently reported for pig and human which showed the presence 
of another species of gastrin, “big gastrin”, a dimer of G17 containing 34 amino acid 
residues (G34) (Gregory and Tracy, 1975). However, it has since been shown that in 
the mammalian species studied (humans, cows, sheep, pigs, dogs, cats, rats, rabbits, 
guinea pigs, mice), only about 5% of gastrin was G34 (Andersen, 1985). This
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confirms the work of Berson and Yalow (1971), who determined that, in man, more 
than 90% of antral gastrin is G17. In the guinea pig, a form of big gastrin has been 
reported which differs fi-om pig G34 in 6 of the 17 NHi-terminal amino acids, as well 
as in the deletion of a glutamic acid in the carboxy-terminus; it is therefore referred to 
as G33 (Bonato, Eng, Pan, Miedel, Hulmes and Yalow, 1986). Furthermore, it was 
discovered that human duodenum and antrum contain very similar amounts of gastrin 
activity. By contrast, in other species including the dog and the pig, approximately 
98% of gastrin is found in the antrum (Nilsson, Yalow and Berson, 1973). Support 
for this comes from Feurle, Menzel and Klempa (1983), who determined that, in the 
dog, less than 4% of circulating gastrin was contributed to by the duodenum. The 
potency for the stimulation of gastric acid secretion in response to either G34 or G17 
in man is very similar (Eysselein, Maxwell, Reedy, Wünsch and Walsh, 1984); 
however, the half-time clearance rates for G17 and G34 differ considerably. The 
clearance rate of G17 fi'om the human circulation is approximately six minutes, 
whereas that for G34 is about six times longer (Walsh, Debas and Grossman, 1974; 
Walsh, Isenberg, Ansfieid and Maxwell, 1976).
1.9.2 Gastrin release
In the stomach, gastrin is released fi'om antral G cells, which are found distributed 
with enterochromaffin, mucus-containing and somatostatin-containing D cells. G 
cells are open type endocrine cells which are thought to sample luminal contents at 
their apical membrane (in chapter by Lloyd and Walsh, 1994).
There are three phases of gastric acid secretion, in which gastrin plays a major role. 
These are the cephalic, gastric and intestinal phases.
1.9.2(i) Cephalic phase
This refers to the period prior to food reaching the stomach, whereby acid secretion is 
enhanced simply by the thought, taste, smell, sight and swallowing of food. This 
response is mediated entirely by the vagus nerves (Pe Thein and Schofield, 1959), by 
way of direct cholinergic stimulation of the parietal cell, and by non-cholinergic 
(GRP-induced) release of gastrin from the G cells (as summarised by Lloyd and 
Walsh, 1994). During the cephalic phase, the rate of acid secretion may be as high as 
40% of the maximal rate. However, in the absence of the buffering effect of food with
43
Introduction
the resultant inhibition of activation of gastrin release elicited by low pH in the 
antrum, the actual amount of secreted acid is small (chapter by Kutchai, 1998).
1.9.2(ii) Gastric phase
Gastric acid secretion during this phase occurs in response to both distension of the 
stomach, and through the actions of partially digested proteins (peptides and amino 
acids) on the antral mucosa to cause gastrin release (Taylor, Byrne, Christie, Ament 
and Walsh, 1982; McArthur, Isenberg, Hogan and Dreier, 1983). The most potent 
effectors are the aromatic amino acids, tryptophan and phenylalanine (Taylor et a/, 
1982). Distension of either the body or antrum of the stomach results in the 
stimulation of mechanoreceptors in the gastric wall, and subsequent elicitation of a 
vago-vagal reflex. This is characterised by excitation of afferent vagal fibres from the 
stomach which pass to the nucleus of the tract solitarius in the medulla oblongata. A 
neural projection from here to the dorsal vagal nucleus, and subsequent excitation of 
pre-ganglionic fibres, results in the release of acetylcholine from post-ganglionic vagal 
fibres in the gastric mucosa. Acetylcholine acts on the parietal cell, both directly and 
indirectly through stimulation of gastrin release from G cells (see chapter by Kutchai, 
1998). Although GRP plays a part in the cephalic phase of acid secretion, it does not 
appear to play any significant role in distension-induced gastric acid secretion 
(Kovacs, Lloyd, Miller, Coy and Walsh, 1989). More recently, a study has 
documented the involvement of vasoactive intestinal peptide (VIP) in gastrin 
secretion induced by gastric distension in the rat (Schubert and Makhlouf, 1993). 
Low distension resulted in a decrease in gastrin release and increased somatostatin 
release, whereas high distension enhanced gastrin release and reduced somatostatin 
release. Moreover, administration of atropine had no effect on the response to low 
distension, but caused reversal of the response to high distension, that is, gastrin 
release was reduced and somatostatin release increased. VIPergic neurones are 
activated in response to both low and high distension. However, in the presence of a 
selective VIP antagonist, both the gastrin and the somatostatin response to low 
distension were abolished. The authors concluded that VIP neurons were activated 
by low distension; VIP stimulates somatostatin release which subsequently inhibits the 
release of gastrin. As distension increased, progressive recruitment of cholinergic 
neurons resulted, and consequently, gastrin release increased.
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The interactions between gastrin and vagal stimulation are of considerable significance 
since gastric acid secretion in response to gastrin is markedly potentiated by the basal 
secretion of acetylcholine in an innervated (Pavlov) pouch, when compared to that in 
a denervated (Heidenhain) pouch (Andersson and Grossman, 1965) (Fig. 1-10).
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Fig. 1-10: Synergistic effect o f  vagal innervation on gastrin, as demonstrated by comparison o f  the 
responses to exogenous gastrin (i.v.) in the Pavlov pouch (innervated) (P-P) and the Heidenhain 
pouch (denervated) (H-P) in the dog. (Taken from Andersson and Grossman, 1965).
Gastrin accounts for most of the acid secreted in response to luminal peptides and 
amino acids, as determined in a study measuring circulating concentrations of gastrin 
in response to graded increases in intragastric concentrations of peptones (Maxwell, 
Eysselein, Kleibeuker, Reedy and Walsh, 1984).
Other chemical components that cause release of gastrin and enhance gastric acid 
secretion in man include decaffeinated coffee (Feldman, Isenberg and Grossman, 
1981) (Wright, Gibson and Hirschowitz (1977) have demonstrated that caffeine itself 
does not evoke gastrin release) and fermented alcoholic beverages (not distilled) 
(Lenz, Ferrai i-Taylor and Isenberg, 1983; Singer, Teyssen and Eysselein, 1991; 
Teyssen, Lenzing, Gonzalez-Calero, Korn, Riepl and Singer, 1997). The stimulation 
of gastrin release by fermented alcoholic beverages has been additionally shown in 
rats (Teyssen, Gonzalez-Calero, Korn and Singer, 1997).
1.9.3(iii) Intestinal phase
This is elicited by the presence of chyme in the duodenum, which brings about neural 
and endocrine responses which in the first instance stimulate but, later, inhibit gastric 
acid output (chapter by Kutchai, 1998).
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Stimulation of secretion occurs through distension of the duodenum, and by the 
presence of peptides and amino acids. Distension-induced secretion occurs by way of 
a vago-vagal reflex in much the same way as mechanical stimulation of the stomach, 
whereas chemical stimulation occurs by way of duodenal and jejunal G cell activation. 
A study by Ayalon, Devitt, Guzman, Suddith, Rayford and Thompson (1982), 
whereby 10% liver extract was instilled into the duodenum and proximal jejunum of 
dogs with innervated antral pouches, reported significantly increased levels of gastrin 
in both gastric venous blood and systemic blood. This lends support to the idea that 
chemical stimulation causes gastrin release during the intestinal phase.
Kosaka and Lim (1930a) established that lipid in the small intestine of the dog caused 
antagonism of gastric secretion by the release of inhibitory substances. In addition to 
luminal lipid, acid, hyperosmolar solutions and elevated intraluminal pressure within 
the intestinal lumen are implicated in the inhibition of gastric acid secretion. The 
substances responsible for inhibition of acid secretion have still not been fully 
established, and are thus referred to as enterogastrones (as derived by Kosaka and 
Lim, 1930b). Peptide YY is likely to be one mediator since plasma concentrations of 
peptide YY in the circulation increase significantly in response to a meal (Taylor, 
1985). Moreover, peptide YY is released from the small intestine in response to lipid 
perfusion of the distal small intestine in dogs (Aponte, Fink, Meyer, Tatemoto and 
Taylor, 1985), and administration of exogenous peptide YY, in doses that mimic 
plasma levels after a meal, results in inhibition of gastric acid secretion (Pappas, 
Debas and Taylor, 1986).
The presence of acid in the duodenum is thought to inhibit gastric acid secretion 
through release of secretin (as summarised by Lloyd and Debas, 1994), although 
inhibition of gastric acid secretion has not always been reproduced by infusion of 
exogenous secretin in physiological doses (Kleibueker, Eysselein, Maxwell and 
Walsh, 1984).
To further complicate matters, a study by OrlofiF, Bunnett, Wong, Walsh and Debas 
(1991), investigating the neural and hormonal mechanisms involved in the 
enterogastric reflex, proposed that somatostatin and CCK were the principal 
enterogastrones. CCK is a gastrointestinal hormone with an amidated carboxy- 
terminal pentapeptide identical to that of gastrin. CCK, thus, possesses some gastrin­
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like attributes, although with considerably less potency, and may thus act as a 
competitive inhibitor of gastrin (for full review consult Liddle, 1994).
Thus, one mediator of the enterogastrone reflex appears to be peptide YY; in 
addition, secretin, CCK and/or somatostatin may also play a role. However, the need 
for fiirther work in this field is apparent.
1.9.4 Mechanism of gastrin-induced gastric acid secretion
Two separate mechanisms for the activation of gastric acid secretion by gastrin have 
been proposed by Code (1965) and by Grossman (1967). In the former, gastrin was 
hypothesised to act by stimulating the release of histamine fi’om enterochromaffin-like 
(ECL) cells, which subsequently acts on the parietal cells. In the latter, the direct 
activation of the parietal cells by gastrin to stimulate gastric acid secretion, was 
proposed.
1.9.4(i) Histamine as the final common mediator
It was suggested that gastrin may act to induce gastric acid secretion by stimulating 
the release of histamine from ECL cells of the stomach. Subsequent activation of the 
parietal cells by histamine follows (Chuang, Chen and Soli, 1991), mediated by 
increased levels of intracellular adenosine 3 '-5 '-cyclic monophosphate (cAMP) (Soil 
and Wollin, 1979). Endorsement of the view that histamine may be a final common 
mediator has come from a number of studies: histamine is in wide abundance in 
gastric tissue (Lonroth, Hakanson, Lundell and Sundler, 1990); administration of 
histamine receptor antagonists in rats attenuated the acid stimulating effect of gastrin, 
as well as that of liistamine (Lloyd et al, 1992); gastrin has been implicated in the 
regulation of the expression and activity of histidine carboxylase, the enzyme 
responsible for the production of histamine (Dimaline and Sandvik, 1991). These 
studies thus indicate that gastrin-induced gastric acid secretion may be mediated 
through the action of histamine on the parietal cell.
1 9.4(ii) Direct action o f gastrin on the parietal cell
The alternative view is a direct action of gastrin on the parietal cells, with no 
involvement of histamine. Synergism between the activities of gastrin and histamine 
in the enhancement of gastric acid secretion in the dog has been demonstrated
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(Andersson and Grossman, 1965), which is consistent with the concept that the action 
of gastrin on the parietal cells occurs by mediation of intracellular pathways separate 
from those mediating the effect of histamine. The apparent inhibition of the response 
to gastrin in the presence of histamine receptor antagonists (Lloyd et al, 1992) 
presumably reflects withdrawal of histamine enhancement of gastrin action (Soil, 
1978a; Soil, 1982).
In an investigation aimed at resolving whether gastrin acts through histamine release, 
Blair (1966) reported that, in anaesthetised cats, neither the histamine output in 
gastric washings nor the histamine concentration in gastric venous blood, following 
gastrin-stimulated secretion of gastric acid, increased to the level which occurred 
when histamine caused the same level of gastric acid secretion. Subsequent studies 
using radioligand binding (Soil, Amirian, Thomas, Reedy and Elashoff, 1984), and 
mammalian cell culture techniques (Soil, 1978a; 1978b; 1980), in addition to fiirther 
reports of the potentiation existing between gastrin and histamine (Soli, 1978a; Soil 
and Grossman, 1981) have established a direct action of gastrin on the parietal cell, 
and it is now generally accepted that histamine release from ECL cells and direct 
parietal cell stimulation are both separate physiological actions of gastrin. The 
mechanism by which gastrin induces its direct action is described more fully below. 
Gastrin enhances acid secretion by binding to receptors, denoted as CCK-B, on the 
parietal cell, initiating a series of cascade events (Fig. 1-11). (Acetylcholine, through 
the activation of muscarinic receptors on the parietal cell membrane, initiates a similar 
series of events.) Occupation of the receptor on canine, porcine or guinea pig parietal 
cells activates a membrane-bound enzyme, phospholipase C (PLC), which catalyses 
the breakdown of phosphatidylinositol 4,5-bisphosphate (PIP2) into two components, 
inositol trisphosphate (IP3) and diacylglycerol (DAG). Ca^  ^release from intracellular 
stores, and influx of extracellular Ca^ ,^ by the action of IP3, results in increase levels 
of free intracellular calcium. DAG, accompanying these increased Ca^  ^ levels, 
stimulates the translocation of protein kinase C (PKC) from the cytoplasm to the cell 
membrane, where it is activated (Chiba, Fisher, Park, Seguin, Agranoff and Yamada, 
1988; Tsunoda, Takeda, Otaki, Asaka, Nakagaki and Sasaki, 1988; Tsunoda, Takeda, 
Asaka, Nakagaki and Sasaki, 1988; Tsunoda, Yodozawa and Tashiro, 1989; Cabero, 
Rehfeld and Mardh, 1989; Del Valle, Tsunoda, Williams and Yamada, 1992). 
Phosphorylation of proteins (which are still to be elucidated, but may involve the
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HT/K  ^ATPase) by PKC occurs, and the result is an increase in gastric acid production 
(as reviewed by Yamada, Chiba, Del Valle and Campbell, 1993).
CCK-B
PIP.
padetal cell 
membraneDAG PLC PKC
Fig. 1-11: Proposed mechanism o f  gastrin-induced gastric acid secretion. G, gastrin; CCK-B, 
gastrin receptor; PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-biphosphate; DAG,
diacylglycerol; IP3, inositol trisphosphate; PKC, phosphokinase C.
1.10 Rationale of the present study
The tetrapeptide of gastrin containing the terminal four amino acids (called 
tetragastrin) was the hormone chosen for transport across the small intestine. In these 
experiments, gastric acid levels were measured in the fasted anaesthetised rat, in vivo, 
as a bioassay for the levels of tetragastrin in the bloodstream.
The first step in the present study was therefore the synthesis of the tetragastrin-cholic 
acid conjugate (G-CA), whereby tetragastrin was coupled at the C-24 position of 
cholic acid. Subsequently, the purity of this compound needed to be determined, and 
its biological activity confirmed.
As a prelude to the main experiments investigating the intestinal absorption of G-CA, 
it was necessary to carry out control experiments to test whether there was ileal 
absorption of tetragastrin, per se. This could then be compared with the results from
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the experiments with G-CA to determine the extent to which the conjugation of 
tetragastrin with cholic acid enhanced absorption. Additionally, it would be necessary 
to investigate the site specificity of the response by testing the transmucosal 
absorption of G-CA across the jejunal wall. This would provide an indication of 
whether the ileal bile salt transporters were being utilised.
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M eth o dS 
2.1 Physiological experiments
Experiments were carried out on 86 anaesthetised male Wistar rats with body weights 
of between 250 and 350g. The rats were starved overnight but had access to a 5% 
glucose drink. The duration of the experiments during which gastric secretions were 
collected ranged between 300 and 675 minutes.
2.1.1 Surgical procedures 
2.1.1(i) Anaesthesia
Anaesthesia was induced with an IP . injection of sodium pentobarbitone (Sagatal, 
Rhone Merieux, Dublin; 80mg kg‘^ ). The criterion for anaesthesia was abolition of 
the hind limb flexor withdrawal reflex. Subsequently, routine administration of 0.1ml 
sodium pentobarbitone (IM .) was carried out every hour in order to maintain the 
level of anaesthesia. In the event of return of the flexor withdrawal response, 
anaesthesia was restored promptly with 4% halothane (May and Baker Ltd., 
Dagenham) in oxygen (1 litre min'^), and an additional injection of 0.1ml sodium 
pentobarbitone (IM .) was made. Once the venous cannula had been inserted, return 
of the withdrawal response was abolished by intravenous injection of 0.1ml sodium 
pentobarbitone (allowing for dead space in the cannula and tap),
2.1.1 (ii) Tracheal and blood vessel cannulations
Tracheostomy was carried out on each rat to allow for artificial ventilation if required 
(using the Harvard rodent ventilator, 100% oxygen, stroke of 1.0ml 100g‘\  rate of 
60ml min'^). The carotid artery was cannulated with a cannula (Portex, 1.02mm outer 
diameter, pink luer) containing 2% heparin (Multiparin, CP Pharmaceuticals Ltd., 
Wrexham) in isotonic saline. This was connected to a transducer and amplifier which 
led to a Lectromed 4 chart recorder, allowing blood pressure to be monitored. The 
external jugular vein was then cannulated with a cannula (Portex, 0.75mm outer 
diameter, blue luer) containing 2% heparin in isotonic saline to allow for the slow 
bolus infusion of drugs, which was done over a period of l.Omin.
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2.1.1 (iii) Gastric cannulation
A midline incision of the abdominal wall was made from the xiphoid cartilage to 5cm 
caudally. The oesophagus was tied off at the oesophago-gastric junction to prevent 
reflux of the gastric contents. This also effected a bilateral vagotomy since the vagus 
nerves passed over the oesophagus at this point. Care was taken to prevent occlusion 
of the left gastric vein running alongside the oesophagus. A small incision was made 
in the duodenum near the pyloro-duodenal junction, and a perforated polythene 
stomach tube (outer diameter of 3.0mm) was inserted into the stomach. This was tied 
firmly in place, and a mosquito clip was used to close the abdominal wall around the 
stomach tube. A thermometer was inserted into the rectum, and body temperature 
was maintained between 35 and 37°C using two external tungsten lamps.
The stomach contents were washed out by infusion and withdrawal, via the perforated 
stomach tube, of 1.0ml glycine/mannitol buffer (see Section 2.1.2 for composition). 
When the washouts were clear, a perforated cannula (Portex, 1.65mm outer diameter, 
red luer) was pushed into place within the stomach tube, and a 2-way tap was inserted 
into the end of the cannula. The stomach tube was supported in the upright position 
with a clamp. Figure 2-1 illustrates the experimental set-up.
2.1.1 (iv) Ileal catmulation
When drugs were to be administered into the ileum, just prior to ileal infusion, a small 
incision was made close to the ileo-caecal junction, and a short length of cannula 
(Portex, 1.65mm outer diameter, red luer) inserted in the orad direction, such that 
drugs would be infiised towards the proximal small intestine. This cannula was tied 
firmly in place.
2.1. l(v) Jejunal cannulation
In the case of jejunal drug administration, a small incision was made close to the 
ligament of Treitz, and a short length of cannula (Portex, 1.65 mm outer diameter, red 
luer) was inserted in the aboral direction such that drugs would be infused distally. A 
further ligature was tied in place, 15cm distal to the jejunal cannula, ensuring that 
absorption fi*om the jejunum and not the ileum was being investigated.
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Fig. 2-1: Schematic representation o f  the experimental set-up for the collection o f  gastric acid 
secretions in the anaesthetised rat.
2.1.2 Composition of glvcine/maiuiitol buffer 
This was made up as follows:
1 part glycine (0.3M) (AnalaR)
4 parts D-mannitol (0.3M) (Sigma Chemical Co., M-9647)
The pH of the buffer was adjusted to 6.5 by addition of NaOH (TOM).
2.1.3 Substances administered in vivo
The following substances were used in the physiological experiments
• Trp-Met-Asp-Phe amide (tetragastrin), 99% peptide content (Sigma Chemical Co. 
T-6515).
• Cholate-Trp-Met-Asp-Phe amide conjugate (G-CA) (synthesised de novo using 
Pioneer Peptide Synthesis System, PerSeptive Biosystems (see Section 2.3)).
• Glycocholic acid (N-[3a, 7a, 12a-trihydroxy-24-oxocholan-24-yl] glycine) (Sigma 
Chemical Co G-7132).
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Both tetragastrin and G-CA were stored in anhydrous form at less than 0°C until 
required. The doses are expressed in terms of weight of peptide per body weight, viz. 
|ig kg‘\
2.1.4 Measurements
2.1 4(i) Measurement ofpH  o f gastric secretions
Gastric secretions were collected over 15 minute periods. Initially, 1.0ml 
glycine/mannitol buffer (pH adjusted to 6.5) was injected into the stomach via the 
stomach tube; this was withdrawn after 15 min, and replaced with 1.0ml fresh buffer 
at 37°C. The volume withdrawn was noted, and the pH of the sample measured 
immediately. The pKa of the buffer was 3.5, and so any H^ secretion was readily 
detectable as a fall in the pH of the sample from pH 6.5. The sample was titrated 
directly to pH 6.5 with lOOmM or lOmM NaOH, as appropriate, using a precision 
lOOpl syi'inge and continuous stirring. The volume of NaOH required to do this was 
noted, and conversion of this volume into mequiv. HCl was then carried out. As a 
precaution, the NaOH solutions were stoppered at all times to prevent the absorption 
of CO2, and the concentration was checked daily by titration against a precise HCl 
standard.
2.1 4(ii) Measurement o f blood pressure
The blood pressure of each animal under investigation was routinely recorded 
throughout the experiments, thereby allowing us to constantly monitor its condition. 
This was of particular importance in the experiments in which an absence of biological 
activity of administered compounds occurred.
Values for the systolic and diastolic blood pressure (SBP and DBF, respectively) of 
each individual animal prior to, subsequent to, and 60, 90 or 180 minutes (depending 
on the time period before the next procedure) after the administration of test 
compounds, were obtained, and mean arterial blood pressure (MABP) was calculated 
as; MABP = 1/3 (SBP - DBF) + DBF.
For ease of comparison, mean arterial blood pressure for every procedure in each 
series of experiments was expressed as mean ± S.D. (standard deviation).
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2.1.4(iü) pH  measurements o f administered agents
In order to provide a more detailed evaluation of the processes involved in the 
transport or lack of transport of intestinally-administered agents, the pH values of all 
solutions were measured prior to administration. These values, together with known 
pKa values, enabled us to determine, with some confidence, the state of ionisation of 
the administered compounds, and thus describe their ability or inability to move 
through the partition of the lipid membranes (see Appendix).
2.1.5 Analvsis of results
The responses to the experimental procedures were expressed in terms of the absolute 
increase in total acidity above baseline levels, that is (response - baseline). Gastric 
acid levels very often fell during the initial collection periods; however, a steady 
baseline value was attained, usually over a period of between 45 and 60 minutes (3 or 
4 collection periods). Then the experimental procedures commenced. Hence, the 
baseline was calculated as the average gastric acid secretion over these 3 or 4 
collection periods prior to drug administration.
Also calculated were the cumulative increases in gastric acid secretion above baseline 
over the hour including and following drug administration. A fixed time period was 
decided upon rather than attempt to measure the total acid secretion of the entire 
response (which often remained elevated for longer than one hour) since, in many 
cases, the gastric acid levels did not return to the same baseline value preceding 
experimental procedures, but rather remained at slightly elevated levels.
It was decided against calculation of the factor by which gastric acid secretion 
increased above baseline in response to experimental procedures. The same absolute 
change in total acidity would present a different factor increase above baseline if the 
baseline varied in the two cases. Since many comparisons were made in response to 
the same procedure repeated in the same animal, i.e. paired procedures, to introduce 
the possibility of differences due to the method of expression of the results was 
deemed unacceptable.
The paired t-test against zero was employed to compare between two procedures in 
the same rat, and the two sample t-test for the comparison of identical procedures in 
different populations of rats. Occasionally the data which could otherwise be judged 
to conform to a normal distribution were skewed by one or two unusually large
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values. In these cases, two procedures were adopted. First, the t-test was undertaken 
after omitting the unusually large values. This was deemed justifiable since the t-test 
is the most rigorous method of comparing two populations which conform to normal 
distribution, i.e. have a mean and standard deviation. Second, the entire data were 
compared with the Wilcoxon statistical test, a non-parametric test. This test is based 
on the relative rankings of the individual data and compares the medians of the 
population. These tests were undertaken using Minitab for Windows version 10 
(Ryan and Joiner, 1994). Statistical significance was taken as P<0.05.
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2.2 Histological studies
An additional study was undertaken to determine whether infusion of G-CA had 
caused any adverse structural changes to the intestinal mucosa. Following completion 
of the experimental procedures, ileal tissue from two rats was excised and prepared 
for light microscopic evaluation. Similarly, slices of ileal tissue from two control 
animals, in which intra-ileal infusion of G-CA was not undertaken, were removed for 
comparison.
2.2.1 Fixation and staining procedures
Sections of ileum, 2.5cm long, were fixed overnight in 10% neutral phosphate- 
buffered formalin at pH 7.4. After fixation, the formalin was washed from the sample, 
the tissue divided into smaller pieces and dehydrated by passing it through a graded 
series of alcohol solutions up to 100 percent, and then through chloroform. Next, the 
tissue was passed through xylene, a nonaqueous liquid miscible with paraffin wax, and 
embedded in paraffin wax (Paraplast). The tissue blocks were sectioned on a Leitz 
rotary microtome to produce 5 pm thick sections, which were mounted on albumin 
coated slides.
For staining, the paraffin wax was dissolved with xylene, and the sections were 
rehydrated by passing them through a graded series of alcohol solutions back to 
water. The sections were stained with Gill’s Haematoxylin and 1% aqueous Eosin 
(H&E) and dehydrated as described above. Finally, the sections were mounted in 
DPX (Distrene 80 Dibutyl Phthalate Xylene).
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2.3 Chemical synthesis of tetragastrin-cholic acid conjugate
The successfiil manufacture of a tetragastrin-cholic acid conjugate is central to the 
outcome of this project. The following account describes the steps undertaken in 
order to achieve this.
2.3.1 Main chemical substances used in svnthesis of conjugate 
2.3.l(i) Reagents
• Glycinamide hydrochloride (Sigma Chemical Co. G-7378)
• 3a, 7a, 12a-trihydroxy-5(3-cholan-24-oic acid (Cholic acid) (Sigma Chemical Co. 
C-1129)
• N, N’“Dicyclohexylcarbodiimide (DCC) (Sigma Chemical Co. D-1328)
• N-Hydroxy-2, 5-pyrrolidinedione (N-hydroxysuccinimide) (Sigma Chemical Co. 
H-7377)
•_ Trp-Met-Asp-Phe amide (Tetragastrin) (Sigma Chemical Co. T-6515)
• Amino acid derivatives: tryptophan, methionine, aspartate, phenylalanine 
(PerSeptive Biosystems Inc.)
2.3.1(ii) Solvents
• Butanol (Fisher Scientific UK Ltd.)
• Glacial acetic acid (Fisher Scientific UK Ltd.)
• Dichloromethane (Aldrich Chemical Co. Ltd.)
• Dimethyl sulphoxide (DMSO) (Sigma Chemical Co. D-5879)
• Acetonitrile (methyl cyanide) (Sigma Chemical Co. A-6914)
• N, N-Dimethyl formamide (Sigma Chemical Co. D-8654)
• N-methyl morpholine (Rathbum Chemicals Ltd.)
2.3.1 (iii) Staining reagents /  miscellaneous
• Iodine crystals (AnalaR)
• 1,2,3-Indantrione (Ninhydrin) (AnalaR)
• p-Dimethylaminobenzaldehyde (AnalaR)
• N-[3a, 7a, 12a-Trihydroxy-24-oxocholan-24-yl] glycine (Glycocholic acid) 
(Sigma Chemical Co. G-7132)
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2.3.2 Background theory to coniugation reaction
Combination of cholic acid (represented by RCOOH) and N, N’- 
Dicyclohexylcarbodiimide (DCC) results in the formation of a cholic acid anhydride, 
and the insoluble by-product, N, N ’-Dicyclohexylurea (DCU), formed by the removal 
of water from cholic acid by DCC (equation 2-1). The resultant cholic acid anhydride 
is a fairly good acylating reagent (acylation is the substitution of a hydrogen atom by 
an acyl  ^group). Removal of DCU is carried out by filtration.
2.r-COOH H- ■N=C = N
O
R -C O +
R -C O
o
N - C - N '
H H
cholic acid DCC cholic acid 
aahydtide
DCU
(Equation 2-1)
In the presence of N-hydroxysuccinimide, each molecule of cholic acid anhydride is 
converted to one molecule of N-hydroxysuccinimide ester and one molecule of cholic 
acid (equation 2-2). The N-hydroxysuccinimide esters are far better acylating agents 
than the acid anhydride.
0
R -C \
R -G
O
0
+ o AN
OH
O
O
R - C ^  +  R - C - O - N
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cholic acid 
anhydride
N-hydf oxy sue cinittùde cholic acid N-hydroxy sue cinindde 
active estei
 ^ The general term for an acyl group is R-CO- .
(Equation 2-2)
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The N-hydroxysuccinimide ester is highly reactive, and when in combination with the 
chosen peptide (represented by H2N-R’) , should readily yield the cholic acid-peptide 
conjugate (equation 2-3). Furthermore, the easy removal of the water soluble by­
product, N-hydroxysuccinimide, makes the process all the more suitable.
Bl- C - O - N
N-hydfoxysuccitiimide peptide
active ester
oIIR - C - N H - R  +
peptide-cholic acid 
conjugate
O N O
OH
N-hydroxjrsuccirumide
(Equation 2-3)
2.3.3 Glvcine-cholic acid conjugation
It was decided to establish first the success of the conjugation procedure by carrying 
out the simplest reaction, that is, the conjugation between an amino acid and a bile 
acid. The amino acid chosen was glycine, and the bile acid was cholic acid, thereby 
enabling a comparison to be made between the attempted conjugation of these two 
compounds with a glycocholic acid standard solution. The chemical structures for 
both glycine and cholic acid are illustrated in Fig 2-2.
H - C H - C O O HINH2
OH
CH-
COOK
CH-
OHHO
(a) (b)
Fig. 2-2: Chemical structures o f  (a) glycine and (b) cholic acid.
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2.3.3 (i) Thin layer chromatography (TLC)
The technique employed initially in the determination of the success of the 
conjugation reaction was thin layer chromatography (TLC). This is a separation 
method, and can be used simply to check the purity of a substance, to attempt to 
separate and identify the components in a mixture, or to obtain a quantitative analysis 
of one or more of the compounds present.
In practice, the sample to be separated is applied on the layer, 1-2 cm from one end of 
the plate (known as the starting point or origin), and separation is achieved by passing 
a solvent (the mobile phase) through the layer. After the front of the mobile phase has 
reached to within a short distance from the top of the layer, the plate is removed and 
allowed to dry, before carrying out detection procedures.
The Rf value provides a useful way of expressing the position of the separated 
components of a sample on a developed chromatogram. It is calculated as the ratio:
Rf = distance from origin to centre of separated zone
distance from origin to solvent front 
Accordingly Rf values fall between 0.0 and 1.0.
It was necessary to establish first the most suitable sorbent (layer) and mobile phase to 
use. Silica gel plates (Silica gel 60, Merck) were selected since they are suitable for 
TLC of amino acids and bile acids. Butanol-glacial acetic acid-water (120 + 10 + 10) 
was chosen as the mobile phase, since it was discovered that TLC of cholic acid 
(lOmg ml'^  methanol), glycine (lOmg mf^ methanol/water (50/50)) and glycocholic 
acid (lOmg ml"^  methanol) resulted in a satisfactory separation between spots of these 
compounds (Fig. 2-3) (Rf values of cholic acid, glycocholic acid and glycine were 
0.833, 0.522 and 0.044, respectively). This was deemed necessary since, when 
comparing TLC of these standards with TLC of the conjugation sample, less 
ambiguity as to whether conjugation had or had not been achieved would arise. TLC 
was run for a period of 2 hours, the plate allowed to dry, and unless otherwise stated, 
stained with iodine crystals, a universal stain.
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Fig. 2-3: Thin layer chromatography of: (1) cholic acid, (2) glycine and (3) glycocholic acid (all 
20/iil spots; JOmg mTf on Silica Gel G layer, developed with butanol-glacial acetic acid-water 
(120+10+10) for 2 hours, and detected with iodine crystals. Exact tracing o f  developed TLC plate.
2.3.3 (ii) Selection o f solvent
The procedure for conjugation of an amino acid or a peptide with cholic acid was 
carried out at room temperature (20^C), and required that the individual reactants be 
dissolved in a non-aqueous solvent, since water vapour could react with the active 
intermediary (N-hydroxysuccinimide active ester; equation 2-3).
Our first choice of non-aqueous solvent was dichloromethane; however, it was 
discovered that cholic acid, glycine and N-hydroxysuccinimide were all insoluble in it. 
Dimethyl sulphoxide (DMSO) was found to dissolve all components of the 
conjugation reaction, except glycine. An attempt to increase the solubility of glycine 
in DMSO by the addition of a highly polar solvent, N-methyl-morpholine, to produce 
a final solution of glycine in 1:1 N-methyl-morpholine:DMSO was not successful.
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Furthermore, increasing the N-methyl-morpholine ratio 10-fold (that is, glycine in 
10:1 N-methyl-morpholine:DMSO) did not result in an increase in glycine solubility. 
Finally, dimethyl formamide was selected as a possible non-aqueous solvent. 
However, similar problems were found, as with DMSO, regarding the insolubility of 
glycine, despite the relative solubility of cholic acid, DCC and N-hydroxysuccinimide. 
As described previously, addition of N-methyl-morpholine to the glycine/dimethyl 
formamide solution, on a 1:1 basis, did not increase solubility; neither did increasing 
N-methyl-morpholine concentration on a 10:1 basis.
The insolubility of glycine was considered to be as a result of its very polar nature. It 
was anticipated that the solubility of the test peptide to be conjugated at a later stage 
would be less problematic, since it would have a less polar nature as a consequence of 
the presence of aromatic groups, thereby reducing the zwitterion effect.
However, despite the insolubiUty of glycine in dimethyl formamide, it was decided to 
attempt the conjugation of glycine with cholic acid. 200mM solutions/suspensions of 
each individual reactant in dimethyl formamide were made up.
2.3.3 (iii) The conjugation procedure
The conjugation between cholic acid and glycine was attempted by performing the 
following procedure. Equal volumes of the cholic acid solution and the DCC 
solution were mixed together. To this was added an equal volume of the N- 
hydroxysuccinimide solution, followed immediately by the addition of the same 
volume of the glycine suspension. Immediate mixing was required in order to 
minimise water vapour reacting with the active intermediary yielded by the reaction 
between the cholic acid, DCC and N-hydroxysuccinimide solutions.
Since glycine was dispersed rather than dissolved in dimethyl formamide, on addition 
of it to the reaction vessel (containing cholic acid, DCC and N-hydroxysuccinimide 
solutions), some glycine crystals were left remaining in the original vessel (that is, the 
vessel in which the glycine dispersion was made up). In an attempt to ensure that all 
the glycine was available for the reaction, the conjugation mixture (contained in 
reaction vessel) was poured back and forth between the original and the reaction 
vessel. Finally, the conjugation mixture was divided into two; half was placed in the 
reaction vessel, and half was placed in the original vessel. These two vessels, labelled
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‘con r  and ‘con 2 \  respectively, were stoppered and vigorously shaken for 
approximately 3 hours, before further analysis was carried out.
2.3.3(iv) Determination o f purity o f conjugate
In order to determine whether the conjugation of glycine with chohc acid had been 
successful, samples of the resultant conjugation mixture (20p,l) were mn on TLC 
alongside standard solutions of glycocholic acid, cholic acid (both 20p,l, lOmg ml'^  
methanol), and glycine (20jal, lOmg ml"^  methanol/water (50/50)). TLC was run for 2 
hours, with the mobile phase as described previously (see Fig. 2-4). The presence of 
compounds were detected by staining the dried plate with iodine.
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Fig 2-4: Thin layer chromatography of: (1) cholic acid (lOmg m l'j (2) con 1 (3) glycocholic acid  
(lOmg niTj (4) con 2 and (5) glycine (lOmg ml'f, (all 20p i spots) on Silica Gel G layer, developed 
with butanol-glacial acetic acid-water (120+ 10+ 10)  for 2 hours, and detected with iodine crystals. 
Exact tracing o f developed TLC plate.
Figure 2-4 demonstrates the outcome of such a procedure. There was nothing to 
indicate that glycine had conjugated with cholic acid, since a spot with an Rf value 
corresponding to glycocholic acid was not obtained. Furthermore, there was no
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evidence of any free glycine present in the two conjugation mixtures (con 1 and 2), 
suggesting that glycine had, therefore, not taken part in the conjugation reaction. 
Thus, it would appear that glycine-cholic acid conjugation had not been successfiil.
2.3.4 Tetragastrin-cholic acid conjugation
Since the conjugation of glycine with cholic acid was unsuccessful, presumably as a 
consequence of the insolubility of glycine in dimethyl formamide, it was decided to 
attempt the conjugation of tetragastrin (the C-terminal tetrapeptide amide sequence 
(Trp-Met-Asp-Phe amide) of gastrin. This was considered feasible since tetragastrin 
is more lipophilic and, therefore, less polar than glycine and was found to be 
completely soluble in dimethyl formamide. The structure of tetragastrin is shown in 
Figure 2-5.
R O H O H O H R3I Ii I I II I I II I I ^N H 2 " C H “ C ” N “ C H - C - N ~ C H “ C - N - C H - C  ^
O
where R CH.
R^  = CH3SCH2CH2
O
OH
R^ =
Fig. 2-5: Chemical stimcture o f  tetragastrin, where R is tryptophan; R  ^ is methionine; R  ^is aspartate 
and R  ^ is phenylalanine.
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2.3.4(i) Thin layer chromatography
First, samples of cholic acid (lOmg ml'^  methanol) and tetragastrin (5mg ml'^  
methanol/water (50/50)) were run on TLC for a duration of 2 hours (Fig. 2-6), the 
mobile phase being equivalent to that described previously. This would enable a 
comparison with the results of TLC for the tetragastrin-cholic acid conjugate, once 
this had been performed.
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Fig. 2-6: Thin layer chromatography of: (1) cholic acid (lOmg mT‘) and (2) tetragastjin (5mg rnl'f 
(both 20fjl spots) on Silica Gel G layer, developed with butanol-glacial acetic acid-water 
(120+10+10) for 2 hours, and detected with iodine crystals. Exact tracing o f  developed TLC plate.
The Rf value of cholic acid was 0.855, a value very much in agreement with earlier 
work. Tetragastrin had a lower Rf value of 0.344. It was decided, by manipulation of 
the components of the mobile phase, to attempt to increase further the separation 
between the Rf values of cholic acid and tetragastrin. This would make identification 
of the tetragastrin-cholic acid conjugate easier. Butanol-glacial acetic acid-water (120 
+ 5 + 5) gave a more satisfactory result (Fig. 2-7) in that the Rf value for tetragastrin 
was reduced to 0.213, whereas the Rf value for cholic acid was relatively unchanged
Methods
(Rf -  0.825). This was the chemical composition of the mobile phase to be used in ail 
subsequent procedures.
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Fig. 2-7: Thin layer chromatography of: (1) cholic acid (lOmg ml' )^ (2) tetragastrin (5mg m hf (both 
20pl spots) on Silica Gel G layer, developed with butanol-glacial acetic acid-water (120+5+5) fo r 2 
hours, and detected with iodine crystals. Exact tracing o f developed TLC plate.
2.3.4(ii) The conjugation procedure
The procedure for tetragastrin-cholic acid conjugation was carried out as follows; as 
before, each individual component of the conjugation reaction was dissolved in 
dimethyl formamide to give solution concentrations of lOOmM, Equal volumes of 
cholic acid and DCC solution were mixed together, and to this was added an equal 
volume of N-hydroxysuccinimide solution. Without delay, the same volume of 
tetragastrin solution was added, and the resultant solution shaken vigorously. For 
ease of determination of the success of conjugation, a control solution was also made 
up, whereby all the components of the conjugation reaction were added, as described 
previously, with the exception of tetragastrin. Figure 2-8 summarises the steps taken 
to produce a control sample and a conjugation sample.
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Control Sample Procedure
Cholic acid +  DCC
N -H y droîîy sue cinimide
Control Sample
Coniugation Sample Procedure
Cholic acid ■+- DCC
N “Hydroxysuc cinimide 
Tetragastrin
Conjugation Sample
Fig.2-8: Diagram to illustrate the steps taken to produce a control and a conjugation sample 
2.3.4(iii) Determination ofpurity o f conjugate
TLC was used to determine whether the conjugation of tetragastrin with cholic acid 
had been successful, by applying spots of the conjugation and control sample on the 
chromatogram, alongside spots of cholic acid (lOOmM) and tetragastrin (lOOmM). In 
this case, 5 pi samples were spotted in order to prevent the spread of each compound 
over an unsuitably large area. The method of TLC was carried out as described 
previously. Detection with iodine (Fig. 2-9) demonstrated that the tetrapeptide 
stained as a thin, extended streak, suggesting that it may not be as pure as was 
originally thought. The lack of staining in the centre of the conjugation sample 
implied that there may be some compound present which is not being detected with 
iodine. It was difficult to draw any conclusions about the success of the conjugation 
using the results from this chromatogram.
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Fig. 2-9: Thin layer chromatography of: (1) cholic acid (lOOmM) (2) tetragastrin (lOOrnM) (3) 
conjugation sample (4) control sample (all 5jjl spots) on Silica Gel G layer, developed with butanol- 
glacial acetic acid-water (120-^5-^5) fo r  2 hours, and detected with iodine crystals. Exact tracing o f  
developed TLC plate.
2.3.4(iv) Partition o f the conjugation sample
It was decided to mn TLC of a chromatographic plate spotted with the individual 
components of the conjugation mixture, in addition to spotting of the control sample, 
in an attempt to simplify the intei-pretation of the resultant plate. Furthermore, we 
added equal volumes of water and chloroform (l.Oral) to what was remaining of the 
conjugation sample from the previous reaction. This served to partition the 
components within the conjugation sample, that is, those that were water soluble 
would remain in the aqueous fraction (top layer), whereas the lipid soluble 
components would be found in the chloroform fraction (bottom layer). This, 
therefore, provided a means of further separating the components within the 
conjugation sample, with the hope that the complex nature of the sample would be 
reduced. A sample from both the aqueous and chloroform fraction was applied to the 
origin of the chromatogram.
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The sample size of each of the spotted samples was adjusted in order to enable a more 
direct comparison. The individual components of the conjugation sample were 
applied as 2.5p.l spots; whereas the spot size of the control sample was T.Sjil, and that 
of the conjugation sample was lOpl. These volumes were decided upon since the 
concentration of each of the individual components in the control sample and in the 
conjugation sample would be 3 and 4 times more dilute, respectively, than in the 
solutions composed solely of either cholic acid, DCC, N-hydroxysuccinimide or 
tetragastrin. Therefore, the spotted samples would be equivalent in quantity of each 
component.
TLC was carried out as described earlier, and iodine crystals were employed as the 
means of detection (Fig. 2-10). Both the sample taken from the aqueous fraction of 
the conjugation sample, and tetragastrin appeared as very similar thin, extended 
streaks, making it difficult to determine whether conjugation had been successful.
SOLVENT FRONT
o
ORIGIN
6 7
Fig. 2-10: Thin layer chromatography of: (I) cholic acid (lOOmM); (2) DCC (lOOmM); (3) N- 
hydroxysuccinimide (lOOmM) (all 2.5p i spots); (4) control sample (7.5pi); (5) aqueous fraction o f  
conjugation sample (lOpl); (6) chloroform fraction o f  conjugation sample (lOpl); (7) tetragastrin 
(lOOmM) (2.5pi) on Silica Gel G layer, developed with butanol-glacial acetic acid-water (120+5+5) 
for 2 hotirs, and detected with iodine crystals. Exact tracing o f  developed TLC plate.
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2.3.4(v) Ninhydrin as a visualising reagent
It was, therefore, decided to stain the same chromatogram with ninhydrin (1, 2, 3- 
Indantrione), since this is a reagent which stains proline and hydroxyproline yellow, 
and all other a-amino acids violet (Touchstone and Dobbins, 1978), and would 
establish whether free peptides were present within the conjugation sample and the 
tetragastrin sample. In order to do this, ninhydrin crystals (0.5g) were dissolved in 
ethanol (100ml), and the resultant solution sprayed evenly onto the plate. The 
chromatogram was then heated using a hairdryer set on the highest heat setting for 
approximately 30 minutes.
Figure 2-11 demonstrates the outcome of such a procedure. As was to be expected, 
there were no free peptides present in the control sample nor within the individual 
components of the control sample. The aqueous fraction of the conjugation sample 
and tetragastrin sample, when stained with ninhydrin, were very similar, indicating the 
presence of amino acids (or free peptides) over an area very close to the origin.
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Fig. 2-11: Thin layer chromatography of: (1) cholic acid (lOOmM); (2) DCC (lOOniM); (2) N- 
hydroxysuccinimide (lOOmM) (all 2.5jA spots); (4) conti'ol sample (7.5/jl); (5) aqueous fraction o f  
conjugation sample (lOpl); (6)  chloroform fraction o f  conjugation sample (lOpl); (7) tetragastrin 
(lOOmM) (2.5pi) on Silica Gel G layer, developed with butanol-glacial acetic acid-water (120+5+5) 
fo r 2 hours, and detected with iodine crystals (unshaded) and ninhydrin (shaded). Exact tracing o f  
developed TLC plate.
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Nevertheless, any indication that conjugation between tetragastrin and cholic acid had 
been achieved was difficult to establish. Furthermore, the long streak of the 
tetragastrin sample, stained by iodine but unstained by ninhydrin, supported the idea 
that the tetrapeptide was not as pure as was hoped, and further, implied that the 
impurity was not an amino acid(s).
2.3.4(vi) Contribution o f dimethyl formamide
In order to determine whether the presence of dimethyl formamide contributed to the 
apparent contamination of tetragastrin, dimethyl formamide alone was spotted 
alongside tetragastrin (25mM, made up in alcohol/water (50/50)), and the aqueous 
fraction of the conjugation sample (Fig. 2-12).
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Fig. 2-12: Thin layer chromatography of: (I) dimethyl formamide (2.5pl); (2) dimethyl formamide 
(7.5pi); (3) tetragastrin (25mM, 10pi); (4) tetragash’in (25mM, 30pi); (5) aqueous fraction o f  
conjugation sample (lOpl); (6) aqueous fraction o f  conjugation sample (30pl) on Silica Gel G layer, 
developed with butanol-glacial acetic acid-water (120+5+5) fo r 2 hours, and detected with iodine 
crystals (unshaded) and ninhydrin (shaded). Exact tracing o f developed TLC plate.
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The chromatographic procedure was as described previously, and after 2 hours, 
visualisation of the samples was carried out by first staining with iodine, and then 
employing ninhydrin, as described earlier. The stained areas provided evidence to 
suggest that dimethyl formamide was not a contributory factor in the contamination of 
tetragastrin, and supported the premise that the tetrapeptide was contaminated with 
an other substance(s). The stained areas of this plate were quite different ft"om the 
previous (Fig. 2-11) in that the ninhydrin-stained areas of tetragastrin were central 
within the iodine stain, rather than close to the origin, and the ninhydrin-stained areas 
of the conjugation sample were found towards the top of the iodine-stained area. 
However, this plate was somewhat unsatisfactory since the iodine staining had left a 
pinkish tinge, making the ninhydrin stained areas difficult to establish.
In order to avoid such a problem, TLC of the individual components of the 
conjugation sample was carried out alongside TLC of the aqueous fraction of the 
conjugation sample, as described earlier; however, the iodine staining process was 
omitted, and the plate stained using ninhydrin (Fig. 2-13). Tetragastrin was detected 
as an extended streak similar to iodine-stained tetragastrin (Figs. 2-11 and 2-12). The 
aqueous fraction of the conjugation sample was detected in two areas of the plate: at 
the origin, and close to the solvent front, at a region not dissimilar to the tip of the 
tetragastrin stained band. However, it was very difficult to conclude whether 
conjugation had been successfiil, although the absence of staining in the central part of 
the conjugation sample band suggests it may have been.
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Fig. 2-13: Thin layer chromatography of: (I) tetragastrin (25mM, made up in methanol/water 
(50/50)) (lOpl); (2) cholic acid (lOOmM) (2.5/jl); (3) DCC (lOOmM) (2.5fjl); (4) N- 
hydroxysuccinimide (lOOmM) (2.5jul); (5) aqueous fraction o f  conjugation sample (lOpl); (6)  
tetragastrin (lOOmM) (2.5pi) on Silica Gel G layer, developed with butanol-glacial acetic acid- 
water (120+5+5) for 2 hours, and detected with ninhydrin. Exact tracing o f  developed TLC plate.
2.3,4(vii) Determination o f purity o f tetragastrin
It was of importance to establish the purity of the tetrapeptide prior to any further 
attempts at conjugation, since any contamination would influence the success of such 
a venture.
This was initially carried out using high performance liquid chromatography (HPLC), 
performed by a Shimadzu LCIO chromatographer with diode ray detector. Analysis 
of a 5^g injection of tetragastrin (Trp-Met-Asp-Phe amide) was carried out at a 
gradient of 20-40% in 0.05% Trifluoracetic acid (TFA)/H20 and 0.05% TFA/Methyl 
cyanide (MeCN), and detected using UV monitoring at 215nm and 280nm, 
Generally, HPLC analysis at 215nm is the traditionally selected option, and 280nm 
discloses compounds containing aromatic groups, such as phenylalanine and 
tryptophan. For this reason, the chromatogram at 280nm provides the best guide for
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assessment of our sample. Furthermore, as time increases (horizontal axis), the 
polarity of the compounds diminishes.
A main peak appearing as a doublet was present (Fig. 2-14). This suggested that 
there were two major components of the tetrapeptide, and may be due to a number of 
factors, for example, racemization of one amino acid, the presence of a free acid with 
an amide, oxidation of methionine, or rearrangement of P-aspartimide.
mAbs
1000  Chi 215nm
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50
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Fig. 2-14: HPLC o f  Trp-Met-Asp-Phe amide (tetragastrin) (5pg) at a gradient o f 20-40% in 0.05% 
TFA/TLO and 0.05% TFA/MeCN. Detection using UV monitoring at 215mn (upper trace) and 
280nm (lower ti^ace). Axes indicate relative abundance against time o f  elution in min.
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In order to obtain a more precise understanding of the composition of tetragastrin, a 
sample of the tetrapeptide was analysed using electrospray mass spectrometry in 
positive ion mode. This was performed on a VG BioTech platform single quadrupole 
mass spectrometer fitted with a pneumatically-assisted electro spray source, and 
controlled via the VG Masslynx software. The carrier solvent was 1:1 (v/v) 
acetonitrile:water with formic acid added to give a final concentration of 0.2% (v/v). 
The mass spectrum (Fig. 2-15) demonstrated the presence of two ions. (The actual 
mass of the detected molecules is equivalent to the value on the horizontal scale 
(Da/e) minus one, taking into account an extra proton (iT) added in the ionisation of 
the compound.) The larger peak shows an ion at 597 Da/e, set to an abundance of 
100%. An ion at 653 Da/e, with a relative abundance of 8%, was also found to be 
present. These results are indicative of the relatively uncontaminated nature of the 
tetragastrin sample, though they do reveal the presence of an additional compound of 
molecular weight 652Da, the identity of which is unknown, but which may have arisen 
in the process of manufacture (see Section 2.3.7).
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Fig. 2-15: Mass spectrum o f  Trp-Met-Asp-Phe amide (tetragastrin) obtained by electrospray mass 
spectrometry. SpecUmm is p lo t o f  relative abundance, with the largest peak assigned 100%, against 
the molecular weight.
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2.3.4(vin) Visualisation using Ehrlich ’s reagent
We decided, therefore, to aim for a more specific stain when carrying out TLC as a 
procedure to determine the success of tetragastrin-cholic acid conjugation.
Ehrlich’s reagent (4-dhnethylaminobenzaldehyde-HCl) has been shown to be specific 
for the detection of citrulline, urea, tryptamine and tryptophan (Stahl, 1965). In order 
to verify this, L-tryptophan (lOmg ml'^  0. IM HCl) was applied to a silica gel G plate 
as 10, 20 and 30p,l spots and allowed to dry, before a fine mist of Ehrlich’s reagent 
(1%) was sprayed evenly over the plate. On drying, tryptophan was found to stain 
bright yellow.
TLC of the individual components of the conjugation sample, the aqueous and 
chloroform fi*actions of the partitioned conjugation sample, and the control sample 
was run as described earlier. Ehrlich’s reagent was employed as the visualisation 
reagent, rather than iodine or ninhydrin (Fig. 2-16).
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Fig. 2-16: Thin layer chromatography of: (1) aqueous fraction o f conjugation sample (10/jl); (2) 
tetragastrin (lOOmM) (2.5pi); (3) DCC (lOOmhI) (2.5pi); (4) control sample (7.5pi); (5) cholic acid  
(lOOmM) (2.5pl); (6) N-hydroxysuccinimide (lOOmM) (2.5 pd); (7) chloroform fraction o f  conjugation 
sample (lOpl) on Silica Gel G layer, developed with butanol-glacial acetic acid-water (120-5-^5) 
for 2 hours, and detected with Ehrlich's reagent. Exact tracing o f  developed TLC plate.
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This step was of considerable importance since it was anticipated that DCC, present 
in both the conjugation sample and control sample, may breakdown into urea-like 
components for which Ehrlich’s reagent would stain positively. However, the spotted 
samples of DCC, cholic acid, N-hydroxysuccinimide and the control sample were 
unstained when the plate was sprayed with Ehrlich’s reagent. The tetrapeptide 
appeared as a bright yellow, extended spot, presumably as a result of the presence of 
tryptophan, and had a very similar appearance to the aqueous fraction of the 
conjugation sample, although the latter stained less brightly. The chloroform fraction 
of the conjugation sample stained as two distinct streaks. One of these was very 
similar to the stain of both tetragastrin and the aqueous fraction of the conjugation 
sample, but the second was displaced nearer to the solvent front. It was considered 
possible that this could be the cholic acid-tetragastrin conjugate.
2.3.4(ix) Elution o f chloroform fraction o f conjugation sample 
Elution is the removal of a solute from the sorbent by the passage of a suitable 
solvent. Such a process is useful in the isolation of a solute, enabling further analysis, 
for example, mass spectrometry, to be carried out.
Since it was anticipated that the chloroform fraction of the conjugation sample may 
contain the tetragastrin-cholic acid conjugate, we wished to carry out elution of this 
fraction, in order to clarify this. A sample of the chloroform fraction of the 
partitioned conjugation sample (lOpl) was applied at either side of a wide streak of 
the chloroform fraction (Fig. 2-17), and TLC was run as before.
Fig. 2-17: Sketch o f  silica gel O plate prior to running TLC where (1) and (3) are spots o f  
chloroform fractions o f  conjugation sample (10/i) , and (2) is a streak o f  chloroform fraction o f  
conjugation sample.
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Strips, consisting of the two vertical margins of the plate where the lOp,! spots were 
applied, were cut away from the central part of the plate (where the streak had been 
applied), and stained with Ehrlich’s reagent. Two distinct bands were noted on each 
strip. Alignment of the stained strips with the unstained central plate allowed us to 
predict where the central streak would have been displaced to. Using pencil, these 
two regions were marked out on the central plate, and were referred to as the top 
section and bottom section (Fig. 2-18).
I
TOP
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Fig. 2-18: Sketch o f  silica gel G plate after running TLC o f  (1) and (3) chloroform fraction o f  
conjugation sample (lOpl), and (2) streak o f  chloroform fraction o f  conjugation sample, using 
butanol-glacial acetic acid-water (120+5+5) as mobile phase, and staining strips (1) and (3) with 
Ehrlich’s reagent. Top section and bottom section bands were marked out on the central plate.
The silica from the bottom section band was scraped from the central plate, and 
poured into a scintered glass funnel. This was repeated, using another scintered glass 
funnel, with the silica from the top section band. These will be denoted as bottom 
section silica, and top section silica, respectively. The top section silica was eluted 
using a solvent composed of 95% butanol: 5% glacial acetic acid. Since cholic acid 
has a high Rf value with this solvent, running near to the solvent front in a similar way 
to the top staining band (top section silica), this solvent was considered suitable for 
the removal of the top staining compound from the silica. The bottom section silica 
was eluted in the same way as the top section, except that this time the solvent chosen 
was 80% glacial acetic acid: 20% water, in order to separate the bottom staining band
so
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from the silica. In both cases, the solvent mnning through the silica was collected in 
pre-weighed vessels. Figure 2-19 illustrates the technique of removal of compounds 
from the silica gel plates.
solvent
silica gel
pre-weighed 
test tube — collected solvent, 
containing compounds 
separated from 
silica gel
Fig. 2-19: Experimental set-up fo r  elution o f  chloroform fraction o f  conjugation sample.
The next step was to blow off the solvent collected in the pre-weighed test tubes, in 
order to leave a solid deposit containing the compounds present in the top and bottom 
section silica. In order to get rid of the 95% butanol: 5% glacial acetic acid, the 
contents of the test tube were warmed in a water bath at 40®C, whilst passing a stream 
of nitrogen over the top of the test tube. The 80% glacial acetic acid: 20% water was 
removed by placing the test tube in a dessicator containing NaOH pellets, and 
attaching it to a water pump. The water pump set up a vacuum in the dessicator, 
helping to evaporate glacial acetic acid (Fig 2-20). In both cases, the solvent was
suction
water pumpdessicator
samples
NaOH pellets water
Fig. 2-20: Diagram o f  apparatus used to evaporate glacial acetic acid:water.
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removed successfially, leaving a white sediment in the test tubes. Dimethyl formamide 
was added to the sediment in both cases, to give a final solution of approximately 
lOmg ml'\
The sediment recovered from elution of each of the top and bottom section silica were 
applied in duplicate as 10pi spots at the origin of a chromatographic plate, and TLC 
was developed using butanol-glacial acetic acid-water (120 + 5 + 5) as the mobile 
phase. After 2 hours, the plate was removed, dried, and bisected vertically so that 
both halves of the plate, each with eluted top and bottom section compounds could be 
stained using different reagents. Iodine (universal stain) was used to visualise the 
displacement of compounds on one plate, whereas Ehrlich’s reagent (stains positively 
for citrulline, urea, tryptamine and tryptophan) was employed as the visualisation 
reagent for the other plate.
The iodine stained plate demonstrated similar displacements of the top and bottom 
section eluted compounds, close to the solvent front, with Rf values very much in 
agreement with that of cholic acid (chromatogram not shown but similar to Fig. 2- 
21). Ehrlich’s reagent did not stain positively, thereby suggesting that neither the 
tetrapeptide nor its cholic acid conjugate was present (chromatogram not shown).
2.3.4(x) Thin layer chromatography o f eluted samples
TLC was carried out again in a similar way to that just described, although this time 
an additional sample of cholic acid (2.5|rl, lOOmM) was applied, in order to provide a 
standard to compare with the eluted samples. The iodine stained plate provided 
evidence to suggest that cholic acid was present in the eluted samples jfrom both the 
top and bottom sections, since stained bands similar to that of cholic acid were 
evident (Fig 2-21). As was shown by the previous plate, there were no positively 
staining compounds when Ehrlich’s reagent was employed as the visual reagent 
(chromatogram not shown).
The entire elution procedure was repeated once more, as has already been described. 
However, this time double the volume of the chosen solvent for elution (that is, either 
95% butanol: 5% glacial acetic acid, or 80% glacial acetic acid: 20% water) was used, 
in order to improve the likelihood of removing the compounds from the silica. 
However, TLC demonstrated that the eluted top and bottom section silica appeared to 
contain the same compound(s), and furthermore, had a very similar Rf value to cholic
8?
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acid. There were no Ehrlich positive staining compounds, suggesting that neither 
eluted samples contained either tetragastrin or the tetragastrin-cholic acid conjugate 
(chromatogram not shown).
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Fig. 2-21: Thin layer chromatography of: (1) and (2) eluted bottom section silica (S m g  mf ,^ lOpl); 
3) cholic acid (lOOmM, 2.5pi); (4) and (5) eluted top section silica (S m g  10pi) on Silica Gel 
G layer, developed mth butanol-glacial acetic acid-water (120+5+5) for 2 hours, and detected with 
iodine. (Rf o f eluted bottom section silica: 0.802; R fo f  eluted top section silica: 0.813; R f  o f  cholic 
acid: 0.855.) Exact tracing o f  developed TLC plate.
2.3.4(xi) Mass spectrometry o f eluted samples
The difficulties encountered in interpretation of the results of TLC indicated that a 
more definitive approach should be taken. It was decided to carry out analysis of the 
eluted top and bottom section silica by electrospray mass spectrometry (as described 
previously), a technique which determines the molecular weights of the components in 
a sample. For reference, the molecular weights of the individual components of the 
conjugation sample are listed in Table 2-1.
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Table 2-1: Molecular weights of components of conjugation sample
Co m p o n e n t M o l e c u l a r  W eight
Cholic acid 408
DCC 206
N-Hydroxysuccinimide 115
Tetragastrin 596
TeP'agastrin-cholic acid conjugate 986
However, as dimethyl formamide was not considered suitable for use in the mass 
spectrometer, a more volatile solvent was required. Therefore, the entire elution 
procedure of top and bottom section silica was carried out once again, and the 
recovered sediment from each region dissolved in 1:1 TFA (0.1%); acetonitrile, to 
give final solution concentrations of approximately 6mg ml'\ Both samples 
underwent analysis in the mass spectrometer.
Mass spectrometry of both the top and bottom eluted sections demonstrated that 
ionisation of the samples produced a huge number of ions (Fig. 2-22). The presence 
of an ion at 413 Da/e, with an assigned abundance of 100%, occurred in both spectra. 
However, there were a considerable number of other ions ranging from between 200 
and 1200 Da/e, of varying relative abundances, making analysis of the samples very 
difficult. The tetragastrin-cholic acid conjugate would be identifiable as an ion at 
approximately 987 Da/e, since the conjugation procedure involves a condensation 
reaction. So, for every molecule of the conjugate produced, a molecule of water 
(molecular mass of 18) would be lost fi'om the two reactants. However, it was 
unlikely that the samples contained the tetrapeptide-choHc acid conjugate, since an ion 
at or close to 987 Da/e was not apparent from the spectrum obtained from either the 
top section or bottom section silica.
M
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Fig: 2-22: Mass spectrum o f eluted top section silica (upper trace) and eluted bottom section silica 
(lower trace), obtained by electrospray mass spectrometry. Spectrum is plot o f  relative abundance, 
with the largest peak assigned 100%, against the molecular weight.
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2.3.4(xii) Tetragastrin-cholic acid conjugation using higher concentration o f 
reaction components
It was therefore decided to attempt the conjugation of tetragastrin with cholic acid a 
further time, using solutions of the individual components with stronger 
concentrations (500mM rather than lOOmM), in order to increase the yield. The 
actual conjugation procedure was as described previously (Fig. 2-8); however, rather 
than carrying out TLC of the conjugation sample, and subsequent elution of the silica 
gel, it was decided that electrospray mass spectrometry of the conjugation sample 
itself should be attempted. Since the final conjugation sample was dissolved in 
dimethyl formamide, a solvent not particularly suitable for use in the mass 
spectrometer, it was necessary to blow off this solvent using a stream of nitrogen 
directed over the sample. The remaining crystals were then dissolved in 1:1 TFA 
(0.1%):acetonitrile to give a final solution of approximately 20mg ml'\
Electrospray mass spectrometry of this sample produced a spectrum (Fig. 2-23) 
demonstrating an unidentifiable ion with an assigned abundance of 100% at 322 Da/e. 
The presence of an ion at 597 Da/e, considered to be tetragastrin, had a relative 
abundance of 30.5%. Ions at 579 and 615 Da/e, vrith relative abundances of 4 and 
6%, respectively, may represent tetragastrin with a molecule of water removed or 
added, respectively. The presence of an N-hydroxysuccinimide derivative of the ion at 
579 Da/e, with a relative abundance of 35%, was indicated by an ion at 693 Da/e. 
Two ions were present at 1005 and 1102 Da/e, both with relative abundances of 11%. 
The ion at 1005 Da/e suggested the presence of the product of the reaction between 
the ion at 615 Da/e and cholic acid, with the resultant loss of a water molecule. The 
ion at 1102 Da/e may have been the product of the reaction between cholic acid and 
the N-hydroxysuccinimide derivative of tetragastrin. However, there was no evidence 
to suggest the presence of the tetragastrin-cholic acid conjugate, since no ion was 
detected at or near 987 Da/e.
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Fig. 2-23: Mass spectrum o f  conjugation sample, as obtained by electrospray mass spectrometry. 
Spectrum is plot o f  relative abundance, with the largest peak assigned 100%, against the molecular 
weight.
2.3.5 Tetragastrin-cholic acid conjugation - modified procedure
The unsuccessful conjugation of cholic acid with tetragastrin suggested that a number 
of modifications be made to the conjugation procedure as required.
2.3.5 (i) Purification and drying o f reagents/solvents
First, it was necessary to purify the DCC source prior to its use, since it was highly 
probable that some N-N’-Dicyclohexylurea (DCU), the hydrated DCC adduct, would 
have been formed on exposure of DCC to the atmosphere. The procedure for doing 
this is outlined overleaf;
R7
Methods
• The top layer of the DCC was scraped off and disposed of.
• The vessel containing DCC was warmed slowly to a temperature of approximately 
40‘’C (DCC has a melting point of between approximately 34 and 35 ”C), and the 
resultant liquid poured into a screw-top bottle.
• DCC was dissolved in excess dichloromethane (DCM), a solvent in which DCC 
has high solubility. The sample was then stored in the fridge overnight in order to 
allow the solid precipitation of DCU to form as a white solid.
• DCU was filtered ofiE, and the DCM removed from the sample by gentle heating in 
a water bath at 40^C under a stream of nitrogen. The purified DCC remaining was 
immediately transferred to a vacuum in order to prevent rehydration.
It was considered essential that the reagents involved be as dry as possible, since 
water would interact with the reactive intermediary of the conjugation reaction. This 
was achieved by placing samples of the reagents in the dessicator with attached water 
pump (Fig. 2-20) in order to create vacuum-like conditions, and allowing any water 
present to evaporate. The glassware to be used was also dried in an oven and placed 
in the dessicator until required, in order to prevent the reabsorption of water. 
Acetonitrile was considered to be a more suitable solvent than dimethylformamide 
(DMF), since DMF is reported to encourage the formation of the N-acylurea side 
product, as well as increasing racemization in chiral carboxylic acids (Paquette, 1995). 
Acetonitrile is also easier to remove from the final product. However, it was 
discovered that cholic acid was highly insoluble in acetonitrile, and we therefore felt 
compelled to resort once again to DMF as the solvent. Since it was considered 
imperative that water should not contaminate the conjugation reaction, DMF had to 
be suitably dried, by stirring over calcium hydride (5.0% w/v) overnight, filtering and 
distilling (56®C at 20mmHg) on to K-Al-silicate porous platelets.
2.3.5 (ii) The conjugation procedure
The procedure for conjugation of tetragastrin with cholic acid was as described 
previously (Fig. 2-8), with the exception that 1.1 equivalents of DCC was reacted 
with 1.0 equivalent of cholic acid, followed by the immediate addition of 1.0 
equivalent of N-hydroxysuccinimide and 1.0 equivalent of tetragastrin. A control 
sample was also produced by omitting the addition of tetragastrin, thus allowing a
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direct comparison with the conjugation sample. The conjugation and control samples 
were left for an hour in order to allow the reaction to occur, before filtering to remove 
any DCU that may have formed. After removal of DCU, the two samples were 
transferred to the fridge where they were stored overnight before re-filtering. DMF 
was then evaporated from the two samples under vacuum, resulting in the production 
of a white and yellow crystalline powder (control and conjugation sample, 
respectively).
2.3.5(iii) Analysis o f products
The conjugation sample was subjected to analysis by fast atom bombardment mass 
spectrometry (FAB-MS). Prior to analysis, the sample was dissolved in glycerol at a 
concentration of approximately Img m l'\ and about 50pl of this was placed on the tip 
of a probe, which was subsequently inserted into the high vacuum of the mass 
spectrometer. In this case, the measurements were carried out on a JEOL 505 HA 
instrument.
The sample solution was then bombarded with a beam of fast xenon atoms. This was 
achieved by first ionising xenon atoms and accelerating the resulting ions through a 
xenon gas chamber where charge transfer occurred (equation 2-4), to give fast atoms. 
The excess of fast xenon ions were deflected, thereby leaving a beam of fast atoms.
Xe^ ‘ (fast) + Xe (thermal) -------—> Xe (fast) + Xe'" * (thermal) (eq. 2-4)
The removal of charge occurs immediately prior to the atoms striking the sample, thus 
they are neutral at this moment. The bombardment of fast atoms on to the metal plate 
coated with the substance to be investigated results in the large amount of kinetic 
energy in the atoms to be dissipated in various ways. For example, the vaporisation 
by momentum transfer and ionisation of the sample can be achieved.
Glycerol was used as a solvent, since it has been noted that the best results are 
obtained by coating the plate with a relatively involatile liquid matrix, and mixing the 
substance under investigation into the liquid matrix (Paquette, 1995). One drawback 
with this, however, is that a background of peaks resulting fi'om the presence of 
glycerol are obtained, which must be taken into account.
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The spectra of the sample obtained by FAB-MS was studied and the presence of the 
tetrapeptide, Trp-Met-Asp-Phe amide was indicated by the small peak at 597 m/z, and 
that of the ethyl ester of cholic acid by the large peak at 437 m/z (Fig. 2-24). (For 
ease of referral, Table 2-1 is reproduced below.) The appearance of an ion at 1176 
mass units (Fig. 2-24) seemed to suggest the presence of two peptide units 
condensed; that is, the formation of tetrapeptide dimers (equation 2-5). Expansion of 
the region around the peptide dimer (Fig. 2-25) revealed the presence of a small ion at 
988 mass units. This was the very close to the expected mass of the cholic acid- 
tetrapeptide conjugate.
Table 2-1: Molecular weights of components of conjugation sample
Co m p o n e n t M o l e c u l a r . W eight
Cholic acid 408
DCC 206
N-Hydroxysuccinimide 115
Tetragastrin 596
Tetragastiin-cholic acid conjugate 986
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Fig. 2-24: FAB-MS spectrum o f  conjugate sample. Spectrum is plot o f  relative abundance, with the 
largest peak assigned 100%, against the molecular weight.
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Fig. 2-25: FAB-MS spectrum o f  conjugation sample showing expansion o f  the region around the 
peptide dimer (1176m/z). Spectrum is plot o f  relative abundance, with the largest peak assigned 
100%, against the molecular weight.
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2.3.6 Tetragastrin-cholic acid conjugation - further alterations to the procedure 
It was apparent that in order to increase the yield of the cholic acid-tetragastrin 
conjugate, it would be necessary to modify the procedure further. Prevention of the 
dimer formation may be achieved by blocking the carboxyl group (-COOH) belonging 
to aspartate, leaving the amino group (-NH2) of tryptophan free to bind to the 
carboxyl group of cholic acid. However, this would be a very specialised task, 
preferably carried out prior to the synthesis of the tetrapeptide. Another option was, 
by use of HPLC, to monitor the time course of completion of the reaction occurring 
between DCC and cholic acid resulting in formation of the acid anhydride (see 
Equation 2-1), prior to addition of N-hydroxysuccinimide and tetragastrin. We could 
thereby assess when cholic acid would be optimally suitable for conjugation with 
tetragastrin. Unfortunately, this method was not feasible since the practice of HPLC 
required solubilization of the reagents in water; however, water would interact with 
the active intermediary of the peptide-cholic acid conjugation reaction, resulting in a 
large reduction in the yield of the peptide-cholic acid conjugate formed.
Two alternative modifications to the conjugation procedure were decided upon in an 
attempt to increase the yield of the required cholic acid-peptide conjugate.
2.3.6(i) Extended reaction time ofprocedure
The first of these was to extend the time interval between combining DCC (1.1 
equivalent) and cholic acid (1.0 equivalent), prior to the addition of N- 
hydroxysuccinimide and tetragastrin (both 1.0 equivalent) to two hours rather than in 
immediate succession, as was the case previously. In doing this, we assumed that the 
reaction between DCC and cholic acid had proceeded almost to completion, if not 
entirely. (Had the use of HPLC been appropriate, we could have monitored the time 
period necessary for the completion of the first stage of the reaction.) As described 
previously, the final sample was refrigerated overnight before filtering to remove any 
white DCU precipitate. It was then transferred to a vacuum where DMF was 
evaporated, leaving a yellow, crystalline product. This was analysed using FAB mass 
spectrometry.
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2.3.6(ii) Omission o f N-hydroxysuccinimide from procedure
A second sample was also produced whereby N-hydroxysuccinimide was omitted in 
order to determine whether this could improve the yield. The conjugation reaction 
differs from that described in Section 2.3.2, in that the cholic acid anhydride, formed 
by reaction of cholic acid with DCC (Equation 2-6), reacts directly with tetragastrin 
to form the tetragastrin-cholic acid conjugate (Equation 2-7).
2.r-C(^ + (  ^ ^ N = C = N
O
R -C
R -C
O +
O
O
- N - C - N -  
H H
cholic acid
R -C
R -C
cholic acid 
anhydride
DCC cholic acid 
anhydride
o
II
R “ C —N H ” R‘ +
peptide peptide-cholic acid 
conjugate
DCU
(Equation 2-S)
o
R - C \ OH
cholic acid
(Equation 2-7)
In order for this to be carried out with some degree of success, it was necessary to 
alter the molarity of the reagents involved in the reaction. With reference to equation 
2-6, it was noted that 2 cholic acid molecules react with one DCC molecule to 
produce one molecule of cholic acid anhydride. This being the case, 2.2 equivalents 
of cholic acid were combined with 1.0 equivalent of DCC. (Cholic acid was slightly 
in excess in order to ensure that no DCC was remaining at completion of the reaction. 
Leftover DCC would be problematic in that it is a very harmful substance, whereas 
remaining cholic acid provides little difficulty.) The sample containing DCC and 
cholic acid was shaken for 30 minutes prior to the addition of tetragastrin (slightly in 
excess of 1.0 equivalent to ensure as great a yield as possible), and the final sample 
refrigerated overnight before filtering off solid DCU and transferring to a vacuum to
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evaporate DMF. This left a yellow crystalline product, similar to that seen previously, 
which underwent analysis using FAB-MS.
2.3.6(iii) Analysis o f products
Figure 2-26 (upper trace) illustrates the results of the mass spectrometry analysis of 
the sample in which the time period between addition of N-hydroxysuccinimide and 
tetragastrin to cholic acid and DCC was extended to 2 hours. There is apparently 
little evidence of an ion at 986m/z, which would correspond to the cholic acid- 
tetragastrin conjugate. This is further verified by Figure 2-26 (lower trace), which 
displays the results obtained over an enlarged scale. It was thereby assumed that the 
method had been unsuccessfijl.
However, Figure 2-27 demonstrates the outcome of the analysis of the sample 
produced by the second modified procedure in which N-hydroxysuccinimide was 
omitted, and provides evidence to suggest the presence of the desired conjugate, 
indicated by a small peak at 989m/z. The size of the yield of the conjugate was 
difficult to determine at this stage, since due to the technique of analysis employed, 
the results were qualitative rather than quantitative, in that ionic compounds were 
under-represented, whereas covalent compounds were fully represented. The modified 
procedure had proved to be more successfiil, with the synthesis of a quantity of the 
tetragastrin-cholic acid conjugate.
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Fig. 2-26: Spectrum obtained after carrying out FAB-MS o f sample in which the time period  
between addition o f N-hydroxysuccinimide and tetragastrin to cholic acid and DCC was extended to 
2 hours. (Lower trace identical to upper, but over enlarged vertical scale.) Spectrum is plot o f  
relative abundance, with the largest peak assigned 100%, against the molecular weight.
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Fig. 2-27: Specttnirn obtained after carrying out FAB-MS o f sample in which N-hydroxysuccinimide 
was omitted from the reaction. (Lower trace illustrates same spectrum, but over an enlarged 
vertical scale.) Spectrum is p lo t o f  relative abundance, with the largest peak assigned 100%, against 
the molecular weight.
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By contrast with HPLC for tetragastrin shown in Fig. 2-14, HPLC (as described 
previously) showed a considerable number of peaks (Fig. 2-28), the identity of which 
could be confirmed only by mass spectrometry of each peak. Thus, the complex 
nature of the sample suggested that the extraction and purification of the conjugate 
would be a time consuming, and not entirely successfiil process.
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Fig. 2-28: HPLC o f  sample in which N-hydroxysuccinimide was omitted from reaction at a gradient 
o f  20-40% in 0.05% TFA/H2O and 0.05% TFA/MeCN. Detection using UV monitoring at 205nm 
(upper trace), 215nm (middle trace) and 280nm (lower trace). Axes indicate relative abundance 
against time o f  elution in min.
2.3.7 SoUd-Phase Synthesis of Tetragastrin-Cholic acid Conjugate 
We were able to gain access to a newly-acquired continuous-flow peptide synthesiser 
(Pioneer Peptide Synthesis Systems - PerSeptive Biosystems) which provided an 
alternative method for the manufacture of tetragastrin-cholic acid conjugate. This
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proved to be simpler, and minimised complications such as the formation of large 
numbers of unknown compounds, which had dogged our previous attempts.
The synthesiser performs solid-phase synthesis, in which peptide chains are assembled, 
on a solid support, from the C-terminus, one amino acid at a time, elongating the 
chain towards the N-terminus, On completion of synthesis, the peptide is cleaved 
from the support to allow isolation of the product.
2.3.7(i) Steps behind solid phase synthesis
The a-amino group of the amino acids used in this procedure were temporarily 
protected by a 9-fIuorenylmethoxycarbonyl (Fmoc) group, thus
Fmoc + HjN-R'-GOOH Fmoc-NH-R*-COOH
amino acid Fmoc-amino acid
In addition, the form of aspartate used was that in which the carboxyl side chain was 
prevented from participation in the reaction by estérification with tertiary butanol, 
thus
O
IICOOH C-0-C(CH3)3
Fmoc-NH-R-COOH + HO-CCCH^)^ Fmoc-NH-R-COOH + H^O
Fmoc-aspaitate tettiaiy butanol side chain protected
Fmoc-aspartate
In the first cycle, attachment of the C-terminal amino acid, Fmoc-phenylalanine, to the 
solid support occurred by way of a linker molecule. In the present study, a PAL 
linker^ [5-(4-Fmoc-aminomethyl-3, 5-dimethoxy-phenoxy) valeric acid] was used, the 
structure of which is shown in Fig. 2-29.
 ^ The PAL linker yields deprotected C-terminal amide peptides. These peptides have structural 
components common to both those peptides yielded by the xanthenyl amide [inker (XAL), and to 
those yielded by the peptide acid support linker (PAC).
OR
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Fig. 2-29: PAL linker structure ( — * denotes polystyrene support).
The free end of the PAL linker has an amine group protected with an Fmoc group. 
During the first cycle of synthesis, the Fmoc group of the PAL linker was removed 
using the secondary amine, piperidine, to expose a free amine group. The carboxyl 
group of Fmoc-phenylalanine was activated and coupled by a condensation reaction 
with the amine group of the PAL linker using O-benzotriazoI-l-yl-N, N, N’, N’- 
tetramethyluronium tetrafluoroborate (TBTU), in the presence of 1- 
hydroxybenzotriazole (HOBt), as the coupling agent.
The Fmoc group attached to the N-terminus of phenylalanine was removed using 
piperidine, and the carboxyl group of Fmoc-aspartate was activated and coupled with 
the exposed amine group of phenylalanine (the side chain protecting group was left 
intact), again using TBTU in the presence of HOBt.
This cycle was repeated (as shown in Fig. 2-30) until the required number of amino 
acids had been added which, in the present case was four (tryptophan-methionine- 
aspartate-phenylalanine). Within each cycle, the reactor was, at the appropriate time, 
flushed through to remove excess amino acids and Fmoc. Fuller details are provided 
in the reference manual (Pioneer™ Peptide Synthesis System User’s Guide).
I  ^ Deblock (remove Fmoc group) support bound amino acid
Repeat for |
each Activate incoming amino acid
amino acid |
 ^ —  Couple to support bound amino acid
Fig. 2-30: Diagram to summarise the manufacture o f  tetragastrin using the continuous-flow peptide 
synthesiser.
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The final stage of the reaction was the attachment of cholic acid to the N-terminus of 
tryptophan. The Fmoc group of tryptophan was removed using piperidine, and 
coupling of the terminal carboxyl group of cholic acid with the amine group of 
tryptophan occurred using TBTU in the presence of HOBt. The condensation 
reaction involved is shown by Equation 2-8.
/OHcOH
CH-
OHHO
C -^----------_ N —  Tip —  M el — Asp —  Phe —  C.
tetiagastrin
■NH,
cholic acid
OH
OH CH.
C — N —  Tip Met —  Phe
CH.
tetiagasbin-cholic acid conjugate
OHHO
 +  H .,0
(Equation 2-8)
Following completion of the tetragastrin-cholic acid conjugate, it was necessary to 
cleave the compound from the PAL linker and polystyrene support, and remove the 
tertiary butanol fi'om the side chain of aspartate. This was done under extremely 
acidic conditions, using trifluoroacetic acid (TFA) (pKa of 0.5), as quickly as possible 
in order to minimise the exposure of the peptide to the acidic reagent.
A 40mg sample was produced in this way. A ninhydrin test on the polystyrene 
support of the synthesiser, on completion of synthesis, was carried out and found to 
be negative, thereby demonstrating that all free amino acids had been utilised in the 
synthesis. The composition of the sample was analysed using FAB mass 
spectrometry.
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2.3.7(ü) Analysis o f sample using FAB mass spectrometry
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Fig. 2-31: Spectrum o f  sample, synthesised using continuous-flow peptide synthesiser, as obtained 
by FAB-MS. Spectrum is plot o f  relative abundance, with the largest peak assigned 100%, against 
the molecular weight.
Figure 2-31 illustrates the results obtained from such an analysis. The spectrum 
obtained appeared to be very much cleaner than the spectra for previous attempts 
(Figs. 2-24 to 2-27), although several peaks relating to different ions were found. 
However, most importantly, an ion at 987m/z was evident, and attributed to the cholic 
acid-tetragastrin conjugate; this was evidence indeed that the conjugation procedure 
had been successful (for ease of referral. Table 2-1 is reproduced below).
Table 2-1: Molecular weights of components of conjugation sample
C o m p o n e n t M o l e c u l a r  W eigkt
Cholic acid 408
DCC 206
N“Hydroxysuccinimide 115
Tetragastrin 596
Tetragastrin-cholic acid conjugate 9,96
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The other peaks presented, notably at approximately 338, 411, 579 and 673m/z were 
more difficult to define; however, the process of FAB mass spectrometry may result 
in the fi-agmentation of the compound under analysis, and it was thought that this may 
account for these peaks. For example, fi-acture of the conjugate at the bond linking 
tiyptophan and methionine, resulting in the production of a cholic acid-tryptophan 
compound, and a separate tripeptide, might account for the ions at 411 and 579m/z. 
Expansion of the spectrum scale (Fig. 2-32) revealed larger ions at approximately 
1010, 1067, 1084, 1106 and 1180m/z. Again, these were difficult to characterise, 
although the ion at 1180m/z was likely to be the tetragastrin dimer, previously 
described. The ion at 1084m/z may be due to trifluoroacetylation of the conjugate, 
since this would increase the mass by 97m/z. (This would have arisen during the 
removal of the tertiary butyl protecting group fi-om the amino acid side chains, and 
also when detaching the final sample fi-om the polystyrene support.) To reiterate, we 
were unable to determine the actual yield of each of these components since, due to 
the technique of analysis employed, ionic compounds were under-represented, 
whereas covalent compounds were fully represented.
Fig. 2-32: Spectrum o f  sample, synthesised using continuoiis-Jlow peptide synthesiser, over an 
enlarged horizontal and vertical axis, as obtained by FAB-MS.
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2.3.7(iii) Analysis o f sample using HPLC system
We required assurance that our sample, synthesised in the continuous-flow peptide 
synthesiser, was reasonably pure, given that many of the ions disclosed in the FAB 
mass spectra presumably occurred as a consequence of fragmentation. It was 
decided, therefore, to carry out further analysis using HPLC, as described previously. 
Figure 2-33 demonstrates the chromatograms obtained at wavelengths 205, 215 and 
280nm. As has been stated, HPLC analysis at 205nm is used for detection of 
compounds containing peptide bonds, 215nm is the traditionally selected option, and 
280nm discloses compounds containing aromatic groups, such as phenylalanine and 
tryptophan. Thus, the chromatogram at 280nm provides the best guide for 
assessment of our sample.
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Fig. 2-33: HPLC o f  the sample, synthesised using continuous-flow peptide synthesiser, at a gradient 
oj 20-40% in 0.05% TFA/H2O and 0.05% TFA/MeCN. Axes indicate relative abundance against 
time o f  elution in min.
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It was clear that there is not a single species present, but rather three pairs of peaks. 
It may be suggested that the pairs of peaks arose as the result of the formation of two 
species of tetragastrin of the same molecular weight, as shown by the HPLC of the 
Sigma tetragastrin sample (Fig. 2-14), which was presumably manufactured in a 
similar way to the present sample. The multiple pairs of peaks indicate, in addition, 
two errors of synthesis of the tetragastrin-cholic acid conjugate, the identity of which 
could be made only by collecting HPLC fractions and performing mass spectrometry 
on them. However, on an intuitive basis, inspection of the trace detected at 280nm 
(Fig. 2-33), would suggest that the major pair of peaks at 30 min represents the 
tetragastrin-cholic acid conjugate, while the other two pairs of peaks represent errors 
of synthesis.
Given the normal high efficiency of this method of chemical synthesis, namely, that it 
manufactures peptides of very high purity, we were constrained not to be deflected 
into seeking the identity of the different peaks observed with HPLC. We accepted, 
for the purpose of this study, that the sample produced by continuous-flow peptide 
synthesis was sufficiently pure.
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R eSu ltS
3.1 Physiological experiments
3.1.1 Gastric acid secretion in response to tetragastrin
Initially, we required to determine the increase in gastric acid secretion above basal 
levels in response to intravenous injection of the test peptide, tetragastrin (Trp- 
Met-Asp-Phe amide), in the anaesthetised rat. The minimum effective dose of 
tetragastrin was established by first administering intravenously a bolus injection of 
12.5|4g kg'  ^ tetragastrin, and observing the effect on gastric acid secretion, which 
was measured for consecutive 15 min periods. If this was ineffective in initiating 
an unequivocal response, the dose was increased stepwise to a maximum of 60pg 
kg '\ A second l.v. injection of the same dosage, prior to completion of the 
experiment, was used to confirm the viability of the preparation.
3.1.1 (i) The effect o f tetragastrin (L V.)  on gastric acid secretion
Atypical experiment (Figure 3-1) demonstrated that injection of tetragastrin (20 pg 
kg '\ l.v.) (first arrow) caused an increase in gastric acid secretion to a peak value 
of 0.73pmol 15min'  ^ above baseline, and resulted in a cumulative increase in acid 
secretion of 2.57pmol hr'\ The response remained elevated above control values 
for 60 minutes. In order to test for reproducibility of the response, a second
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Fig. 3-1: The effect on intravenous tetragastrin (20pg kg' ,^ first and second arrows) on gastric 
acid secretion in the anaesthetised rat (rat 5 in Table 3-1).
105
Results
identical injection of tetragastrin was administered (second arrow) 135 minutes 
after the first. This was seen to produce a peak increase in acidity of 1.26pmol 
15min\ 1.7 times larger than the peak response seen in response to the initial 
injection of tetragastrin. The peak increase in acidity in response to both the first 
and second injection was observed to occur in the second collection period, that is 
between 15 and 30 minutes after introduction of the tetrapeptide into the venous 
system. However, the response to the second injection of tetragastrin remained 
elevated above baseline for a duration of 90 minutes, and a cumulative gastric acid 
secretion totalling 3.24pmol hr"^  was seen, demonstrating a 1.3-fold increase over 
the previous cumulative response.
Table 3-1: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to intravenous tetragastrin (G4) (minimum effective dose) as a first 
and second procedure.
Rat Initial I.V. G4 Second l.v. G4
Peak increase Cum. increase Peak increase Cum. increase(Mmol ISmin'b (Mmolhr’^) (Mmol ISmin’b (Mmol hr')
1 0.13 0.46 0.76 1.52
2 0.62 1.57 1.12 3.21
3 0.46 0.69 0.87 1.3
4 0.72 1.62 0.49 1.97
5 0.73 2.57 1.26 3.24
Mean 0.53+0.25 1.38+0.84 0.90 + 0.30 2.25 + 0.92
+ S.D. (P=0.009) (P-0.021) (P-0.003) (P=0.006)
P-values denote sta tistical significance fo r  comparison with baseline.
Similar experiments were carried out on a total of 5 animals, the results of which 
are presented in Table 3-1. A further animal died prior to completion of the 
experiment. The mean values demonstrated that an initial injection of tetragastrin 
(minimum effective dose, l.v.) resulted in a significant peak increase in gastric acid 
levels, above baseline, to 0.53 ± 0.25pmol 15min^ (P=0.009). A mean cumulative 
response of 1.38 + 0.84pmol hr'  ^ was found to be significant (P=0.021). A 
subsequent injection of tetragastrin (the same min. effective dose, l.v.) was 
administered between 65 and 180 minutes later (actual period of injection was
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dependent on the time taken for the baseline to settle after the response to the first 
injection), and led to an increase in peak gastric acid levels of 0.90 ± 0.30p.mol 
15min'  ^ (P=0.003). Increased gastric acid levels over a period of one hour 
following administration were found to total a mean cumulative value of 2.25 ± 
0.92p,mol hr"‘ (P=0.006). A paired t-test demonstrated that the peak increases in 
gastric acid secretion in response to the first and second intravenous injection were 
not statistically different (P=0.075), whereas the cumulative responses to the 
second intravenous injection were considered to be significantly larger than the 
response to the first (P=0.018). This was likely to be due to the fact that the 
duration of the increase in acid secretion in response to the first injection of 
tetragastrin was typically of shorter duration than that in response to the second (a 
mean value of 51 minutes compared with 81 minutes).
3^1.1 (ii) Effect o f intra-ileal (I. I.)  infusion o f tetragastrin on gastric acid 
secretion
It was central to the project to determine whether biologically active tetragastrin 
could be absorbed across the wall of the small intestine, thereby enhancing gastric 
acid secretion. In order to investigate this, a series of experiments was undertaken 
in which the following protocol was followed. First, the minimum effective dose 
of tetragastrin (between 12.5 and 60jag kg'^) was administered intravenously, and 
gastric acid levels were shown to increase, as was anticipated. On return to 
baseline, 600|ag kg"^  tetragastrin (in 1.0ml isotonic saline) was infused into the 
ileum via a cannula inserted close to the ileo-caecal junction (see Methods). After 
an interval of 90-105 minutes, a subsequent injection of tetragastrin (same 
minimum effective dose, l.v.) was administered.
Figure 3-2 illustrates a typical response to such a procedure. The initial dose of 
tetragastrin (15pg kg"\ l.v.) (first arrow) resulted in an elevated gastric acid level 
to a peak value of l.llpm ol 15min \  occurring in the second collection period. 
The overall response lasted for a duration of 45 minutes, giving a cumulative rise 
in total acidity above baseline of 2.02|imol hr'\ Following the return of gastric 
acid secretion to pre-injection levels, administration of ileally-infiased tetragastrin
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(600p,g kg'  ^ in 1.0ml isotonic saline) (second arrow) had no discernible effect on 
gastric acid secretion which actually fell to slightly below basal level by O.Olpmol 
over the 90 minute duration, prior to subsequent intravenous infusion of 
tetragastrin (ISpg kg"^ ) (third arrow). This second intravenous injection resulted 
in a peak increase in total acidity of 1.14|rmol 15min \  which occurred in the 
collection period in which the injection was given. The increase in gastric acid 
secretion lasted for 45 minutes before falling back to the control level. A 
cumulative response of 2.43pmol hr"^  was thereby attained.
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Fig. 3-2: The effect o f  intravenous tetragastrin (ISfxg kg'\ first and third arrows), and ileally- 
infused tetragastrin (600pg kg' ,^ second arrow) on gastric acid secretion in the anaesthetised rat 
(rat 4 in Table 3-2).
Eleven such experiments were carried out following the above standard procedure 
(the experiment did not go to completion in a further two rats); the results are 
presented in Table 3-2. Overall, the initial intravenous injection of tetragastrin (15, 
30 or ôOjig kg'^) resulted in a significant increase of gastric acid levels above 
baseline to a mean peak value of 0.58 ± 0.33p,mol ISmin'^ (P=0.001), and a mean 
cumulative acidity of 1.27 ± 0.83p,mol hr"^  (P=0.001). With the exception of three 
animals, in which the peak increase was present in the second collection period (i.e. 
the collection period following the one in which the injection was administered), 
the peak increase in acidity was found to occur in the period of injection. The 
mean duration of the response was 48 minutes, a value comparable to that of the 
response to the initial intravenous injection of tetragastrin in the previous 
experiment. In response to ileal infusion of tetragastrin (600pg kg'^), a mean drop
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in total acidity of 0.26 ± 0.40pmol 90min'^ was found not to be significant 
(P=0.055). Subsequent infusion of tetragastrin (15, 30 or 60|xg kg '\ l.v.) resulted 
in a significant increase in gastric acid levels of 0.81 ± 0.53|j,mol 15min  ^
(P=0.001). This occurred typically in the period of injection, although one rat 
presented a peak response in the fourth collection period, 45 to 60 minutes after 
injection. However, a sizeable response was present in the first collection period 
of 0.48pmol 15min'\ The duration of response was difficult to determine, since in 
only four rats did the gastric acid levels return to pre-injection levels whereas, in 
the other seven, acid levels remained elevated. However, a significant cumulative 
increase in total acidity of 2.43 ± 1.86p.mol hr"^  (P=0.002) resulted.
Table 3-2: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to ileally-administered tetragastrin (G4) (600pg kg  ^ in 1.0ml saline) 
over 90 minute period, and to intravenous tetragastrin (15, 30 or 60pg kg^) 
as a first and final procedure.
Rat Initial I.V. G4 Ileal G4 Second l.v. G4
Peak Cum. Cumulative increase Peak Cum.
increase increase 90min’') increase increase(jimol ISmin'b (jLunoI hr’') (fxmol ISmin ') (jumollir’')
1 0.44 0.87 -0.28 0.52 1.59»
2 0.85 2.82 -0.31 2.01 6.95»
3 1.01 2.37 -0.68 0.93 3.11»4 1.11 2.02 -0.01 1.14 2.43
5 0.31 0.49 0.01 0.20 0.47
6 0.49 1.21 -1.25 0.50 1.18
7 0.33 0.89 0.00 0.30 0.93*
8 0.27 0.48 -0.43 0.40 1.30»
9 0.28 0.31 -0.06 0.56 1.54
10 0.30 0.88 0.09 1.17 3.99»
11 0.96 1.63 0.01 1.13 3.25»
Mean 0.58+0.33 1.27+0.83 -0.26 + 0.40 0.81+0.53 2.43+1.86
± S.D. (P=0.001) (P-0.001) (P=0.055) (P-0.001) (P-0.002)
P-values denote sta tistica l significance f o r  com parison with baseline.
* denotes establishm ent o f  new baseline which was elevated com pared with that a t sta rt 
o f  experiment.
A paired t-test demonstrated that, although the mean peak responses to the first 
and second intravenous injections were not significantly different from each other, 
the cumulative responses were (P=0.095 and P=0.018, respectively). As before.
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the elevation of acid levels over a longer period of time in response to the second 
intravenous injection would appear to account for this.
From this series of experiments, we deduced that ileally-infused tetragastrin was 
unable to cross the wall of the ileum over a 90 minute sampling period, and 
therefore showed no discernible effect on gastric acid levels. However, the 
significantly greater mean cumulative increase in gastric acid levels in response to 
the second intravenous injection of tetragastrin indicates the possibility that 
potentiation of the response may have occurred by the absorption of biologically 
active tetragastrin across the ileal wall. It may be the case that a duration of 90 
minutes, in which the effects of ileally-infijsed tetragastrin were measured, was not 
sufficient to allow the passage of tetragastrin, or perhaps subliminal levels 
permeated the ileal wall but were ineffective in inducing a perceivable enhancement 
of gastric acid secretion. Experiments were subsequently carried out to investigate 
these questions.
3.1.1 (iii) Effect o f a higher dose o f tetragastrin (LI.)  on gastric acid secretion 
A series of experiments similar to the aforementioned protocol was undertaken on 
four rats. As before, the minimum effective dose (in this case, 12.5p.g kg‘^ ) was 
administered intravenously; however, 2500pg kg"^  tetragastrin (in 5.0ml) was then 
infused into the ileum and gastric acid secretion was followed over a period of 90 
minutes, in order to determine whether the increased total amount of tetragastrin 
would raise gastric acid levels above baseline values. This was followed by a 
second intravenous injection of tetragastrin (12.5|ig kg'^), as described previously.
An example of the outcome of such an experiment is shown in Figure 3-3. 
Intravenous administration of tetragastrin (12.5pg kg'^) (first arrow) resulted in 
enhancement of gastric acid secretion to a peak value of 0.40pmol 15min"^  above 
baseline in the period of injection. The response lasted for 30 minutes before 
settling at a total gastric acidity elevated above pre-injection value. This amounted 
to a cumulative total acidity of l.lOpmol hr"\ Following the re-establishment of a 
settled baseline, albeit at a raised value from the previous level, ileal infiision of 
tetragastrin (2500pg kg'  ^ in 5.0ml isotonic saline) was carried out (second arrow).
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and samples collected at 15 minute intervals for a further 90 minutes. Ileal 
tetragastrin had no apparent effect on gastric acid levels over this period of time; a 
cumulative drop in acidity of O.OSpmol hr"^  was determined. Following this 90 
minutes period, an intravenous injection of tetragastrin, identical to the first, was 
administered (third arrow), resulting in a peak increase in acidity of 0.39pmol 
15min'\ This occurred in the period of injection, with acid levels remaining above 
baseline for 30 minutes before returning to pre-injection level. A cumulative 
increase in total acidity of 0.65pmol hr’^  above baseline was observed in response 
to this injection.
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Fig. 3-3: The effect o f  intravenous tetragastrin (12.5 jug kg'\ first and third arrows), and ileally- 
infused tetragastrin (2500jug kg'  ^ in 5.0ml saline), second arrow) on gastric secretion in the 
anaesthetised rat (rat 4 in Table 3-3).
In this series of experiments, the peak response to both the first and second 
intravenous injection of tetragastrin (12.5pg kg"^ ) typically occurred in the period 
of injection, and the increased response above baseline lasted between 30 and 45 
minutes. The mean peak increase in gastric acid secretion in response to the initial 
procedure was 0.47 ± 0.16pmol 15min \  and that to the second intravenous 
injection was 0.36 ± 0.06pmol 15mih\ both of which were significantly increased 
with respect to baseline (P=0.010 and P=0.002, respectively) (Table 3-3). Further, 
the cumulative increases in acid secretion above baseline over the hour following 
both the first and second intravenous injection of tetragastrin were significant when 
compared to baseline (1.15 ± 0.36pmol hr'\ P=0.008; 0.64 + 0.29pmol hr"\ 
P=0.022, respectively). Similar to the previous experiments, ileal infusion of
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2500pg kg‘^  tetragastrin did not significantly enhance gastric acid secretion over a 
90 minute period. Indeed, a mean cumulative drop of 0.13 ± 0.19pmol hr'  ^was 
demonstrated, though this was not significant (P=0.26).
Table 3-3: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to ileally-administered tetragastrin (G4) (2S00pg kg  ^ in 5.0ml 
saline) over 90 minute period, and to intravenous tetragastrin (minimum 
effective dose) as a filrst and final procedure.
Rat Initial I.V. G4 IlealG4 Second l.v. G4
Peak Cum. Cumulative increase Peak Cum.
increase increase (nmol 90min'‘) increase increase
(jjmol 15niiii'‘) (junol hr'h (nmol 15min'') (nmollir"')
1 0.60 1.35 0.07 0.41 1.04*
2 0.28 0.66 -0.38 0.35 0.46
3 0.59 1.48 -0.13 0.27 0.39
4 0.40 1.10* -0.08 0.39 0.65
_Mean 0.47+0.16 1.15+0.36 -0.13 + 0.19 0.36+0.06 0.64+0.29
+ S.D. (P=0.010) (P=0.008) (P=0.26) (P=0.002) (P=0.022)
P-values denote statistical significance for comparison with baseline.
* denotes establishment o f new baseline which was elevated compared with that at start 
of experiment.
A paired t-test demonstrated that there were no significant differences either in the 
peak or in the cumulative responses to the first and second intravenously infused 
tetragastrin (P=0.29 and P=0.082, respectively). This thereby demonstrated some 
discrepancy when comparing the cumulative responses of this series of experiments 
with the cumulative responses of previous experiments. This discrepancy appears 
to lie with the fact that the duration of the response to the second intravenous 
injection, in this set of experiments, lasted for a shorter duration than in previous 
experiments. However, we can still have confidence that the preparation was 
viable in the latter stages of the experiment. Furthermore, this series of 
experiments provides evidence to suggest that ileal tetragastrin was unable to cross 
the wall of the ileum and further enhance the secretion of gastric acid in response 
to the second intravenous infusion.
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3.1. l(iv) Higher dose o f intra-ileal tetragastrin as higher concentration over 
extended time period 
As before, a minimum effective dose (12.5 or 25pg kg'l) of tetragastrin (l.v.) was 
followed by intra-ileal infusion of tetragastrin and then, finally, by a second 
intravenous infusion of tetragastrin. However, this time the increased dose of 
ileally-infused tetragastrin (2500jag kg'^), now in 1.0ml isotonic saline, representing 
a five-fold increase in concentration, was allowed to remain in the intestine for 180 
minutes, that is, almost double the length of time in previous experiments, before 
the second intravenous injection of tetragastrin was administered. In addition to 
allowing us to test fiirther the two questions as to whether intra-ileal tetragastrin in 
much higher concentration increased gastric acid levels, per se, and whether it 
potentiated the response of the second intravenous injection of tetragastrin, by 
increasing the duration of the experiment, this would also resolve whether ileal 
tetragastrin absorption had, in fact, been limited by the 90 to 105 minute period 
allowed in the previous experiments. In order to minimise the volume of fluid 
injected into the small intestine, the tetragastrin was fi-eeze-dried and then 
dissolved in 1.0ml isotonic saline, rather than injecting 5.0ml solution, as described 
previously.
Figure 3-4 demonstrates the outcome of a typical experiment. Tetragastrin 
(12.5pg kg '\ I.V.) (first arrow) caused gastric acid secretion to increase to a peak 
value of 0.40pmol 15min'  ^ above baseline and, although this occurred in the third 
collection period following injection, a noticeable increase was observed in the 
collection periods prior to this (0.12pmol 15min  ^ in the period of injection, and 
0.34pmol 15min  ^ in the second period). The response remained elevated for a 
total duration of 60 minutes, whereby a cumulative gastric acid secretion of 
1 06pmol hr'  ^above baseline was attained. Consistency with previous experiments 
resulted as regards the invariance of the level of gastric acid secretion in response 
to ileally-infiised tetragastrin (2500pg kg'  ^in 1.0ml isotonic saline) (second arrow).
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Fig-3-4: The effect o f  intravenous tetragastrin (I2.5fjg kg'\ first and third arrows), and ileally- 
infused tetragastrin (2500ftg kg'  ^ in 1.0ml saline, second arrow) on gastric acid secretion in the 
anaesthetised rat (rat 2 in Table 3-4).
This was ineffective in producing any noticeable change in the gastric acid 
secretion from basal levels over a 180 minute period. A second intravenous 
injection of tetragastrin, identical to the first, was administered subsequently (third 
arrow), and resulted in an increase in peak total acidity of 0.45pmol 15min'  ^ in the 
period of injection, resulting in a cumulative rise in titratable acidity above baseline 
of 0.85pmol hr"\ Thus, the viability of the preparation at this late stage in the 
procedure was assured.
Table 3-4: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to ileally-administered tetragastrin (G4) (2500pg kg  ^ in 1.0ml 
saline) over 180 minute period, and to intravenous tetragastrin (minimum 
effective dose) as a first and final procedure.
Rat Initial I .V . G4 IlealG4 Second l.v. G4
Peak Cum. Cumulative increase Peak Cum.
increase increase (nmol ISOrain ’) increase increase
(nmol ISniin'h (nmol lir ‘) (nmol 15mm') (nmol hr"')1 0.54 0.87 -0.33 0.73 1.982 0.40 1.06 0.00 0.45 0.853 0.45 1.06 -0.37 0.57 1.534 0.29 1.00 0.05 0.38 1.255 0.34 0.62 -0.46 0.53 0.79
6 0.51 0.41 -0.26 0.35 0.78
Mean 0.42+0.10 0.84+0.27 -0.23+0.21 0.50+0.14 1.20+0.49±S.D. (P-0.001) (P-0.001) (P-0.043) (P=0.001) (P=0.002)
P-values denote sta tistica l significance fo r  comparison with baseline
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A total of six such experiments were carried out, and the results are tabulated in 
Table 3-4. A significant increase in mean gastric acid secretion, with respect to 
baseline, of 0.42 ± O.lOpmol 15min'  ^ (P-0.001) was observed in response to an 
initial administration of intravenous tetragastrin (12.5 or 25pg kg“^ ). The peak 
response occurred in either the period of injection or the subsequent collection 
period (between 0 and 15 minutes, or between 15 and 30 minutes, respectively), 
with the exception of one rat, in which the peak response occurred in the third 
collection period (see Fig. 3-4). Gastric acid levels remained elevated above 
baseline for a duration of between 30 and 60 minutes, and a mean cumulative 
increase in gastric acidity was calculated as being 0.84 ± 0.27pmol hr'  ^(P-0.001). 
Ileal infiision of tetragastrin (2500pg kg"^  in 1.0ml isotonic saline) resulted in a fall 
in gastric acid levels of 0.23 ± 0.21pmol hr'  ^which was significant (P=0.043), and 
we can thus infer that tetragastrin was unable to cross the wall of the ileum and 
enter the bloodstream to any detectable extent over a 180 minute period. A 
second intravenous injection of tetragastrin (12.5 or 25pg kg'^) resulted in a 
significant mean peak increase in acidity of 0.50 ± 0.14pmol 15min  ^ (P=0.001), 
which typically occurred in the period of injection. Gastric acid secretion remained 
elevated above basal levels for a duration of between 45 and 60 minutes, resulting 
in a mean cumulative titratable acidity of 1.20 ± 0.49pmol hr'  ^ (P=0.002). By 
comparison of the mean peak response to the initial dose of intravenous 
tetragastrin with that to the second, it was determined that the mean peak response 
to the second l.v. injection was significantly larger (P=0.027), while the mean 
cumulative response was not significantly different (P-0.099).
It is therefore likely that ileal tetragastrin did not exert a detectable increase on 
gastric acid secretion during its presence in the ileum over 180 minutes but rather 
may have caused a decrease. Likewise, it did not cause an unequivocal 
potentiation of the increased cumulative gastric acid levels observed in response to 
the final intravenous injection of tetragastrin. This is shown by the ratio of the 
second to the first cumulative acid secretion which, in the present experiment was 
1.43. This is actually less than the ratio for either the 600pg kg'  ^ intra-ileal 
infusion experiment (Table 3-2) which was 1.91 or the control experiment (Table
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3-1) which was 1.63. Furthermore, in the present series of experiments, the 
sensitivity of the animal to the final intravenous injection of tetragastrin confirmed 
the viability of the preparation in every case.
3.1.2 Gastric acid secretion in response to intravenously administered 
tetragastrin-cholic acid conjugate (G-CAl 
Our previous experiments have demonstrated an increase in gastric acid secretion 
in response to intravenous administration of between 12.5 and 60pg kg'  ^
tetragastrin as a minimum effective dose. In order to provide a direct comparison 
of G-CA-elicited response with the previously observed response to tetragastrin, a 
similar dose of G-CA was administered intravenously. Since G-CA is comprised 
of tetragastrin and cholic acid in an approximate weight ratio of 3:2 (formula 
weights of tetragastrin and cholic acid are 597 and 408, respectively), the dose 
injected in the first instance was 40pg kg"^  (i.e. equivalent to 25pg kg'  ^tetragastrin 
alone). This was successful in every case (n=4) in evoking an increase in gastric 
acid secretion for which both the mean peak increase of 0.62 ± 0.22pmol 15min  ^
and the mean cumulative increase in acidity over the first hour following 
administration of 1.45 ± 0.14pmol hr'  ^were statistically significant (P=0.011 and 
P=0.001, respectively) (results not tabulated).
However, it was later considered necessary to reduce this intravenous dose to a 
minimum effective dose of 15pg kg'  ^ (for reasons explained in Section 3.1.3); 
nevertheless, in the experiments in which 15pg kg"^  was administered, a significant 
increase in both the mean peak response (0.49 ± 0.13pmol 15min'\ P=0.002; n=5), 
and the mean cumulative response (1.10 ± 0.73pmol hr' ;^ P=0.027; n=5) was 
present (Table 3-5). There was a divergence in the collection period, after the 
intravenous injection, in which the peak response occurred. In 3 rats, it arose in 
the first collection period (i.e. the same one in which the injection was given), 
whereas in 2 rats, it was presented in the second and in the third collection period. 
The increase in total gastric acidity above baseline in response to intravenous G- 
CA lasted for between 15 and 30 minutes in 3 out of 5 rats. Since the gastric acid 
levels did not return to baseline, but remained slightly elevated, in 2 rats, the 
duration of response was difficult to quantify.
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Interestingly, the mean increases in total gastric acidity evoked by 15pg kg’  ^G-CA 
(I.V.) were very similar in magnitude with the rise in gastric acidity obtained in 
response to 20pg kg'  ^ intravenous tetragastrin (Table 3-1) (mean peak absolute 
increase in acidity of 0.53 ± 0,25pmol 15min'\ c,f, 0.49 ± 0.13pmol 15min'  ^
elicited by 15pg kg'^ l.v. G-CA, and mean cumulative increase in acidity of 1.38 ± 
0.84pmol hr"% cf. 1.10 ± 0.73pmol hr'  ^elicited by 15pg kg"^  l.v. G-CA). A two 
sample t-test determined that neither the peak responses nor the cumulative 
responses to tetragastrin and to G-CA were significantly different in these two sets 
of experiments (P=0.77 and P-0.56, respectively).
A typical experiment is illustrated in Figure 3-5, whereby 15pg kg“^ G-CA was 
administered intravenously (arrow), following attainment of a steady baseline, 45 
minutes after sampling had begun. A peak increase in gastric acid secretion in 
response to G-CA was observed in the first collection period containing 
administration (that is, between 0 and 15 minutes after bolus injection), and total 
acidity was seen to rise to 0.43pmol 15min  ^above control values. The cumulative 
increase in gastric acid levels over the hour following injection was 1.13 pmol hr'  ^
(although the response could reasonably be considered to last for only 30 minutes, 
since a new elevated baseline was reached after 45 minutes).
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Fig. 3-5: The effect oJ intravenous G-CA (15jug kg' )^ (arrow) on gastiic acid secretion in the 
anaesthetised rat (rat 5 in Table 3-5). Figure illustrates the initial results for this particular 
experiment in order to show the biological activity o f G-CA. The full record is given in Figure 
3-6.
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The reproducibility of the response was tested with a second intravenous injection 
of G-CA (15pg kg"\ I.V.) administered 180 minutes after settling of the baseline 
following the first intravenous injection of G-CA in 5 rats. This was to determine 
whether the response to the second intravenous injection differed significantly fi*om 
the response to the first, thereby allowing us to compare our results from these 
experiments with those obtained in later experiments in which G-CA was 
administered intra-ileally in-between the intravenous infusions of G-CA 
The initial intravenous injection of G-CA (15pg kg"^ ) elicited a significant mean 
peak increase in acidity of 0,49 ± 0.13pmol ISmin'^ (P=0.002) above baseline, and 
a mean cumulative rise in gastric acid secretion of 1.10 ± 0.73pmol hr  ^(P-0.027), 
which may be compared with the subsequent administration of an equivalent dose 
of G-CA, which resulted in a mean peak increase in acidity of 0.65 ± 0.28pmol 
15min'  ^ (P=0.007) and a cumulative increase of 1.46 ± 0.84pmol hr'  ^ (P=0.018) 
(Table 3-5). Application of a paired t-test demonstrated that the absolute peak 
increase and the cumulative increase in acidity above baseline elicited by the first 
and second injections of G-CA were not significantly different (P=0.35 and 
P=0.57, respectively).
Table 3-5: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to LV. tetragastrin-cholic acid conjugate (G-CA) (15pg kg ) as a 
first and final procedure.
Rat Initial l.v. G-CA Second I.V. G-CA
Peak increase Cum. increase Peak increase Cum. increase(Mmol I5niin'') (Mmol hr'*) (Mmol 15miii'*) (Mmol hr'*)
1 0.46 1.18* 0.54 1.43*
2 0.73 2.25* 0.54 1.19
3 0.43 0.43 1.13 2.89
4 0.42 0.53 0.43 0.72
5 0.43 1.13 0.61 1.08
Mean 0.49+0.13 1.10 + 0.73 0.65+0.28 1.46+0.84
+ S.D. (P=0.002) (P=0.027) (P=0.007) (P=0.018)
P-values denote sta tistical significance fo r  com parison with baseline.
* denotes establishm ent o f  new baseline which was elevated com pared with that a t s tart 
o f  experiment.
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The results of a full typical experiment are illustrated in Figure 3-6, in which 15pg 
kg'  ^ G-CA was injected 45 minutes after collections began (first arrow), and a 
settling of the basehne had been attained (second arrow). The initial 15pg kg'  ^
dose elicited a peak increase of 0.43pmol 15min'  ^ above baseline in the first 
collection period (that is, between 0 and 15 minutes after administration), and the 
increased response lasted for a total of 30 minutes before returning to control 
levels, resulting in a cumulative enhanced response of 1.13 pmol hr'\ The response 
to the second intravenous injection was similar in both magnitude and duration. A 
peak increase of 0.61 pmol in the first collection period, and a cumulative rise of 
1.08pmol hr'  ^ were recorded. Again, the duration of increased acidity above 
original levels was 30 minutes.
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Fig. 3-6: The effect o f  inti'ovenous G-CA (I5pg kg'\ first and second arrow) on gastric acid 
secretion in the anaesthetised rat (rat 5 in Table 3-5). The initial part o f  this figure is shown in 
Fig. 3-5.
3.1.3 Gastric acid secretion in response to ileallv-administered tetragastrin-cholic 
acid conjugate (G-CAl
3.1.3 (i) Ileal administration o f G-CA (1600jug k g f
The establishment of an unequivocal increase in acidity in response to 
intravenously administered G-CA prompted us to proceed with our experiments to 
test the ability of ileally-administered G-CA to enhance gastric acid secretion.
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In these experiments, a similar experimental protocol to that carried out in the 
control experiments using tetragastrin was followed. Therefore, we initially 
administered 40pg kg'  ^ I.V. G-CA, followed by 1600pg kg'  ^ ileal G-CA for a 
period of 180 minutes, followed finally by a subsequent injection of G-CA (40pg 
kg '\ I.V.). This procedure was carried out on four rats, and produced the 
following results (Figure 3-7A-D).
Figure 3-7A illustrates the results obtained for one of these rats. Intravenous 
administration of G-CA (40pg kg'^) (first arrow) elicited a peak increase in gastric 
acidity of 0.46pmol 15min'  ^ above baseline over the first 15 minutes following 
injection. The response lasted for a total of 15 minutes before settling at an 
elevated baseline. Ileal administration of 1600pg kg'  ^ G-CA (in 1.0ml isotonic 
saline) (second arrow) gave a surprising response. In the first period after 
administration, gastric acid levels rose to 0.17pmol 15min^ above baseline; a peak 
response of 0.28pmol 15min"^  was observed after 60 minutes. The enhanced 
response was still present at 135 minutes, when the total cumulative increase in 
gastric acid secretion above basal levels was 1.89pmol 135min\ A second 
intravenous injection of G-CA (40pg kg“^ ) (third arrow) was then administered, 
and resulted in a peak increase in gastric acid levels above baseline of 0.31 pmol 
15min"^  in the first 15 minutes. The response to G-CA (l.v.) lasted for 30 minutes, 
giving an increased total acidity of 0.61 pmol overall.
The results of a second similar experiment (Fig. 3-7B) demonstrated that 
intravenously administered G-CA (40pg kg"^ ) (first arrow) resulted in an increase 
in gastric acid levels above baseline which, in this case, was unusually high, with a 
peak rise of 0.93pmol 15min  ^ in the first collection period. The elicited response 
lasted for a duration of 30 minutes, and the total increase in acid levels was 
1.13 pmol 15min'\ Ileal administration of G-CA (1600pg kg'  ^ in 1.0ml isotonic 
saline) (second arrow) did not result in an increase in acidity; rather, gastric acid 
levels over the 180 minute duration were observed to drop by a total of 6.76pmol. 
In order to confirm that the preparation was still sensitive to G-CA, a second
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intravenous injection of G-CA (40|ig kg'^) (third arrow) was administered, which 
resulted in a similar peak increase in acidity as that elicited by the first intravenous 
injection. The peak increase of 0.92jj.mol 15min  ^ was observed in the second 
collection period, that is, between 15 and 30 minutes after injection. However, the 
duration of the response, and a value for the cumulative response were difficult to 
quantify since acidity appeared to settle down at a higher gastric acid level, that is, 
the baseline appeared to shift upwards.
The conflicting results observed in these two experiments were puzzling. It was 
noted that the gastric acid levels prior to ileal administration of G-CA were very 
much lower in the rat in which ileally-administered G-CA was effective in evoking 
increased levels of gastric acid secretion than in the rat in which ileal G-CA was 
ineffective (0.12pmol 15min'  ^and 1.34pmol 15min\ respectively). However, why 
the initial baseline should influence the response to ileal G-CA, especially when 
intravenous injection of G-CA evoked a normal response, is difficult to explain. 
Similar procedures were attempted on a further two rats (Figs. 3-7C and 3-7D). 
Intravenous administration of G-CA (40^g kg'^) (first arrow) elicited an increase in 
gastric acid levels in the first 15 minutes after injection to a peak value of 
1.31timoI 15min \  and O.ôOjrmol 15min'\ in rats 3 and 4, respectively. The 
response remained raised above baseline for 45 minutes in rat 3, and for 30 minutes 
in rat 4, resulting in a total increase in acidity of 2.76pmol (rat 3) and 1.17(xmol 
(rat 4). However, ileal administration of 1600|ig kg“^ G-CA (in 1.0ml isotonic 
saline) (second arrow) appeared to have a detrimental effect on both rats, with rat 
4 dying only 15 minutes after introduction of ileal G-CA. Rat 3 survived for only 
30 minutes following administration of ileal G-CA
3.1.3(ii) Ileal administration o f G-CA (600fig kg f
As a precaution, we decided to reduce considerably the dose of the intravenously 
and ileally-administered drugs in an attempt to ensure the viability of the rat, 
thereby reducing the risk of incomplete experiments. We therefore adopted a new 
protocol using reduced doses in which 15 or 20p,g kg’^  G-CA was intravenously 
injected prior to and following the administration of 600pg kg“^ ileal G-CA, and the 
changes in total gastric acidity were measured in the same way. Experiments were
1 2 2
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carried out on 7 rats in total, of which 5 provided evidence to suggest that ileally- 
administered G-CA (600|rg k % \p e r  se, evoked an unequivocal increase in gastric 
acidity (Table 3-6). Figure 3-8 illustrates the results of such an experiment.
Table 3-6: Peak and cumulative (cum.) increases (inc.) in gastric acid
secretion in response to ileally-administered tetragastrin-cholic acid 
conjugate (G-CA) (600|ig kg  ^ in 1.0ml saline) over 180 minute period, and to 
intravenous G-CA (15pg kg^) as a first and final procedure.
Rat Initial I.V. G-CA Ileal G-CA Second l.v. G-CA
Peak Cum. Cumulative increase Peak Cum.
increase increase (pmol ISOmiti' )^ increase increase
(mnol ISniin'^) (liimol hr' )^ (nmol 15min') (nmol hr')
1 0.30 0.48 1.34 0.30 0.49
2 0.86 1.78* 0.83 0.67 1.62
3 0.57 1.49 2.01 0.90 2.20
4 0.84 1.48 7.66 0.93 1.49
- 5 3.21^ 8.11^ 3.62 0.79 1.34
6 0.17 0.28 -1.28 1.50 4.41
7 0.73 2.07* 0.25 0.81 1.63*
Mean ® 0.64+0.26 1.31+0.57 2.80 + 2.17 0.72+0.26 1.43±0.62
(rats 1-5) (P=0.017) (P-0.019) (P=0.045) (P-0.003) (P=0.007)
Mean ®
(rats 6-7) 0.45 1.18 -0.52 1.15 3.02
* denotes establishm ent o f  new baseline which was elevated  com pared with that a t s ta rt 
o f  experiment.
 ^ denotes value om itted from  analysis due to disproportionately large value (see text 
fo r  details)
® mean responses are grouped depending on the effectiveness o f  ileally-adm inistered in 
inducing elevation o f  gastric a c id  secretion (see text fo r  details)
Intravenous injection of G-CA (15p,g kg'^) ( first arrow) led to a peak increase in 
gastric acidity of O.57|rmol ISmin'^ in the fourth collection period, although a 
strong response was also present between 15 and 30 minutes after injection 
(0.44pmol 15min'^). The increase in gastric acidity lasted for 75 minutes, and the 
cumulative increase in acidity over the hour following injection was 1.49pmol hr"\ 
Administration of ileal G-CA (600pg kg“^ in 1.0ml isotonic saline) (second anow) 
was then undertaken. The peak increase in acidity of 0.59pmol 15min'  ^ occurred
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between 75 and 90 minutes after administration, though a sizeable increase in acid 
levels of 0.37|imol 15min  ^ was noted 15 to 30 minutes following addition of G- 
CA.
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Fig. 3-8: The effect o f  intravenous G-CA (15/jg kg'\ first and third arrow), and ileally-infused 
G-CA (600fig kg'\ second arrow) on gastric acid secretion in the anaesthetised rat (rat 3 in 
Table 3-6).
The gastric acid levels maintained their increased level above baseline for 150 
minutes before falling back to control levels. A transitory drop in gastric acid 
levels of 0.62pmol 15min'  ^ back to the original baseline was recorded 45 minutes 
after ileal administration of G-CA had been conducted, lasting no longer than 15 
minutes; however, we are unsure as to why this occurred. Nevertheless, a 
cumulative increase in acidity of 2.01 pmol 180min  ^ was found in response to the 
presence of G-CA in the ileum. Finally, an injection of G-CA (15pg kg'^) (third 
arrow) intravenously, elicited a peak response of 0.90pmol ISmin'^ in the first 
collection period. The increased response above baseline lasted for a duration of 
45 minutes, and gave a cumulative increase in total acidity of 2.20pmol hour'\
Analysis of the responses obtained in these 5 experiments provided the following 
results. A significant mean peak increase above baseline in total acidity of 0.64 ± 
0.26pmol 15min'  ^ (P=0.017) elicited by 15pg kg'  ^ G-CA (I.V.) was observed, as 
was a cumulative increase in acid levels above baseline of 1.31 ± 0.57pmol hr'  ^
(P=0.019). The results of one experiment in which the peak and the cumulative 
increases in gastric acid secretion were 3.21 pmol 15min'  ^ and 8.11 pmol h r'\
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respectively, were omitted from the two sample t-test, since they would have 
biased the results by a disproportionately large amount. The peak value obtained 
generally occurred in the first or second collection period, and the response 
typically lasted for between 30 and 60 minutes after administration. Ileally- 
administered G-CA (600pg kg'^) resulted in a significant mean peak increase in 
acidity of 0.71 ± 0.43pmol ISmin'^ (P=0.002) and a total increase in gastric acid 
levels, over a period of 180 minutes, of 2.80 ± 2.17pmol (P=0.045). Peak acid 
levels were observed to occur between 75 and 105 minutes after ileal infusion. 
However, two rats did demonstrate a peak response in the 11th and the 12th 
collection period (165 minutes and 180 minutes after administration, respectively). 
Nevertheless, strong responses were observed prior to this in the first collection 
period (the 15 minutes containing the ileal administration). Subsequent 
intravenous injection of G-CA (15pg kg'^) evoked elevated acid levels of similar 
magnitude to those elicited by the first intravenous injection. A mean peak 
increase of 0.72 ± 0.26pmol 15min  ^(P=0.003), and a mean cumulative increase of 
1.43 ± 0.62pmol hr'  ^(P=0.007) were attained. The peak gastric acid values were 
typically obtained in the period of injection of G-CA, and the acid levels appeared 
to remain elevated above baseline for a duration of 30 to 45 minutes. 
Furthermore, a paired t-test demonstrated that, similar to the experiments in which 
a first and a second l.v. injection of G-CA (15pg kg'^) were administered in the 
absence of ileally-administered G-CA, the evoked peak and cumulative responses 
to intravenous injection of G-CA prior to and following ileal administration of G- 
CA in this case were not significantly different (P=0.63 and P=0.51, respectively). 
This suggests that the presence of G-CA in the ileum did not enhance the elicited 
increase in acidity in response to the second intravenous injection of G-CA.
Of the experiments carried out in this series (n=7), two rats failed to show any 
evidence of an enhanced gastric acid secretion following administration of ileal G- 
CA, even though intravenously injected G-CA (15pg kg" )^ evoked increases in 
gastric acid output as in previous experiments. Figure 3-9 demonstrates the 
outcome of one of these experiments. As can be seen, intravenous injection of G- 
CA (first arrow) elicited an increase in acidity to a peak value of 0.73 pmol 15min ^
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(N.B. baseline lies below zero at a gastric acidity of -0.35|imol 15min )^. This was 
seen to occur in the first collection period. The actual duration of the response 
was difficult to define, as was the cumulative increase in acidity, since there 
appeared to be a substantial decline in acid levels to zero after 30 minutes; 
however, this was followed by a steady rise in acidity over a period of 60 minutes 
to a new control level of 0.33 pmol 15min \
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Fig. 3-9: The effect o f intravenous G-CA (15jug kg'( first and third arrow), and ileally-infiised 
G-CA (600fig kg'( second arrow) on gastric acid secretion in the anaesthetised rat (rat 7 in 
Table 3-6).
Following administration of ileal G-CA (600pg kg'^) (second arrow), gastric acid 
levels remained steady at between 0.31 and 0.37|imol 15min  ^ over a 180 minute 
period. When this was compared with the baseline taken to be the mean of the 
three collection periods preceding the intra-ileal injection, this amounted to a 
calculated total increase in acidity of 0.25timol ISOmin'  ^which, when averaged out 
over each 15 minute sampling period, resulted in an increase of only 0.02[imol 
15miri\ This was assumed to be negligible. A second intravenous injection of G- 
CA (ISjig kg'^) (third arrow) produced a comparable increase in acidity with the 
initial injection, although the peak value of O.Slpmol 15miri^ occurred in the 3rd 
collection period, rather than the first. The response was considered to last for 45 
minutes, totalling a cumulative increase in gastric acid levels of 1,63[imol hr"\ The 
viability of the preparation was therefore confirmed.
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A noteworthy result was present in the other rat in this group of two, in that 
although ileally-administered G-CA was ineffective in evoking gastric acid 
secretion above basal levels, the response to the second intravenous injection of G- 
CA elicited an increase in total acidity greatly potentiated compared with the 
response to the first. Figure 3-10 illustrates the results obtained. Initial 
intravenous injection of G-CA (15pg kg'^) (first arrow) was effective in producing 
a peak increase in total acidity, though only of 0.17p,mol 15min'% in the period of
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Fig. 3-10: The effect o f  intravenous G-CA (15 jug kg \  first and third arrow), and iieally-infused 
G-CA (ôOOfÀg kg' ,^ second arrow) on gastric acid secretion in the anaesthetised rat (rat 6 in 
Table 3-6).
administration. Gastric acid levels remained notionally elevated above baseline for 
60 minutes, culminating in a small total increase in gastric acid secretion of 
0.28p.mol hr'\ Following this, ileal administration of G-CA (600[ig kg" )^ was 
carried out (second arrow), and over a period of 3 hours, changes in gastric acid 
secretion amounted to a drop of 1.28jj,mol 180min"  ^below pre-administration acid 
levels. A surprising result came in response to a second intravenous injection of 
G-CA (15pg kg" )^, 180 minutes after ileal administration (third arrow). A 
relatively very large peak increase in gastric acid levels of l.SOpmol 15min  ^ was 
recorded in the period after injection (between 15 and 30 minutes after intravenous 
infusion). A cumulative increase in gastric acid secretion above baseline of 
4.41gmol hr’^  was attained and gastric acid levels remained greatly elevated above 
pre-injection value for 135 minutes in total. Therefore, the peak response and the
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cumulative response to the second injection (l.v.) were 8.82 and 15.75 times 
larger, respectively, than those in response to the first injection. These were 
exceptional in that they were very much larger than had been observed in any of 
the other experiments in the course of this study. It could be suggested that the 
greatly enhanced acid secretion in response to the second intravenous injection 
may have arisen due to potentiation by the presence of subthreshold doses in the 
circulation emanating from the ileal G-CA, although if that were the case, the 
noticeable lack of any response over the period of three hours prior to intravenous 
injection is somewhat surprising.
Nonetheless, the outcome, as seen in two rats, in which the animal remained 
unresponsive to the effects of ileally-administered G-CA provided us with 
confidence that our method of administration (via an ileal cannula) was not in itself 
accountable, for example, by leakage of G-CA, for the increases in gastric acid 
levels elicited by iieally-infused G-CA in the other five experiments. This was 
further supported by our control experiments in which ileal tetragastrin was 
unsuccessful in increasing gastric acid levels above baseline, even though 
intravenously administered tetragastrin evoked a sizeable augmentation of acidity.
The application of statistical analysis of the results obtained from the experiments 
in which ileal G-CA was ineffective in inducing enhanced gastric acid levels was 
not considered appropriate with a group of only two, and the variation in response 
was considerable. Therefore, the mean responses were calculated, and were as 
follows. Intravenous administration of G-CA (15pg kg'^) resulted in a mean peak 
increase of 0.45p,mol 15min^ above control gastric acid levels, a value not 
dissimilar to that obtained in the five rats in which ileal G-CA was effective in 
enhancing gastric acid secretion. In both rats, the peak was noted to occur in the 
first 15 minutes after administration. A mean cumulative acidity of 1.18p.mol hr'  ^
was calculated although, due to the gastric acidity settling at a higher level than the 
original baseline, the actual duration of response was difficult to define. Following 
ileal injection of the G-CA (600pg kg" )^, a mean decrease in gastric acidity of 
0.52[imol 180min"  ^ was observed. We therefore concluded that ileal injection of 
G-CA had been ineffective in inducing any discernible increase in gastric acid
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levels. A second injection of G-CA (15pg kg'^), intravenously, enabled us to 
demonstrate the retained sensitivity of the animal to the effects of G-CA An 
increase in the mean peak acidity, occurring in the second collection period, of 
l.lSjimol 15min  ^ above baseline (2.56 times greater than the response to the 
initial I.v. G-CA injection), and a total cumulative acidity of 3.02p,mol hr'  ^ (2.56 
times greater than that initiated by the initial injection) was demonstrated.
3.1.3(iii) Ileal administration o f tetragastrin (3000jug kg 'f subsequent to intra- 
ileal G-CA (600jug kg 'f 
Based on our observations that ileally-introduced G-CA appeared able to cross the 
wall of the small intestine and enter the bloodstream, thereby increasing gastric 
acid secretion, we were interested to determine whether any changes caused by G- 
CA to the small intestine were long lasting and non-specific. To this end, we 
decided to carry out a series of experiments similar to those described previously, 
whereby the infusion of ileal G-CA (600pg kg'^) was followed 180 minutes later by 
ileal administration of tetragastrin (3000pg kg"^  in 1.0ml isotonic saline). The 
principle behind this protocol lay with the premise that when testing for a 
physiological effect, a modest dose was administered (in this case, 600pg kg'  ^G- 
CA), whereas when testing for the absence of an effect, a very high dose was used 
(in this case, 3000pg kg'  ^ tetragastrin). The dose of G-CA administered was 
equivalent to that introduced in previous experiments, where there was evidence of 
an elicited physiological response, and the dose of tetragastrin used was similar to 
earlier studies where there was no evidence of a response being evoked.
The outcome of a typical experiment is illustrated over (Fig. 3-11). Intravenously 
administered G-CA (15pg kg '\ first arrow) elicited a peak increase in gastric acid 
secretion of 0.39|amol 15min  ^ above control levels in the collection period in 
which injection was carried out. The gastric acid levels remained elevated for 30 
minutes, resulting in a cumulative increase in total gastric acidity of 0.75pmol hr % 
before falling to a level slightly below pre-injection levels.
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Fig. 3-11: The effect o f  inh'ovenous injection o f G-CA ( 1 5 kg'\ first and fourth arrows), and 
ileal infusion o f  G-CA (600jug kg'\ second arrow), followed 180 minutes later by iieally-infused 
tetragastrin (SOOOjl^  kg'\ third arrow) on gastric acid secretion in the anaesthetised rat (rat 6 in 
Table 3-7).
Following return of gastric acid levels to a steady level, infusion of G-CA (600fig 
kg'^) into the ileum was performed, and resulted in a peak increase in acid 
secretion of O.Slpmol 15min^ in the 5th collection period (between 60 and 75 
minutes after administration of ileal G-CA). Nonetheless, a sizeable increase in 
total acidity was presented in the period of infusion of 0.20|imol 15min'\ Elevated 
levels were maintained above basal levels for 120 minutes, culminating in a total 
increased level of 1.87pmol 180min"\  In order to determine whether the increased 
response above basal levels to ileal G-CA was mediated via a non-specific and 
long-lasting change to the ileal ultrastructure, we gave an ileal infusion of 
tetragastrin (SOOOpg kg" )^ 180 minutes after iieally-infused G-CA. This resulted in 
a considerable increase in gastric acid secretion of O.53pmol ISmin"’^ in the period 
of adminstration. The increased total acidity rose steadily to a peak value of 
0.63|imoi 15min"^  in the third collection period, that is, between 30 and 45 minutes 
after injection. The response lasted for a duration of 90 minutes before falling to a 
slightly elevated baseline. The cumulative increase in gastric acid secretion was 
3.13pmol 180min \  i.e. larger than that evoked by 600|ig kg'  ^ G-CA. Finally, we 
carried out an identical intravenous injection of G-CA to the first, which resulted in 
a response of comparable size and duration. A peak increase in gastric acid levels 
of O.Slpmol 15min'  ^ was attained in the first collection period, and gastric acid
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levels remained elevated above baseline for 30 minutes, resulting in an overall 
cumulative response of 0.78p,mol hr’\
Seven such experiments were carried out. The mean values (Table 3-7) 
demonstrated that an initial injection of G-CA (15pg kg"\ i.v.) resulted in a 
significant peak increase in gastric acid levels above baseline of 0.57 ± 0.24|imol 
15min^ (P=0.001). The peak value obtained generally occurred in the first or 
second collection period, and the response typically lasted for between 30 and 45 
minutes before returning to baseline. This elevation of gastric acid levels above 
baseline resulted in a mean cumulative response of 1.09 ± 0.52pmol hr"% which 
was statistically significant (P-0.004).
Table 3-7: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to ileally-administered tetragastrin-cholic acid conjugate (G-CA) 
(éOOpg kg  ^ in 1.0ml saline) over 180 minute period, subsequent ileally- 
administered tetragastrin (G4) (3000pg kg ) over 180 minute period, and 
intravenous G-CA (15pg kg ) as a first and final procedure.
Rat Initial I.V. G-CA Ileal G-CA Ileal 04 Second I.V. G-CA
Peak Cum. Cum. Cum. Peak Cum.
increase increase increase increase increase increase
ISmin'b (nmol hr') (nmol (ntnol (nmol 15miii‘) (nmol lir')
180min-') 180mm')
1 0.47 1.55 1.40 5.25 0.34 0 80
2 1.03 1.45 9 89? 6.01 1.62 2.27?
3 0.49 1.67 0.84 2.30 0.68 1.61
4 0.77 2.87*T 0.90 0.94 0.68 0.96
5 0.38 0.56 4.70? 1.98 0.64 0.98
6 0.39 0.75 1.87 3.13 0.51 0.78
7 0.47 0.58 1.53 1.77 0.46 0.61
Mean 0.57+0.24 1.09+0.52 1.31+0.44 3.05+1.89 0.70+0.42 1.15+0.59
+ S.D. (P-0.001) (P=0.004) (P=0.003) (P=0.006) (P=0.005) (P-0.003)
P-values denote sta tistica l significance f o r  comparison with baseline.
* denotes establishm ent o f  new baseline which was elevated com pared with that a t  s ta rt 
o f  experiment.
 ^ denotes value om itted from  analysis due to disproportionately large value (see text 
fo r  details)
The result of one experiment was omitted fi-om the analysis; a cumulative response 
of 2.87pmol hr'  ^ was recorded which deviated fi-om the normal distribution of 
responses. However, application of the Wilcoxon statistical test (in which the
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median of the sample is tested, thereby allowing the population to deviate from a 
normal distribution) confirmed the significance of the elevated gastric acid levels in 
response to intravenous tetragastrin; a cumulative response with an estimated 
median of l.lSpmol hr'  ^ (P=0.022) was found.
In all seven experiments, without exception, ileal infusion of G-CA (600j_ig kg" )^, 
subsequent to intravenous G-CA, produced an increase in gastric acid levels. A 
mean peak increase in total acidity of 0.53 ± 0.42pmol ISmin^ was observed, 
which was statistically significant, with respect to baseline (P=0.015), although its 
period of occurrence was variable (results not tabulated). In one rat, the peak 
response was presented in the period of administration; in another it appeared in 
the third. A further two rats demonstrated the peak in the fifth collection period, 
whereas it was achieved in the sixth and in the seventh collection period in two 
others. Finally, in one rat, the peak increase in gastric acid secretion occurred in 
the twelfth collection period (Fig. 3-12). Nonetheless, in every case, a sizeable 
increase in gastric acid secretion was achieved in the period of administration 
followed by a typically steady increase to peak levels.
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Fig. 3-12: The effect o f  intravenous injection o f  G-CA (ISfjg kg'\ first and Jburth arrows), and 
ileal infusion o f G-CA (600jug kg'\ second arrow), followed 210 minutes later by iieally-infused 
tetragastrin (3000fjg kg'\ third arrow) on gastric acid secretion in the anaesthetised rat (rat 2 in 
Table 3-7).
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The duration of response was shown to be somewhat more consistent amongst 
individual rats, ranging between 105 and 135 minutes. In only one rat was a 
slightly more long lasting elevation of gastric acid levels of 180 minutes observed 
(Fig. 3-12). Thus, a mean cumulative increase of 1.31 ± 0.44pmol 180min  ^ was 
found to be statistically significant (P=0.003). The analysis did not include the 
results of two experiments in which the cumulative increases in gastric acidity were 
4.70 and 9.89pmol 180min'\ since this would have biased the results by a 
disproportionately large amount. However, application of the Wilcoxon statistical 
test to all the data confirmed that the cumulative increase of gastric acid, compared 
with baseline, presented an estimated median value of 1.79pmol 180min \  which 
was indeed statistically significant (P=0.022).
The administration of ileal tetragastrin (3000pg kg’^ ), 180 minutes after inftision of 
ileal G-CA, caused, unequivocally, a large increase in gastric acid secretion, 
compared with baseline. Over a period of 3 hours following infusion, total gastric 
acidity evoked above baseline amounted to a mean cumulative increase of 3.05 ± 
1.89pmol 180min"\ which was found to be statistically significant (P=0.006). Also 
recorded was a significant mean peak increase in gastric acid secretion of 0.71 ± 
0.67pmol 15min'  ^ (P=0.030) although, as for the peak response to iieally-infused 
G-CA, the period in which it occurred was variable. In five experiments, the peak 
occurred in either the first (n=l), second (n=l), third (n=2) or fourth (n=l) 
collection period; however, in two other experiments, the peak increase was 
evoked in the seventh and in the seventeenth period after injection. With the 
exception of two rats, a sizeable increase in gastric acid secretion was elicited in 
the period of ileal infusion of tetragastrin, which steadily increased to peak values. 
In the exceptions, a response above baseline was not evoked until the second and 
the third collection periods after infusion. The response above pre-infusion levels 
generally lasted for between 90 and 105 minutes; however, a notable exception 
was the rat in which gastric acid levels remained elevated above control value for 
255 minutes (Fig. 3-12). This was the same rat which had presented the peak 
increase in total gastric acidity in the seventeenth period in response to ileal 
tetragastrin, and the peak increase in response to ileal G-CA in the twelfth period.
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The viability of the preparation in the final stages of the investigation was 
confirmed when, on injection of G-CA (15pg kg"\ I.V.) as the final procedure, a 
peak response of 0.70 ± 0.42|amol 15min“^ and a cumulative response of 1.15 ± 
0.59|rmol hr'  ^were presented and statistically significant, with respect to baseline 
(P=0.005 and P=0.003, respectively). The observed cumulative response of one 
animal to intravenous G-CA as the final procedure was not included in the 
statistical analysis, since it demonstrated an increase in gastric acid secretion, 
outwith the normal distribution of results, of 2.27pmol hr'\ However, application 
of the Wilcoxon test to all the data confirmed a significant increase in gastric acid 
secretion, with an estimated median value of 0.96pmol hr \  (P=0.022).
Furthermore, there was no significant difference between either the peak or the 
cumulative responses of the first and second intravenous infusions of G-CA 
(P=0.21 and P=0.57, respectively), which suggest that, at this late stage of the 
investigation, the presence of ileal tetragastrin did not further augment the 
response.
3.1.3(iv) Ileal administration o f the components o f G-CA (600pg kg^)
It was necessary to determine whether the introduction of the components making 
up G-CA, that is, tetragastrin and cholic acid, into the ileum would evoke a similar 
increase in gastric acidity as that seen when G-CA (600pg kg'^) was administered 
ileally. Unfortunately, cholic acid is quite insoluble in isotonic saline, and we were 
therefore obliged to resort to an alternative, glycocholic acid, which was easily 
dissolvable. A solution of tetragastrin and glycocholic acid (in total, 600pg kg'^) 
was made up, so that the ratio of peptide and bile acid in solution were identical to 
those of the iieally-infused conjugate (approx. 3:2 ratio by weight). Therefore, the 
600pg kg'  ^ solution was comprised of 356.4pg kg‘^  tetragastrin (59.4%), and 
243.6pg kg'  ^glycocholic acid (40.6%). This solution was then infused subsequent 
to an initial intravenous injection of G-CA (15pg kg'^). An example of the 
outcome of such an experiment is illustrated (Fig. 3-13). Initially, an intravenous 
injection of G-CA (15pg kg'^) (first arrow) was administered to ensure the animal 
was responsive. This was shown to evoke increased secretion of gastric acid to a 
peak value of 0.42pmol 15min'  ^ above baseline in the second collection period
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after administration. The acid levels remained elevated above control levels for a 
duration of 30 minutes before returning to their original value, amounting to a 
cumulative increase in acidity of 0.64jamol hr'  ^ above baseline.
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Fig. 3-13: The effect o f  intravenous injection o f  G-CA (15fig kg'\ jirs t and third arrows), ileal 
infusion o f  tetragastrin:glycocholic acid (3:2 ratio, total ôOOjug kg'( second arrow), and 
intravenous injection o f  tetragashin:glycocholic acid (3:2 ratio, total 15fig kg'( fourth arrow) 
on gastric acid secretion in the anaesthetised rat (rat 4 in Table 3-8).
Following the return of gastric acid levels to their original value, ileal infusion of 
the solution containing tetragastrin and glycocholic acid (600pg kg'% in a 3:2 ratio) 
was carried out (second arrow), and demonstrated that, over a 180 minute period, 
there was little evidence of any increase in gastric acid levels. A cumulative 
decrease of 0.18p.mol 180min  ^with respect to the baseline was actually presented. 
A second intravenous injection of G-CA (15pg kg'^) (third arrow) was then 
administered, resulting in a peak increase in acidity of 0.48pmol 15min'\ a value 
very similar to that obtained initially. The peak occurred in the first collection 
period, and the acid levels remained enhanced above baseline for 30 minutes, 
producing a cumulative increase in acidity of 0.69pmol hr'\ This again was 
comparable with the total increase in acidity obtained following the initial 
intravenous injection of G-CA
Finally, in order to ensure that the solution consisting of the components of the 
conjugate was able to elicit a change in gastric acid secretion, we decided to 
intravenously inject 15pg kg"^  of the same stock solution already inftised ileally
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(fourth arrow). This produced a peak increase of 0,54pmol 15min  ^in the first 15 
minutes following infijsion, and a cumulative increase in acidity of 1.16pmol hr"\ 
The elevated response appeared to last for 45 minutes before returning to baseline. 
We were therefore satisfied that the stock solution was biologically active and, 
furthermore the presence of glycocholic acid did not exert any inhibitory action on 
the effectiveness of tetragastrin in inducing an increase in gastric acid secretion.
This experiment was carried out on five rats, and the results produced were very 
much in agreement (Table 3-8). Intravenous infusion of G-CA (15pg kg'^) 
resulted in a significant mean peak enhancement of acidity of 0.47 ± O.Mpmol 
15min"^  (P=0.002), occurring in either the first (n=2) or second (n=3) collection 
period. The total mean increase in acidity above baseline was found to be 0.84 ± 
O.35pmol hr'  ^ (P=0.007), with enhanced acidity lasting for between 30 and 45 
minutes.
Table 3-8: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to ileally-administered tetragastrin/glycocholic acid (G4/Gly) (600pg 
kg  ^total in 3:2 ratio) over 180 minute period, intravenous G-CA (ISpg kg^) 
as the first and third procedure, and intravenous tetragastrin/glycocholic 
acid (ISpg kg^ in 3:2 ratio) as the final procedure.
Rat Initial I.^  
Peak 
increase
(pmol
15mm b
/. G-CA 
Cum. 
increase
(fmiol hr'b
Ileal G4/Gly 
Cumulative 
increase
(|4inol ISOmin'b
Second I. 
Peak 
increase
(jjmol
15mm
V. G-CA 
Cum. 
increase
(|omol hr'b
I.V. G 
Peak 
increase
(imiol
15mm b
4/Gly
Cum.
increase
(l-imoi hr'b
1 0.43 1.43* -0.04 0.67 1.99* - -
2 0.30 0.53 -0.47 0.28 0.28 0.43 0.88
3 0.54 0.75 0.05 0.46 0.84 0.20 0.47
4 0.42 0.64 -0.18 0.48 0.69 0.54 1.16
5 0.66 0.84 0.05 0.54 0.71 0.73 1.84
Mean 0.47 0.84 -0.12 ±0.22 0.49 0.90 0.48 1.09
+ S.D. ±0.14 ±0.35 ±0.14 ±0.64 ±0.22 ±0.58
P-value 0.002 0.007 0.28 0.002 0.035 0.023 0.033
P-values denote sta tistica l significance fo r  com parison with baseline.
* denotes establishm ent o f  new baseline which was elevated com pared with that a t start 
o f  experiment.
- denotes procedure not carried  out.
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All five experiments demonstrated very little change in acidity in response to ileal 
infusion of 600pg kg'  ^ tetragastrin/glycocholic acid (3:2 ratio). A mean drop in 
acidity of 0.12 ± 0.22pmol 180min  ^occurred, which was not significantly different 
from baseline levels (P=0.28). Intravenous injection of G-CA (15pg kg" )^ for a 
second time resulted in similar increases in gastric acidity as the first. A significant 
mean peak increase of 0.49 + 0.14pmol 15min'  ^(P=0.002) was found to have been 
evoked, occurring in the first (n=4) or second collection period (n=l). The total 
increase in acidity above baseline was discovered to be significant and of a value of 
0.90 ± 0.64pmol hr'  ^(P=0.035), and the response was found to last for between 30 
and 45 minutes, as was noted previously.
To confirm the biological activity of tetragastrin/glycocholic acid (3:2 ratio), we 
administered 15|ag kg‘^  of the stock solution intravenously, and discovered that a 
mean peak increase in acidity of 0.48 ± 0.22pmol ISmin'^ was evoked (P=0.023), 
typically in the first or second collection period (n=4 and n=l, respectively), which 
was statistically significant. The total mean increase in acidity above control levels 
was calculated as being 1.09 ± 0.58pmol tir'  ^ (P=0.033). Such a response to 
intravenous administration of tetragastrin/ glycocholic acid (3:2 ratio) confirmed 
that the preparations were viable in the latter stages of the experimental 
procedures. Furthermore, ileally-infijsed tetragastrin and glycocholic acid (3:2 
ratio) was an “active” preparation, as confirmed by the responsiveness to 
intravenous injection, and thus, tetragastrin was fully able to exert its biological 
activity without being compromised by the presence of glycocholic acid. It would 
appear, therefore, that tetragastrin requires to be chemically coupled to cholic acid 
rather than simply be in its presence in order to evoke enhanced gastric acid levels. 
In addition, these experiments enable us to rule out the unlikely possibility that 
intravenously administered G-CA, per se, increases the permeability of the ileal 
wall, thereby allowing the transmucosal passage of G-CA and tetragastrin (as seen 
in the previous set of experiments), resulting in elevated gastric acid levels.
137
Results
3.1.4 Gastric acid secretion in response to jejunallv-administered tetragastrin and 
tetragastrin-cholic acid conjugate (G-CA)
The mechanism by which iieally-infused G-CA exerted its stimulatory effect on 
gastric acid secretion was puzzling, since our histological studies signified no 
apparent structural changes to the intestinal wall (Section 3.3), and yet subsequent 
ileal administration of tetragastrin resulted in a prominent elevation of basal gastric 
acid levels, not seen in our previous control experiments. To this end, we felt it 
necessary to carry out a series of experiments which would bring us closer to 
determining the mechanisms behind ileal G-CA-induced gastric acid secretion. The 
effect of jejunally-administered G-CA was investigated, our reasoning being that if 
structural damage to the ileal wall were occurring, resulting in the transfer of G- 
CA into the circulation, similar effects would be expected in the jejunum. 
However, should the site of action be through the bile salt transporter, which is 
exclusive to the ileum, similar elevation of gastric acid levels in response to 
jejunally-infijsed G-CA would not be expected.
3.1 4(i) Effect o f intrafejm al infusion o f tetragastrin on gastric acid secretion 
A series of control experiments were carried out, whereby we investigated the 
ability of jejunally-infused tetragastrin to elevate gastric acid levels above baseline 
(Table 3-9). The experiments followed along the same lines as our previous 
control experiments, in that we first demonstrated the responsiveness of the 
preparation by administering an intravenous dose of tetragastrin (15pg kg“^ ). A 
mean peak increase in gastric acid secretion of 0.44 ± 0. lOpmol 15min'  ^was found 
to be significantly elevated above baseline (P=0.001; n=5). In every case, the peak 
response was found to occur in the period of injection, that is, between 0 and 15 
minutes following administration. The response remained elevated above baseline 
for between 15 and 30 minutes, resulting in a mean cumulative increase of 0.54 ± 
O.lVpmol hr \  which was found to be significant when compared with baseline 
(P=0.003). Thus, having confirmed unequivocally the viability of the animals with 
regard to their responsiveness to intravenously administered tetragastrin, we 
proceeded with the determination of the effectiveness of intra-jejunal infusion of 
tetragastrin (3000pg kg'  ^in 1.0ml) in evoking increased gastric acid secretion. The 
results of this were unequivocal in that there was no evidence to indicate
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stimulation of gastric acid secretion in response to jejunal tetragastrin. Over a 
period of 180 minutes, gastric acid secretion fell by a mean value of 0.05 ± 0.26 
pmol 180min'\ This was deemed to be not significantly different fi*om pre-infusion 
levels (P=0.71).
Table 3-9: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to jejunally-administered tetragastrin (G4) (3000pg kg^ in 1.0ml 
saline) over 180 minute period, and to intravenous tetragastrin (15pg kg'*) as 
a first and final procedure.
Rat Initial I.v. G4 Jejunal G4 Second I.v. G4
Peak Cum. Cumulative increase Peak Cum.
increase increase (nmol ISOmin'b increase increase
(^unol ISmin'b (mnol hr b (nmol 15min‘b (nmol hr'b
1 0.33 0.33 -0.25 0.51 0.57
2 0.41 0.50 0.40 0.48 0.57
3 0.61 0.76 -0.06 0.62 0.794 0.45 0.45 -0.18 0.53 0.63
- 5 0.41 0.67 -0.15 0.44 0.54
Mean 0.44±0.10 0.54+0.17 -0.05 ±0.26 0.52±0.07 0.62+0.10
±S.D. (P=0.001) (P=0.003) (P-0.71) (P-0.001) (P=0.001)
P-values denote statistical significance for comparison with baseline.
Our concerns regarding the viability of the preparation towards the latter stages of 
experimentation were reassured when, on administration of a second intravenous 
dose of tetragastrin (15pg kg'*), gastric acid levels were significantly elevated 
above baseline. A mean peak increase of 0.52 ± 0.07jimol 15min * (P“0.001) was 
measured, occurring in the period of injection, as was a mean cumulative increase 
of 0.62 ± 0. lOpmol hr * (P=0.001). Elevation of gastric acid levels above control 
levels was maintained for between 30 and 45 minutes before returning to baseline. 
A paired t-test confirmed the reproducibility of the response to intravenous 
tetragastrin, since both the peak elevation and the cumulative elevation of gastric 
acid levels in response to the first and second injection were found to be not 
significantly different from each other (P=0.056, and P=0.340, respectively).
An example of the outcome of a typical experiment is illustrated in Figure 3-14. 
Intravenously administered tetragastrin (15pg kg"*) as the first procedure (first 
arrow) resulted in an elevation of gastric acid secretion to a peak value of
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OAljimol 15min *, in the first 15 minutes after injection. The response remained 
elevated above baseline for 30 minutes, resulting in a cumulative increase of 
0.67pmol hr'*. Intra-jejunal infusion of tetragastrin (3000p,g kg'*) (second arrow) 
was ineffective in evoking an increase in gastric acid levels above baseline; a fall of 
0.15p,mol was actually recorded over a period of 180 minutes.
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Fig. 3-14: The effect o f intravenous injection o f  tetragastrin (ISftg kg’\  first and third arrows) 
and jejunal infusion o f  tetragastrin (3000fig kg'  ^ in 1.0ml, second arrow) on gastric acid  
secretion in the anaesthetised rat (rat 5 in Table 3-9).
Finally, confirmation of the viability of the animal was obtained when, in response 
to a second intravenous injection of tetragastrin (15j.ig kg'*) (third arrow), gastric 
acid levels rose to a peak of 0.44pmol 15min'* in the period of injection, and 
remained elevated for a duration of 45 minutes, resulting in a cumulative increase 
in gastric acid levels of 0.54pmol hr *.
3.1.4(ii) Effect o f intra-jejunal infusion o f G-CA on gastric acid secretion 
Our previous experiments had demonstrated the inability of jejunally-infused 
tetragastrin to stimulate increased levels of gastric acid secretion. The 
effectiveness of jejunally-administered G-CA was then tested. The procedures 
carried out were similar to those for the previous set of experiments, with the 
exception that tetragastrin was replaced with G-CA
The results of a typical experiment, illustrated in Figure 3-15, demonstrated that an 
initial intravenous injection of G-CA (15pg kg'*) (first arrow) caused an increase in 
gastric acid levels to a peak value of 0.48 pmol 15min'* above baseline in the
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period of injection. Because the response lasted for only 15 minutes, the 
cumulative increase in gastric levels was also 0.48 pmol hr'*.
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Fig. 3-15: The effect o f  intravenous injection o f  G-CA (15jug kg'\ first and third arrows) and 
jejunal infusion o f  G-CA (600j l ^  kg'( second arrow) on gastric acid secretion in the 
anaesthetised rat (rat 3 in Table 3-10).
Measurement of gastric acid levels over a 180 minute period following jejunally- 
infiised G-CA (600pg kg'* in 1.0ml) (second arrow) provided little evidence to 
suggest that G-CA had entered the circulation in a biologically active form. 
Indeed, attenuation of gastric acid levels by O.OSpmol 180min * was recorded. A 
mean peak increase in gastric acid levels in the period after intravenous injection of 
G-CA (15pg kg'*) (third arrow) of 0.33 pmol 15min* assured us of the retained 
responsiveness of the animal in the final stages of experimentation. Sustained 
elevation of gastric acid levels above baseline for 45 minutes after injection 
resulted in a cumulative increase of 0.65 pmol hr'*.
Five such experiments were carried out, producing very similar results (Table 3- 
10). A significant mean peak increase of gastric acid secretion of 0.44 ± 0.13pmol 
15min'* (P=0.002) was presented in response to initial intravenous infusion of G- 
CA (15|ig kg'*). This generally occurred in either the period of, or the period 
following injection, and lasted for between 15 and 30 minutes. (In the case of two 
animals, gastric acid levels did not return to their original value, but remained 
elevated, and therefore, the duration of response was difficult to define.) This led 
to a mean cumulative increase in total acidity of 0.58 ± 0.13 pmol hr'*, which was
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significant compared to baseline (P=0.001). (The cumulative response of 
2.42pmol hr * presented by one animal was omitted from statistical analysis since it 
would have biased the results by a disproportionately large amount.)
In each of the five experiments, very little change in gastric acid levels was 
observed over a 180 minute period following intra-jejunal administration of G-CA 
(600pg kg'* in 1.0ml). A mean decrease in gastric acid levels of 0.10 ± 0.28 pmol 
180min * was found not to be significantly different from baseline (P-0.46). 
However, as a final procedure, intravenous infusion of G-CA (15pg kg'*) elicited a 
significant increase in gastric acid secretion to a mean peak value of 0.42 ± 0.09 
pmol 15min* (P=0.001) in the period of injection, and remained elevated for 
between 15 and 45 minutes, thus resulting in a significant cumulative increase of 
0.59 ± 0.16 pmol hour * (P=0.002). Comparison of the responses to the first and 
to the second intravenous G-CA injection demonstrated no significant differences 
between either the mean peak or the mean cumulative increase in gastric acid levels 
(P=0.60, and P=0.96 respectively). We were, therefore, confident that the lack of 
response to jejunally-administered G-CA was not due to poor condition of the 
preparation.
Table 3-10: Peak and cumulative (cum.) increases in gastric acid secretion in 
response to jejunally-administered tetragastrin-cholic acid conjugate (G-CA) 
(fiOOpg kg'* in 1.0ml saline) over 180 minute period, and to intravenous G-CA 
(15pg kg'*) as a first and final procedure.
Rat Initial I.V. G-CA Jejunal G-CA Second i.v. G-CA
Peak Cum. Cumulative increase Peak Cum.
increase increase (nmol ISOmin'b increase increase
(nmol ISmiii'b (nmol lir'b (nmol ISmiii'b (nmolhr'b
1 0.62 2.42*^ 0.08 0.55 0.84
2 0.28 0.75* 0.25 0.36 0.52
3 0.48 0.48 -0.08 0.33 0.654 0.44 0.44 -0.44 0.39 0.41
5 0.39 0.65 -0.32 0.46 0.51
Mean 0.44+0.13 0.58+0.13 -0.10 + 0.28 0.42+0.09 0.59+0.16
±S.D. (P-0.002) (P-0.001) (P=0.46) (P=0.001) (P=0.002)
P-values denote sta tistica l significance fo r  com parison with baseline.
* denotes establishm ent o f  new baseline which was elevated  com pared with that a t s ta rt 
o f  experiment.
 ^ denotes value om itted  from  analysis due to disproportionately large value (see text fo r  
details).
142
Results
3.1.5 Comparison of intra-iejunal and intra-ileal infusion of G-CA on gastric acid 
secretion
Our final series of experiments was aimed at removing any doubt firom our minds 
that jejunally-infused G-CA was ineffective in evoking elevated gastric acid levels 
simply as a result of diminished activity of stock solutions. Since earlier 
experiments had demonstrated the effectiveness of ileally-administered G-CA in 
eliciting increased levels of gastric acid, we decided to compare the responsiveness 
of the same rat to intra-jejunal G-CA (600pg kg'  ^ in 1.0ml), followed 180 minutes 
later with intra-ileal G-CA (600|ig kg'  ^ in 1.0ml), This was carried out in five rats, 
the results of which are described below. Figure 3-16 illustrates the sequence of 
procedures and the results obtained in a typical experiment.
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Fig. 3-16: The effect o f  intravenous injection o f G-CA (ISjjg kg'\ first arrow), jejunal infusion 
o f  G-CA (ôOOjugkg'  ^ in 1.0ml, second arrow) and ileal infusion o f  G-CA (ôOOfjg kg~‘ in 1.0ml, 
third arrow) on gastric acid secretion in the anaesthetised rat (rat 1 in Table 3-11).
As a matter of course, an initial intravenous injection of G-CA (15p.g kg'^) was 
administered in order to demonstrate the responsiveness of the preparation. A 
mean peak increase in gastric acid levels of 0.35 ± 0.05 pmol 15min"^  was 
presented, and shown to be significant compared to baseline (P=0.001), as was the 
mean cumulative increase of 0.44 ± 0.10 jamol hr'  ^ (P=0.004) (Table 3-11). (The 
calculated mean cumulative increase did not take into account the elevated 
response, presented by one rat, of 1.12pmol h r'\ since this was outwith the normal
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distribution of responses.) In ail five experiments, the peak response occurred in 
the period of injection, and gastric acid levels remained elevated above baseline for 
between 15 and 30 minutes. The results illustrated in Figure 3-16 demonstrate the 
nature of the response to intravenous G-CA (first arrow), in that a peak increase in 
gastric acid levels, presented in the period of injection, of 0.30|imol 15min'  ^ was 
observed. Gastric acid levels remained elevated for 30 minutes, totalling a 
cumulative increase above baseline of 0.39pmol hr'\
Table 3-11: Peak and cumulative increases in gastric acid secretion in
response to i.v. tetragastrin-cholic acid conjugate (G-CA) (ISpg kg"^ > as a 
first procedure, subsequently administered jejunal G-CA (600pg kg  ^ in 
1.0ml saline) over 180 minute period, and ileally-administered G-CA (600pg 
kg  ^in 1.0ml saline) as a final procedure.
Rat Initial i.v. G-CA Jejunal G-CA Ileal G-CA
Peak increase Cumulative Cumulative Cumulative
- (junol ISmin’h increase increase increase
(Minol hr b ISOmitt'b (|imol ISOmin’b
1 0.30 0.39 -0.93 1.41
2 0.36 0.36 -0.57 1.82
3 0.32 1.12*^ -1.09 1.26
4 0.43 0.43 -0.87 1.63
5 0.32 0.59 -0.06 2.02
Mean 0.35 + 0.05 0.44 + 0.10 -0.70 + 0.41 1.63+0.31
+ S.D. (P=0.001) (P-0.004) (P-0.018) (P-0.001)
P-values denote sta tistica l significance fo r  com parison with baseline.
* denotes establishm ent o f  new baseline which was elevated com pared with that a t s ta rt 
o f  experiment.
 ^ denotes value om itted  from  analysis due to disproportionately large value (see text f o r  
details).
On return of gastric acid levels to baseline, jejunal infusion of G-CA (600pg kg‘‘ in 
1.0ml) was carried out (second arrow), as in the previous series of experiments. 
Over the following 180 minute period, gastric acid levels were measured and, 
consistent with earlier results, there was no evidence to suggest any enhancement 
of gastric acid secretion. In actual fact a significant mean reduction in gastric acid 
levels of 0.70 ± 0.41pmol 180min  ^ (P=0.018) was observed in 5 rats. The results 
of the individual experiment (Fig. 3-16) demonstrated a total drop in gastric acid 
levels of 0.93pmol 180min'\
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As the final procedure, we introduced G-CA (600pg kg'^) intra-ileaily (third 
arrow) and measured the gastric acid levels that resulted, in order to determine 
whether the inability of jejunally-administered G-CA was as a consequence of 
diminished biological activity of the stock solution. The results, in which an 
increase in gastric acid secretion to a mean peak of 0.42 ± 0.13pmol 15min'  ^ above 
baseline was statistically significant (P=0.002), were convincing. Figure 3-16 
illustrates a rise in gastric acid levels to a peak of 0.33jimol 15min  ^ occurring in 
the 7th collection period; however, the time of occurrence of such a peak in the 
four other animals was variable, presenting itself in either the 3rd, 4th, 5th or 7th 
collection period after infusion. Elevation of gastric acid levels above baseline in 
response to iieally-infused G-CA was maintained for a duration of between 90 and 
135 minutes after inftision, resulting in a mean total enhanced gastric acid secretion 
of 1.63 ± 0.31pmol, which was deemed to be significant (P-0.001). The results of 
the individual experiment support this finding (Fig. 3-16); gastric acid levels 
remained elevated for 120 minutes, amounting to a total enhancement of gastric 
acid levels above baseline of 1.41pmol. We were therefore confident that the 
ineffectiveness of jejunally-administered G-CA in eliciting increases in gastric acid 
secretion was due to physiological factors rather than the chemical instability of 
G-CA
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3,2 Arterial blood pressure
This was recorded to check that the gastrointestinal tract was adequately perfijsed 
during the course of what turned out to be extended experiments of up to ten hours 
duration. Of particular concern was the possibility, in those cases when responses 
were not evoked, that this might be attributable to poorer perfusion of the internal 
viscera.
In the initial analysis, the systolic and diastolic blood pressure were measured, and the 
diastolic pressure was taken to represent the basal tone of the systemic vasculature. 
The pulse pressure, that is, the difference between systolic and diastolic pressure, was 
taken to represent a measure of the cardiac contractility. For ease of comparison, the 
mean arterial blood pressure (MABP) was also calculated.
After completion of surgical procedures and prior to the commencement of the 
experimental procedures, the arterial blood pressure was typically 135/107mmHg with 
a MABP of 116mmHg. For all the experimental animals, a MABP (± s.D.) of 117 ± 
9mmHg (n-67) was recorded. It was clear that as the experiments progressed, there 
was a steady decline in arterial blood pressure. Figure 3-17 presents the mean arterial 
blood pressure and the pulse pressure values obtained fi*om a typical animal during an 
experiment of approximately 500 min duration (but not including surgical 
procedures).
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Fig. 3-17: Illustration o f the MABP (o) and pulse pressure (+) over time, recorded in the same 
anaesthetised rat (rat 5 in Table 3-7). Time zero reflects the time after completion o f  surgical 
procedures but prior to commencement o f  experimental procedures.
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Over an initial period of 200 min (after completion of surgical procedures), a 
relatively high MABP was maintained at a value of approximately 130mmHg. A 
gradual decline then followed over a period of 300 min (between 200 and 500 min 
after completion of surgical procedures), so that towards the end of the experiment, a 
MABP of 64mmHg was recorded. This was a typical response observed in all 
animals. However, balanced against this was the fact that, over the same duration, the 
pulse pressure changed very little, an observation again seen in all animals. The 
typical example described in Figure 3-17 shows the pulse pressure of the rat remaining 
at a fairly steady value of approximately 30mmHg over a 500 min duration. This 
suggested that the cardiac contractility was being maintained over this period of time. 
Further, it was observed from an examination of the blood pressure records that the 
intravenous or intestinal injection of tetragastrin, G-CA, or a mixture of tetragastrin 
and glycocholic acid was without a sustained effect on arterial blood pressure. 
Occasionally there was observed a transient disturbance which was attributed to the 
physical disturbance caused by the injection.
3.2.1 Comparison of arterial blood pressure in responsive and unresponsive rats to 
intestinally-administered agents
3.2. l(i) Intravenously-administered tetragastrin and G-CA
At the end of each experiment, the responsiveness of the preparation was confirmed 
by the increase in gastric acid secretion in response to intravenously administered 
tetragastrin or G-CA, at a level not significantly different from that evoked by the 
initial injections of tetragastrin or G-CA given at the start of the experiment. 
Nonetheless, the MABP was considerably lower when the response to the second 
intravenous injection was being recorded, compared with the MABP during the 
response to the initial intravenous injection of tetragastrin or G-CA The MABP 
values are presented in Tables 3-12 and 3-13. The comparable increases in gastric 
acid secretion in response to the second I.v. injection of either tetragastrin or G-CA, 
as appropriate, thus reflect the satisfactory metabolic status of the parietal cells which 
have high metabolic demands, though it does not necessarily indicate the metabolic 
state of the small intestine.
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3.2.l(ü) Intra-ileal tetî'agastrin
There is the possibility that a compromised metabolic status of the small intestine may 
have been responsible for the failure of those animals, in which tetragastrin or G-CA 
was administered intestinally, to demonstrate an increase in total gastric acidity. 
Therefore, a comparison of the mean arterial blood pressure was made between 
animals in which no response was obtained, and those animals in which the same (or 
similar) procedure had been successful in eliciting gastric acid secretion, in order to 
provide a means of assessment of the relative metabolic status of the small intestine. 
When iieally-infused tetragastrin (SOOOjag kg'^) was undertaken after prior infusion of 
G-CA (600pg kg" )^, it elicited a marked increase in gastric acid secretion (Fig. 3-11). 
In this case, at the time of intra-ileal administration, a typical blood pressure of 
77/58mmHg (MABP -  64mmHg) was recorded. After a further 180 minutes had 
elapsed, blood pressure had fallen to 70/50mmHg (MABP = 57mmHg) (Fig. 3-18A). 
Thus, although mean arterial blood pressure for the period of intra-ileal infusion had 
declined to approximately one-half of the value at the start of the experimental 
procedures (Section 3.2), the preparation was still responsive to the intra-ileal 
stimulus.
By contrast, intra-ileal infusion of tetragastrin (600 and 2500pg kg'^) over a 90 min or 
180 min period, without the conditioning infusion of G-CA, did not elicit increased 
gastric acid secretion (Figs. 3-2, 3-3 and 3-4). In these cases, the rats showed much 
higher systolic and diastolic blood pressures. For example, in one instance, a typical 
blood pressure at the time ileal inftision of tetragastrin (600pg kg'^) was 
112/81mmHg, while at 90 min a value of 94/62mmHg was recorded (Fig. 3-18B). A 
second animal demonstrated a typical blood pressure of 119/88mmHg at the time of 
ileal administration of tetragastrin (2500pg kg’ )^, which gradually fell to 100/72mmHg 
over a period of 90 min (Fig. 3-18C). The blood pressure in a third animal at the time 
of administration of tetragastrin (2500pg kg'^) was 107/74mmHg while, at 180 min, 
this had fallen to 104/65mmHg (Fig. 3-18D). Therefore, an absence of a response to 
iieally-infused tetragastrin was associated with a notably higher blood pressure than in 
those animals in which the ileal tetragastrin did elicit a response. This was also the 
case for the recorded pulse pressure which ranged from 28 to 39mmHg in 
unresponsive animals, compared with 19 to 20mmHg in the responsive animals. It
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Fig. 3-18: Blood pressure records in which (A), ileal tetragastrin (G4) (3000fjg kg'[) evoked 
increased levels o f  gastric acid secretion over a period o f  180 min (rat 7 in Table 3-7), and (B, C 
and D), in which ileal tetragastrin (G4) (600 or 2500jug kg' )^ evoked no increase in gastric acid 
levels over 90 or 180 min period (rat 7 in Table 3-2; rat 4 in Table 3-3; rat 1 in Table 3-4, 
respectively). (Dotted line represents central segment o f  record which has been omitted, to 
represents time zero o f  ileal administration o f tetragastrin, and too tmd tiso indicate 90 and 180 min 
after administration, respectively.)
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would, thus, appear there is little evidence to suggest that the absence of a response 
to ileally-infiised tetragastrin arose from impaired vascular perfusion. Table 3-12 
presents the mean blood pressure measurements of the animals employed in 
investigation of the response to ileal infusion of tetragastrin, and confirms that an 
absence of response is associated with a higher blood pressure than animals in which 
an increase in gastric acid secretion was observed.
Further evidence that blood pressure per se was not a limiting factor is provided by 
the recorded values at the time of the initial and second intravenous injections of 
tetragastrin, as shown in Table 3-12, and the initial and second intravenous injections 
of G-CA (or tetragastrin), as shown in Table 3-13. These illustrate that a lowered 
blood pressure at the time of the second i.v. injection is not associated with a reduced 
gastric acid secretory response.
3.2. l(iii) Intra-ileal infusion of tetragastrin and glycocholic acid 
The absence of response to ileally-infiised tetragastrin and glycocholic acid (in ratio of 
3:2; 600pg kg*^  in total) (Fig. 3-13) was also unlikely to be attributable to the reduced 
perfusion of the animal, since the recorded blood pressure in a typical experiment was 
122/lOOmmHg at the time of administration, falling only to 114/86mmHg, 180 min 
later, which suggested that blood flow to the small intestine was not compromised 
(Fig. 3-19). Indeed, analysis of the recorded blood pressure obtained from all six rats
Î J  l  T ' i i
T -:t: I P 1 mill
. 4...Ü :: -i i ' 1 1
' ■ i Î' t 1
Fig. 3-19: Arterial blood pressure record o f rat (rat 2 in Table 3-8) in which ileal infusion o f  
tetragastrin (G4) and glycocholic acid (Gly) (in 3:2 ratio, total dose o f  600/jg kg' )^ did not evoke 
increased levels o f  gastric acid secretion over a period o f  180 min. (Dotted line represents central 
segment o f  record which has been omitted, to represents time zero o f  administration and tjso 
indicates 180 min after administration.)
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used in such procedures demonstrated a mean arterial blood pressure (± s.D.) of 110 
± 5mmHg at the time of ileal administration, which fell gradually to 96 ± 8mmHg after 
180 min. Reference to Table 3-12 indicates that gastric acid secretion may be 
observed at a very much lower blood pressure, and we can thus assume that in this 
particular experiment, the absence of response to the individual components of G-CA 
was not attributable to restricted blood flow to the intestine.
3.2.1(iv) Intra-jejunal infusion o f tetragastrin
Tetragastrin, infused jejunally, did not elicit any increases in gastric acid levels (Fig. 3- 
14), even though measured blood pressure values suggested that the perfusion state of 
the small intestine was not compromised. In a typical experiment, on intra-ileal 
administration of tetragastrin (3000p,g kg'*), blood pressure was recorded as 
114/81 mmHg, giving a MABP of 92mmHg, and a pulse pressure of 33mmHg (Fig. 
3-20). After a duration of 180 min, the blood pressure, and hence MABP, had fallen 
to 103/64mmHg and 77mmHg, respectively, while an increase in pulse pressure to 
39mmHg was observed. These are considerably higher values than recorded in the 
animals in which ileal tetragastrin, injected after G-CA, evoked increased levels of 
total gastric acidity (e.g. Fig. 3-18A), yet there was no evidence of an increase in 
gastric acid secretion. The higher level of blood pressure and pulse pressure provided 
us with assurance that the absence of a response in this experiment was not as a 
consequence of compromised perfusion of the jejunum.
100
mmHg
0
■SOOOngkg' ;L_ Î ' ! ! H -
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Fig. 3-20: Arterial blood pressure record o f  rat (rat 3 in Table 3-9) in which jejunal tetragastrin 
(G4) (3000pg kg' )^ did not evoke increased levels o f  gastric acid secretion over a period o f  180 min. 
(Dotted line represents central segment o f  record which has been omitted, to represents ileal 
administration o f  tetragastrin, and t,so indicates 180 min ajler administration.)
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3.2. l(v) Intra-jejunal infusion o f G-CA
As with jejunally-infused tetragastrin, intra-jejunal G-CA (600pg kg’*) did not elicit 
any increase in the level of gastric acid secretion (Figs. 3-15 and 3-16), while recorded 
blood pressure values indicated that this was not attributable to impaired vascular 
perfusion in the rat. For example, in a typical experiment, a blood pressure of 
l00/70mmHg (MABP = SOmmHg), recorded at the time of administration of jejunal 
G-CA, fell to 96/57mmHg (MABP = 70mmHg) after 180 min (Fig. 3-21 A). Over this 
duration, pulse pressure actually increased fi’om 30 to 39mmHg.
m
600^g kg' G-CA
K,"  I !
600^g kg ' G-CA
—  T
Fig. 3-21: Arterial blood pressure records o f  the same rat (rat 3 in Table 3-11) in which A, jejunal 
G-CA (600pg kg' )^ did not evoke increased levels o f  gastric acid secretion over a period o f  180 min, 
and B, ileal G-CA (600pg kg' )^ did evoke an increase in gastric acid levels over a 180 min period. 
Record also shows point o f  demise o f  animal at Ow (Dotted line represents central segment o f  
record which has been omitted, to represents time zero o f  administration o f  G-CA and tjso indicates 
180 min after administration.)
By contrast, when intra-jejunal infusion was followed by intra-ileal inftision of G-CA, 
the blood pressure was considerably lower, and yet an increased level of secretion of 
gastric acid was elicited (Fig. 3-16). At the time of ileal administration of G-CA, a 
typical blood pressure in the same rat as above was 91/54mmHg (MABP = 
66mmHg), while after a further 180 min this had diminished to 47/16mmHg (MABP 
= 26mmHg) (Fig. 3-2IB). Even at this low value of blood pressure, an increase in
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gastric acid secretion was, nevertheless, evoked in response to ileally-administered G- 
CA.
The mean arterial blood pressure of all experimental animals, expressed as the mean ± 
S.D., in each of the experiments designed to investigate the stimulatory effect of 
ileally- and jejunally-infused G-CA (and jejunally-infused tetragastrin) are tabulated 
(Table 3-13). These results provide unequivocal evidence that even at low blood 
pressures, gastric acid secretion can be evoked.
3.2.1(vi) Summary o f intestinal infusion results
From Table 3-14, the mean arterial blood pressures of the rats in which ileal or jejunal 
infusion of tetragastrin or G-CA did not result in increased gastric acid secretion 
(experiments 1-7) were indistinguishable from those of the animals in which responses 
were evoked (experiments 8-11). We were thus confident that the absence of 
response in the former cases were not attributable to poorer perfusion of the internal 
viscera.
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Table 3-14: Mean arterial blood pressure, expressed as the mean (± S.D,), of 
animals in which intestinal infusion of either tetragastrin (G4), G-CA or 
tetragastrin/glycocholic acid was carried out. The response of the preparation 
to the administered agents is also presented.
Experiment Mean arterial blood pressure
(mmHg) (+ S.D)
to t90 tl80 acid n
1 (Section 3. l.l(ii)) 88 ± 2 1 7 6 ±  14 - no 11
2 (Section 3.l.l(iü)) 82 +  26 81 ± 2 0 - no 4
3 (Section 3.l.l(iv)) 8 7 + 1 1 6 0 ±  15 no 6
4 (Section 3.1.3(iv)) 110 +  15 - 93 ± 1 7 no 5
5 (Section 3.1.4(i)) 9 6 + 1 5 “ 7 2 ±  11 no 5
6  (Section 3.1.4(ii)) 96 +  14 73 ± 2 2 no 5
7 (Section 3.1.5) 91 ±  14 - 76 ± 6 no 5
8 (Section 3.1.3(ii)) 110 +  17 93 ± 1 7 yes 5^
9 (Section 3.1.3(iii)) 105 +  25 79 ± 9 yes 7
10 (Section 3.1.3 (iii)) 75 +  15 - 61 ± 1 8 yes 7
11 (Section 3.1.5) 71 ± 1 0 34 ± 2 1 yes 5
Experiments 1, ileal tetragastrin (60Qpg kg'^); and 2, ileal tetragastrin (2500pg kg^); both over 90 
min period. Experiments 3, ileal tetrgastrin (2500pg kg' )^; 4, ileal tetrgastrin and glycocholic acid 
(in 3:2 ratio, 600fjg kg'  ^total dose); 5, jejunal tetragastrin (SOOOpg kg^); 6, jejunal G-CA (600pg 
kg' )^; 7, jejunal G-CA (600pg kg' )^ prior to ileal G-CA; 8, ileal G-CA (600pg kg^); 9, ileal G-CA 
(600pg kg' )^ prior to ileal tetragastrin; 10, ileal tetragastrin (3000pg kg' )^ subsequent to ileal G-CA; 
and 11, ileal G-CA ( 6 0 0 kg' )^ subsequent to jejunal G-CA; all over 180 min period.
to , time zero o f  administration; tgo, 90 min after administration; tjso, 180 min after administration; 
‘acid’ signifies whether the employed procedure resulted in increased levels o f  gastric acid 
secretion: n, number o f rats; omission o f  results from two rats in which measurable increases in
gastric acid levels were not recorded.
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3.3 Histological analysis
Figures 3-22A and B illustrate two representative samples of light microscopic 
sections of ileal mucosa, removed from a rat in which no instillation of G-CA had 
occurred. These may be compared with the sections of ileal mucosa excised from a 
rat in which instillation of G-CA (600pg kg'*) was performed (Figs. 3-22C and D). 
At this level of resolution, the integrity of the epithelial wall was maintained with no 
visible damage in both cases. There is no evidence of any major lesions to the ileal 
mucosa through which enhanced absorption of G-CA may have occurred. In 
addition, the presence of mucus-releasing goblet cells in both the perfixsed and 
unperfused tissue is apparent (Figs. 3-22B and D), as is a well-defined brush-border 
(Figs. 3-22A and C)
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BFig. 3-22: Light m icroscopic sections o f  epithelium  o f  ileum, with lumen uppermost, 
o f  tw o rats. A and B, non-perfused ileum; C  and D, ileum perfu sed  with 600p g  kg-t 
G-CA. Sections show  enterocytes (e), g ob le t cells (g) and brush border  ( —►). 
Sections sta ined  with H&E, x700.
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D isc u ssio n
4.1 Summary of results
The present study has demonstrated a number of unequivocal results. First, intra- 
intestinal instillation of tetragastrin was shown not to result in a measurable increase 
in gastric acid secretion, suggesting that the tetrapeptide was not absorbed across the 
intestinal wall in any measurable amount, if indeed at all. The biological activity of 
the synthesised tetragastrin-cholic acid conjugate (G-CA) was confirmed when 
intravenous injection (15(ig kg'*) evoked measurable increases in gastric acid output. 
Furthermore, in contrast with tetragastrin, intra-ileal administration of G-CA (600pg 
kg'*) caused a marked increase in gastric acid secretion from which it was inferred 
that it had been transported across the ileal mucosa, while retaining considerable 
biological activity. The individual components of G-CA, that is, tetragastrin and 
glycocholic acid (cholic acid was insoluble in isotonic saline and, thus, could not be 
used) (in the ratio of 3:2; total dose of 600(ig kg'*) were shown not to be effective 
since there was no evidence of an increased level of gastric acid secretion following 
intra-ileal instillation of these compounds. The transmucosal movement of G-CA 
appeared to be specific to the ileum, as there was no evidence of transport across the 
intestinal mucosa following intra-luminal instillation in the jejunum.
4.2 Biological activity of G-CA and tetragastrin
The biological activity of synthetic tetragastrin-cholic acid conjugate (G-CA) was 
confirmed when intravenous injection (15pg kg'*) evoked an increase in gastric acid 
secretion from the stomach of the rat preparation. Very good consistency was 
demonstrated between the responses to the first and second intravenous injections of 
G-CA within a particular experiment. Between the different sets of experiments, 
broadly similar results for the mean peak increase in gastric acid output were 
measured, although there was some variation in the mean cumulative responses 
(Table 4-1).
With respect to tetragastrin, there was some potentiation of the peak and cumulative 
responses to the second intravenous injection of tetragastrin (minimum effective doses 
of between 12.5 and 60pg kg'*) in experiments 1 and 2, whereas experiments 3, 4 and
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5 showed no evidence of potentiation for both the peak and cumulative increases in 
gastric acid secretion following intravenous injection of tetragastrin as a first and final 
procedure (Table 4-2).
Table 4-1: Mean peak and cumulative (cum.) increases in gastric acid secretion 
in response to i.v. tetragastrin-cholic acid conjugate (G-CA) (15pg kg *) as a 
first and final procedure, as carried out in 6 sets of experiments.
Experiment
(showing section 
of results)
Initial lA 
Mean peak 
increase
(|imol 15min'± S.D.)
+ G-CA 
Mean cum. 
increase
(jjmol hr' 
±S.D.)
Second i.) 
Mean peak 
increase
()unol 15mm' 
±S.D.)
Ï . G-CA 
Mean cum. 
increase
(jjmol hr' 
±S.D.)
n
1 (3.1.2) 0.49  +  0.13 1.10 +  0.73 0.65 ±  0.28 1.46 +  0 .84 5
2 (3.L3(ii)) 0.64  +  0 .26 1 . 3 1 + 0 . 5 7 0.72 ±  0 .26 1.43 +  0.62 5
3 (3.1.3 (iii)} 0.57 +  0 .24 1.09 +  0 .52 0.70 +  0 .42 1.15 +  0.59 7
4  (3.1.3(iv)} 0.47 +  0 .14 0.84 +  0.35 0.49 +  0 .14 0 .90  +  0 .64 5
5 (3.1.4(ti)) 0.44 +  0.13 0.58 +  0.13 0.42 ±  0.09 0.59 +  0 .16 5
6 (3 .L 5) 0.35 +  0.05 0.44 +  0 .10 n/a n/a 5
Wei^ted 
mean ± S.D. 0.50 +  0.18 0 . 9 1 + 0 . 4 7
0.60 +  0.28 1 . 1 1 + 0 . 6 1 32 (1 s t)  
27 (2nd)
All values were statistically significant when compared with zero baseline (P<0.05); n, number o f  
animals.
Experimental sections from which results in Table were taken were: 1, intravenous G-CA followed 
by second intravenous G-CA: 2, ileal G-CA (OOOfjg kg' )^ over 180min period; 3, ileal G-CA (600pg 
kg' )^ Pf'ior to ileal tetragastrin, overl80min period; 4, ileal tetragastrin and glycocholic acid (ratio 
o f  3:2, total dose o f  600pg kg' )^, over 180min period; 5, jejunal G-CA (600pg kg' )^ over 180min 
period: 6, jejunal G-CA (600pg kg' )^ prior to ileal G-CA, over 180 min period.
Reference to the weighted mean peak and cumulative increases in gastric acid, 
presented in Tables 4-1 and 4-2, in response to the first intravenous injection of G-CA 
or tetragastrin, as seen in a total of 32 and 31 rats, respectively, demonstrate a general 
similarity in magnitude. Comparable responses are also shown by the weighted mean 
peak responses to intravenous G-CA (n=27) and tetragastrin (n=31), as a final 
procedure, while the weighted mean of the cumulative increase in gastric acid 
secretion was approximately 47% higher in the rats in which tetragastrin was
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administered intravenously, compared with those rats in which G-CA (i.v.) was 
administered as a final procedure.
Table 4-2: Mean peak and cumulative (cum.) increases in gastric acid secretion 
in response to intravenous tetragastrin (G4) (between 12.5 and 60pg kg ) as a 
first and final procedure, as carried out in 5 sets of experiments.
Initial i.v. G4 Second i.v. G4
Experiment
(showing section 
of results)
Mean peak 
increase
(nmol ISmin"' 
± S.D.)
Mean cum. 
increase
(nmol hr' 
±S.D.)
Mean peak 
increase
(nmol ISmin"' 
± S.D.)
Mean cum. 
increase 
(nmol hr' 
±S.D.)
n
1 (3.1.1 CO) 0.53 ±0.25 1.38 ±0.84 0.90 ±0.30 2.25 ± 0.92 5
2 (3.1.1(H)) 0.58 ±0.33 1.27 ±0.83 0.81 ±0.53 2.43 ±1.86 11
3 (3.1.1 (Hi)) 0.47 ±0.16 1.15 ±0.36 0.36 ±0.06 0.64 ±0.29 4
A  (3.1.1(iv)) 0.42 ±0.10 0.84 ±0.27 0.50 ±0.14 1.20 ±0.49 6
5 (3.1.4(0) 0.44 ±0.10 0.54 ±0.17 0.52 ±0.07 0.62 ±0.10 5
Weighted 0.50 ±0.06 1.07 ±0.39 0.66 ±0.12 1.64 ±1.42 31
mean ± S.D.
All values were statistically significant when compared with zero baseline (P<0.05); n, number o f  
animals.
Experimental sections from which results in Table were taken were: 1, intravenous tetragastrin 
followed by second intravenous tetragastrin: 2, ileal tetragastrin (600jl^  kg') over 90min period: 3, 
ileal tetragastrin (2500pg kg') over 9Qmin period: 4, ileal tetragastrin (2500pg kg') over 180min 
period; 5, jejunal teti^agastrin (3000pg kg ') over 180min period.
G-CA is composed of tetragastrin and cholic acid in an approximate ratio of 3:2. 
Thus, the general similarity observed between the intravenous responses to G-CA 
(15pg kg'*) and tetragastrin (minimum effective dose, most commonly 15pg kg"*) 
suggests that the same level of response is recorded to G-CA at two-thirds the 
effective dose of tetragastrin administered. Had the synthesised conjugate contained 
appreciable amounts of fragments of the entire G-CA molecule, such as tripeptide- 
cholic acid or dipeptide-cholic acid, neither would be biologically active since the 
complete tetrapeptide amide sequence is required for full biological activity (Morley, 
Tracy and Gregory, 1965), the biological activity would be reduced. This lends 
assurance that G-CA was of reasonable purity.
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4.3 Heal administration of G-CA
The results of the present study demonstrated unequivocally that instillation of the 
conjugate into the ileum resulted in the stimulation of gastric HCl secretion (Table 4- 
3). From this we can infer that G-CA has crossed the ileal wall, entered the systemic 
circulation and subsequently stimulated the parietal cells. The extent to which levels 
increased varied (shown by individual mean s.D.values), but for 17 rats, the weighted 
mean was calculated as 1.84 ± 1.22|amol 180min*, a value approximately twice as 
great as the cumulative response to the intravenous injection. Omitted from these 
results are the two rats in which ileal G-CA elicited marginal or no measurable 
increases in gastric acid levels (see Table 3-6).
Table 4-3: Mean cumulative increases in gastric acid secretion in response to 
ileally-infused tetragastrin-cholic acid conjugate (G-CA) (600pg kg'*), as carried 
out in 3 sets of experiments.
Experiment
(showing section o f results)
Ileal G-CA 
Mean cumulative increase
(umol 180m in' ±  S.D.)
n
1 (3.1.3(H)) 2.80 + 2.17 5
2  (3.1.3(iii)) 1.31+0.44 7
3 (3.1.5) 1.63 + 0.31 5
Weighted mean ± S.D. 1.84+1.22 17
A ll values were statistically significant when compared with zero baseline (P<0.05); n, number o f  
animals.
Experiments 1, ileal G-CA (600pg kg') over 180min period; 2, ileal G-CA (600pg kg') prior to 
ileal tetragastrin, over 180min period; 3, ileal G-CA (600pg kg') subsequent to jejunal G-CA, over 
180min period.
It is difficult to state accurately the quantity of G-CA reaching the systemic 
circulation without carrying out radioimmunoassay of the systemic blood. In any 
case, comparison of the increased level of gastric HCl secretion elicited in response to 
intra-ileal G-CA, with the response to intravenous G-CA, is perhaps a more reliable 
way of estimating the absorption of G-CA into the systemic circulation, simply 
because radioimmunoassay of levels in the bloodstream may be affected by
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hydrolysed fragments of G-CA (Ziv et al, 1987). So, radioimmunoassay may not 
have provided any additional information; indeed a degree of ambiguity may have 
been introduced.
Intravenous injection of G-CA (15pg kg'*), as a first procedure, evoked a mean 
cumulative increase in gastric acid levels of 0.91 ± 0.47gmol hr'*, and as a final 
procedure, caused gastric acid secretion to increase by 1.11 ± 0.61 gmol hr'* above 
baseline (Table 4-1). Comparison of these values with the degree to which ileally- 
infiised G-CA (600pg kg'*) enhanced gastric acid secretion (weighted average of 1.84 
± 1.22|imol 180min'*; Table 4-3) would suggest that, on the basis of simple 
proportion, just under 5% of the intra-ileally administered dose was absorbed from 
the ileum. This calculation is complicated by the half-lives of tetragastrin and G-CA. 
The clearance rate (half life) of G17 from the human circulation is approximately six 
minutes, whereas that for G34 is about six times longer (Walsh et al, 1974; Walsh et 
al, 1976). From this we may deduce that the clearance rate for tetragastrin (G4) 
would be in the region of six minutes or less. Undoubtedly, a considerable amount of 
tetragastrin may be “wasted” through clearance by the liver and kidneys. This is 
consistent with the fact that the minimum effective dose of tetragastrin is of the order 
12.5|ig kg'* and, thus, the instantaneous distribution of tetragastrin in the plasma of 
the rat (approximately 10ml) results in a plasma concentration which is seemingly 
very high. The clearance rate of G-CA is unknown, but will involve factors such as 
the degree to which G-CA is hydrolysed into free tetragastrin, in addition to how 
much of the administered G-CA is removed by the hepatocytes which avidly take up 
bile salts. Since the minimum effective dose of G-CA was 15pg kg'*, giving an 
effective tetragastrin dose of approximately lOgg kg'*, compared with the commonest 
minimum effective dose of tetragastrin alone of 15gg kg'*, this would indicate a 
greater efficacy of G-CA possibly resulting from a longer half life.
The encouraging outcome of this study is perhaps more apparent if we consider the 
comparative oral bioavailability of other peptides, for example, insulin. In general, 
bioactivity of orally-administered peptides is very low indeed (see Table 1-2). Co­
administration of insulin with protease inhibitors and permeation enhancers is one of 
the more successfiil approaches and yet, still less than 1.0% of the administered dose 
reaches the systemic circulation (Ziv et al, 1987).
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4.3.1 Comparison with ileal and jejunal administration of tetragastrin 
The results for ileal administration of G-CA (600gg kg"*) were in contrast to those for 
ileal infusion of tetragastrin (2500gg kg'*); measurable increases in gastric acid 
secretion were not elicited in response to the latter (see Tables 3-2, 3-3 and 3-4). 
This was the case even though the dose of tetragastrin was up to 4 times greater than 
the dose of G-CA (and thus, on a weight for weight basis, approximately 6.25 times 
greater than the dose of tetragastrin contained within G-CA). Additionally, jejunal 
infiision of tetragastrin (3000gg kg'*) produced no discernible increase in gastric acid 
secretion (see Table 3-9).
Since the intravenous injection of tetragastrin, as a first procedure, demonstrated its 
biological activity, and as a final procedure, demonstrated its continued biological 
activity as well as the viability of the animal preparation (see Tables 3-2, 3-3, 3-4 and 
3-9), we were confident that the lack of response to intestinal infusion of tetragastrin 
(as the second procedure) was as a consequence of absence of any substantial level of 
transmucosal movement. Furthermore, measurement of the arterial blood pressure of 
these rats, during the infiision of ileal tetragastrin, indicates that the lack of response 
was not attributable to reduced vascular perfusion, since an increase in gastric acid in 
response to ileal G-CA has been demonstrated at considerably lowerjblood pressures 
(see Tables 3-12 and 3-13). An absence of response may be contributed to by the 
degradative activity of the proteolytic enzymes in the gut, in particular the intestinal 
brush border peptidases (listed in Table 1-la). These are capable of hydrolysing 
peptides of up to ten amino acid residues, but have a preference for tripeptides 
(Matthews and Payne, 1980). The wall of the small intestine may also act as a 
physical barrier to the absorption of tetragastrin since, before targeting the parietal 
cells, tetragastrin has to penetrate the mucosal membrane of the intestinal wall in 
order to enter the systemic circulation. Di- and tripeptide transport systems exist in 
the intestinal brush border membrane, allowing the intact transport of such molecules 
(Newey and Smyth, 1960; 1962); however, peptides composed of greater numbers of 
amino acid residues are not taken up. Uptake by hepatocytes of any intestinally- 
infused tetragastrin which reaches the mesenteric circulation may also play a role in 
the absence of a measurable increase in gastric acid secretion (Doherty and Pang, 
1997). Chemical modification of tetragastrin by acylation with various fatty acids has
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been shown to not only increase its lipophilicity, but also reduce degradation of 
tetragastrin, thereby enhancing intestinal absorption in the rat (Yodoya, Uemura, 
Tenma, Fujita, Murakami, Yamamoto and Muranishi, 1994). In addition, hepatic 
first-pass metabolism of the modified tetragastrin was slightly suppressed in these 
experiments, suggesting that the stability of such compounds in the systemic 
circulation would be enhanced, compared with tetragastrin.
At variance with the results of the present study is the outcome of a study, carried out 
in the stomach-perfused rat preparation, in which tetragastrin, injected into the jejunal 
or ileal loop, produced a measurable increase in gastric acid secretion (Jennewein et 
al, 1974). Jejunal or ileal administration of tetragastrin (lOmg kg’*) was reported to 
elicit a maximal increase in gastric acid secretion of 62% and 80% of the maximal 
increase in response to intravenous tetragastrin (30|tg kg’*), respectively. Intra- 
duodenal adminstration of tetragastrin did not evoke any measurable increases in 
gastric acid secretion, though the authors demonstrated that the exclusion of 
pancreatic enzymes, which led to enhanced absorption fi'om the duodenum, may have 
been the factor which accounted for the enhanced absorption recorded from the 
jejunal and ileal loops.
The differences in results reported in this study, and in our study may arise from the 
different doses administered, since Jennewein et al injected tetragastrin into the 
intestinal loops at a dose approximately 3 times the maximum dose that we instilled. 
A fiirther consideration may be the means by which tetragastrin was introduced into 
the intestinal loops. In the present study, leakage of tetragastrin into the internal 
viscera was prevented by the insertion of a short length of cannula at the site of 
intestinal instillation, through which compounds were administered. This was deemed 
necessary since we had observed in earlier experiments that direct injection of 
pentagastrin (G5) through the ileal wall resulted in a doubling of gastric acid output 
above control levels, as a consequence of leakage, visible at the site of injection. One 
is under the impression that Jennewein and colleagues introduced tetragastrin into the 
intestinal loops by direct injection through the intestinal wall. It is, thus, conceivable 
that at least some of the tetragastrin may have escaped, and entered the surrounding 
capillaries, although the absence of a response after intra-duodenal administration 
tends to exclude this possibility. Nonetheless, despite the resultant increase in gastric
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acid secretion, the authors proposed that no more than approximately 0.04% of the 
administered dose was absorbed after jejunal or ileal loop infusion.
4.3. l(i) Degree o f ionisation o f G-CA and tetragastrin solutions 
The dissimilarity observed between the transport of ileally-infused G-CA and the non­
transport of ileally-infused tetragastrin may, theoretically, have occurred as a result of 
differences in the ionisation states of these compounds, since non-ionised forms are 
absorbed by passive diffusion on the basis of their oil/water partition coefficient. It is 
well established that, in general, the unionised form of a weak acid or base is able to 
penetrate the intestinal wall at a much faster rate than the corresponding ionised acid 
or base, unless there is a specific transport mechanism in operation. Validation of this 
principle comes from the outcome of investigative studies using artificial membrane 
systems (Doluisio and Swintosky, 1964; Samuelov, Donbrow and Friedman, 1979), 
and gastrointestinal membranes such as the gastric mucosa, and the small and large 
intestines (Hogben, Schanker, Tocco and Brodie, 1957; Shore, Brodie and Hogben, 
1957; Schanker, Shore, Brodie and Hogben, 1957; Schanker, Tocco, Brodie and 
Hogben, 1958; Schanker, 1959; Hogben, Tocco, Brodie and Schanker, 1959). 
However, our calculated estimates of the degree to which tetragastrin and G-CA are 
ionised (see Appendix) appear to refute this proposal. Since both compounds are 
fairly complex molecules, these calculations had to be carried out by consideration of 
the degree to which the major side groups (COOK, NH2 and NH) of the molecules 
were ionised. In the case of tetragastrin, ionisation was estimated to be 100%, except 
for COOH which was calculated to be 14% ionised, while for G-CA, with the 
exception of the carboxyl (COOH) group which was calculated to be about 57% 
ionised, the degree of ionisation was calculated to be approaching 100%. We can, 
therefore, confidently rule out differences in the rate of passive diffusion on the basis 
of lipid solubility as a means of explaining the differences in ileal transport between G- 
CA and tetragastrin.
4.3.1 (ii) Permeability changes elicited by bile salts
Bile salts are well recognised for their efficacy in enhancing transmucosal permeation 
and, thus, have been widely used as such in studies investigating the potentiation of 
intestinal permeation of otherwise poorly absorbed macromolecules (Kidron et al.
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1982; Ziv et al, 1987; Bendayan et al, 1990). Unfortunately, considerable mucosal 
damage effected by some bile salts has been reported (Gaginella et al, 1977; Nadai et 
al, 1975; Nakanishi et al, 1983). There was, thus, a possibility that G-CA, instilled 
into the ileum, caused an increase in gastric acid secretion through permeability 
changes to the intestinal wall, elicited by cholic acid contained within G-CA. The 
results of the present study, however, appear to refute this possibility, since we have 
shown that simultaneously-infiised tetragastrin and glycocholic acid (we were 
compelled to use glycocholic acid due to the insolubility of cholic acid in isotonic 
saline), in a ratio of 3:2, into the ileum did not elicit any measurable increases in 
gastric acid secretion above baseline (see Table 3-8). This was in contrast to the 
unequivocal response evoked by intravenous infiision of the same solution (at a dose 
40 times less than the ileal dose). This allowed us to conclude a number of points. 
First, the intravenously administered solution had a very similar biological activity to 
tetragastrin and G-CA and, thus, the presence of glycocholic acid does not exert an 
inhibitory action on the activity of tetragastrin.
Second, instillation of G-CA (in conjugated form), rather than simultaneous infusion 
of the components of G-CA into the ileum, is a prerequisite for the increase in 
transmucosal transport of tetragastrin with resultant levels which are sufficient to 
stimulate increased gastric acid secretion. This, perhaps, lends support to the idea 
that the ileal bile salt carrier is the means by which this occurs during these 
experiments.
Finally, in both this series of experiments which investigated the biological activity of 
simultaneously infused tetragastrin and glycocholic acid into the ileum, and the series 
of experiments in which the activity of ileal G-CA was investigated, the first 
experimental procedure carried out in each case was an intravenous injection of G- 
CA. The outcome of the former experiments in which ileal tetragastrin infused along 
with glycocholic acid did not elicit a measurable increase in gastric acid secretion 
provides evidence to suggest that the i.v. injection of G-CA did not increase the 
permeability of the ileal wall, by some mechanism acting from the blood side thereby 
allowing G-CA to enter the circulation when administered ileally. This is further 
corroborated by the experiments in which jejunal inftision of G-CA, subsequent to 
intravenous G-CA, did not elevate gastric acid levels above baseline (see Tables 3-10
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and 3-11), and additionally, by the normal histology of the ileal wall, as determined by 
light microscopic analysis (Figures 3-22A and B) (see later).
4.4 Site-specificity of response to intestinally-administered G-CA
Of considerable interest was the absence of response to jejunally-infused G-CA 
(600pg kg'*) in the same rats in which responsiveness to intravenously-infused G-CA 
(ISpg kg'*), as first and final procedures, was demonstrated (see Table 3-10). We 
were, thus, confident that neither the prepared solution of G-CA had lost its biological 
activity nor that the animal preparation had become unresponsive to the effects of G- 
CA Further reinforcement of this view was provided in a further series of 
experiments when, subsequent to jejunally-infused G-CA (600gg kg'*), which was 
without effect, ileally-infiised G-CA (600pg kg'*) did cause an increase in gastric acid 
secretion (Tables 3-11 and 4-3). Such an outcome is indicative of a location-specific 
mechanism, of which there a number of possibilities which require consideration.
4.4 . 1  Ileal bile salt active transport system
The rationale behind the present study was to produce a tetragastrin-cholic acid 
conjugate which would have the structural requirements necessary for recognition by 
the ileal bile salt active carrier system. Utilisation of such a system was envisaged to 
effect an improved bioavailability of intestinally-administered tetragastrin. Although 
transport of bile salts occurs across the entire length of the small intestine by both 
ionic and non-ionic diffusion (Dietschy, 1973), the active carrier-mediated uptake is 
specifically localised to the ileum (Lack and Weiner, 1961).
A review of the current literature reveals that for optimal recognition of a bile salt by 
the transport system, the characteristics of naturally occurring bile salts should be 
retained as far as is possible. Thus, a negative charge in the side chain attached to 
position C-17, and at least one hydroxyl group at position C-3, C-7 or C-12 of the 
steroid nucleus (see Figs. 1-2 and 1-3) are necessary (Lack and Weiner, 1967; Anwer 
et al, 1985; Hardison et al, 1991; Kramer et al, 1993). In addition, it has been 
determined that conjugate molecules in which the drug moiety is attached to the C-3 
position are recognised like natural bile acids by the hepatic bile acid transport system 
(Kramer et al, 1992; Wess, Kramer, Bartmann et al, 1992). Indeed, a comprehensive
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Study in the rat in vivo, carried out by Kramer et al (1994), demonstrated the uptake 
of a conjugate of cholic acid and a synthetic tetrapeptide (labelled with an additional 
fluorescent group) by the ileal bile salt active carrier system, in which the tetrapeptide 
was coupled to the C-3 position of the steroid nucleus, and the side chain attached to 
C-17 was unmodified. However, while Kim and colleagues (1993) had previously 
shown that renin-inhibitory peptides (RIPs), coupled with cholic acid or taurocholic 
acid at position C-3, resulted in a high affinity binding with the bile salt transporter in 
the Caco-2 cell, in the perfiised rat ileum, measurable amounts of RlP-chohc acid 
were not detected in the mesenteric blood. This suggested that, although uptake by 
the ileal bile salt active carrier system was possible, complete transfer of the conjugate 
to the circulation was impeded, either in passage through the enterocyte, or efflux 
from the enterocyte.
In the present study, we were of the view that conjugation of tetragastrin with cholic 
acid at the site at which glycine or taurine naturally attach (C-24) may provide a 
feasible alternative to the approach of Kramer and colleagues. The negative charge of 
cholic acid was retained through the presence of the carboxyl group of aspartate. 
Indeed, our study has produced considerable evidence to demonstrate the transport of 
G-CA across the ileal wall, but the non-transport of G-CA across the jejunal wall. 
Although we have no absolute evidence that the bile salt active transport system is 
being utilised to produce this response, the fact that we are confident that our 
compound is of reasonable purity and a response was recorded only when G-CA was 
instilled into the region of small intestine where the bile salt carrier system is localised, 
lends support that this is indeed the case.
Over the past ten years, previous studies have adopted a set of criteria contrary to 
those suggested by Lack and Weiner (1967), Anwer et al (1985), Hardison et al
(1991) and Kramer et al (1993). As in the present study, modifications at the C-24 
position of the bile acid, rather than at the C-3 position of the steroid nucleus, have 
been investigated as a possible means of facilitating the uptake of otherwise poorly 
absorbable macromolecules. In a study by Maeda and Takahashi (1989), para- 
aminobenzoic acid (PABA) was covalently coupled to ursodeoxycholic acid at the C- 
24 position. Consequently, using the rat everted gut sac technique, PABA- 
ursodeoxycholic acid was reported to be transported against a concentration gradient 
via the ileal bile salt active carrier system. A subsequent investigation revealed that
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conjugation of L-triiodothyronine (L-T3) with cholic acid at the C-24 position, so that 
a negative charge of the C-17 side chain remained, resulted in significant 
hypocholesterolaemic activity following oral administration of the conjugate, in vivo, 
to lipaemic rats (Stephan, Yurachek, Sharif, Wasvary, Steele and Howes, 1992). 
However, the rationale behind this study was not to increase intestinal uptake; rather, 
the authors aimed to produce a thyromimetic with a high affinity for the hepatocytes, 
whilst reducing cardiac and pituitary-associated side effects.
The former study (Maeda and Takahashi, 1989), along with the present study, 
demonstrates that through the coupling of an otherwise poorly absorbed drug moiety 
with the C-24 position of bile acids, transfer across the intestinal wall may be 
achieved. So, while the retention of the negative charge at the bile acid side chain 
(position C-17) still remains a prerequisite for the successful transportation of 
macromolecules via the bile salt carrier system, the view that attachment of these 
compounds could only be at position C-3 of the steroid nucleus of the bile acid has 
now been refiited.
4.4.2 Ileal localisation of membranous epithelial cells (M-cells)
Lymphoid tissue in the intestinal mucosa becomes especially prominent in the ileum, 
resulting in the formation of Peyer’s patches from the aggregated lymphoid tissue. 
Overlying these aggregates are the M cells, which have been shown to be able to take 
up antigens fiom the gut lumen, and transport them to the underlying lymphocytes 
(Owen, 1977).
M cells have been found in a number of mammalian species including humans, 
monkeys, dogs, rabbits, guinea pigs and rodents (Bockman and Cooper, 1973; Owen 
and Jones, 1974; Owen and Nemanic, 1978; Trier, 1991). They have a unique 
structural morphology. The apical surface is covered with a variable number of 
irregular microvilli which are shorter, wider and fewer in number than exhibited by the 
neighbouring enterocytes (Owen and Jones, 1974; Owen and Nemanic, 1978; Smith 
and Peacock, 1980). The presence of numerous endocytotic vesicles, capable of 
transporting macromolecular tracers such as horseradish peroxidase (Owen, 1977) 
and ferritin (Bockman and Cooper, 1973; Bye, Allan and Trier, 1984) is evident. The 
transport of macromolecular substances, such as cationised ferritin, certain lectins 
and the B subunit of cholera toxin, from the intestinal lumen to the basolateral
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membrane of the M cell or the subepithelial intercellular space has been reported to 
occur within minutes by adsorptive endocytosis (Owen, 1977; Bye, Allan and Trier, 
1984; Neutra, Phillips, Mayer and Fishkind, 1987). Macromolecules, such as 
albumin, that do not adhere to the apical surface of M cells may also cross the 
epithelial barrier via the M cell by fluid-phase endocytosis, although this process has a 
markedly reduced efficiency compared with adsorptive endocytosis (Neutra et al, 
1987). In a review of the current literature, Trier (1991) concluded that virtually any 
component of the intestinal luminal contents may be transported across the mucosa by 
this means, if that component is resistant to enzymatic hydrolysis.
With this in mind, it is perhaps not inconceivable to suggest that the differences in the 
permeation of G-CA, demonstrated in the ileum and jejunum, are attributable to the 
differences in the morphology of the small intestine, and more specifically to the M 
cells of the ileum. If the coupling of tetragastrin with cholic acid in some way results 
in an increase in the stability of tetragastrin compared with the native tetragastrin 
(which is likely to undergo considerable proteolysis), this may be a feasible proposal. 
Nevertheless, the possibility remains to be fully resolved.
4.4.3 Hormonal release
The likelihood that ileal instillation of G-CA evokes an increase in gastric acid 
secretion through the release of a hormone(s) which ultimately results in the 
stimulation of the parietal cells must be considered. We are able to rule out mediation 
through a vago-vagal reflex since ligation of the oesophagus at its junction with the 
stomach (see Methods), includes the anterior and posterior branches of the vagus 
nerves which run over the surface of the oesophagus, with the result that these nerves 
are blocked. This has been confirmed experimentally (Morrison, personal 
communication). An intrinsic reflex mediated through the gastrointestinal tract may 
also be excluded. Apart from the very considerable distance from the ileum to the 
stomach, and the presence of the hyponeural segment between the duodenum and the 
antrum, ligation of the stomach tube at the gastroduodenal junction would further rule 
out this possibility.
A review of the literature has not revealed any evidence that ileal instillation of 
foodstuffs leads to stimulation of gastric acid secretion. Indeed, the converse seems 
to be true. In human volunteers, ileal perfusion of carbohydrates and lipids resulted in
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decreased gastric acid output, whereas ileal perfiision of peptones had very little effect 
(Layer, Holst, Grandt and Goebell, 1995). The reduced gastric acid secretion was 
closely correlated with an increase in the levels of glucagon-like peptide-1 (GLP-1). 
Similarly, in the anaesthetised dog, ileal infusion of bile induced a significant decrease 
in gastric acid secretion, which was accompanied by elevated plasma concentrations 
of gut glucagon-like immunoreactivity (gut GLI) (Namba, Matsuyama, Itoh, Imai, 
Horie and Tarui, 1986). This response bears a remarkable parallelism with the “ileal 
brake” mechanism, in which ileal infusion of fatty acids, triglycerides and complex 
carbohydrates delays gastric emptying and intestinal transit time (Holgate and Read, 
1985; Fone, Horowitz, Read, Dent and Maddox, 1990; Lin, Doty, Reedy and Meyer, 
1990; Pironi, Stanghellini, Miglioli et al, 1993), thereby constituting a negative 
feedback mechanism. In humans and dogs, instillation of mixed nutrients into the 
ileum resulted in the reduction of gastric emptying, which was closely correlated with 
plasma levels of Peptide YY (Pironi et al, 1993; Wen, Phillips, Sarr, Kost and Holst, 
1995). In addition, GLP-1 may play a small role in this reflex, in the dog at least 
QN m e ta l,  1995).
The outcome of such studies would, thus, appear to indicate that the response to 
ileally-administered G-CA is unlikely to occur as a result of a known hormonal 
mechanism. Otherwise, the only other possibility is that a hitherto unreported 
hormonal action underlies the responses caused by G-CA.
4.5 Consideration of the mechanisms involved in ileal tetragastrin-induced 
gastric acid secretion
A surprising outcome of this study was that, after ileal administration of G-CA 
(bOOgg kg'*), there did arise a measurable increase in gastric acid secretion in 
response to instillation of tetragastrin (3000gg kg'*) into the ileum. This was a 
striking effect, recorded in seven rats, which resulted in a mean increase in gastric acid 
secretion above baseline of 3.05 ± 1.89gmol 180min *. (The mean increases ± s.D. in 
gastric acid output, presented in Table 3-7, are reproduced in Table 4-4). In 
attempting to explain these results, several possibilities must be considered.
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Table 4-4: Mean peak and cumulative (cum.) increases (± S.D.) in gastric acid 
secretion in response to ileally-administered tetragastrin-cholic acid conjugate 
(G-CA) (600pg kg * in 1.0ml saline) over 180 minute period, subsequent ileally- 
administered tetragastrin (G4) over 180 minute period, and intravenous G-CA 
(ISgg kg *) as a first and final procedure (restatement of Table 3-7).
Initial V  
Peak 
increase
(|xmol 15min'')
/. G-CA 
Cum. 
increase
(fiinolhr'b
Ileal G-CA 
Cum. 
increase
(fomol
180min b
Ileal G4 
Cum. 
increase
(nmol
180mm b
Second I. 
Peak 
increase
(nmol 15mm')
V . G-CA 
Cum. 
increase
(nmol hr')
Mean
±S.D.
0.57+0.24
(P-0.001)
1.09+0.52
(P=0.004)
1.31+0.44
(P=0.003)
3.05+1.89
(P=0.006)
0.70+0.42
(P=0.005)
1.15+0.59
(P=0.003)
P-values denote sta tistica l significance f o r  com parison with zero baseline.
4.5.1 Permeability changes caused bv G-CA
The possibility that G-CA caused a lasting permeability change in the ileal mucosa 
which, thus, allowed permeation by tetragastrin must be considered. The increase in 
gastric acid secretion evoked by intra-ileal tetragastrin above baseline levels was 
generally prolonged over a period of between 90 and 105 minutes, although in one 
rat, gastric acid levels remained elevated above baseline for considerably longer (225 
minutes). The corollary of these experiments is that the absence of a response to 
ileally-infused tetragastrin, without the conditioning effect of G-CA, could not be 
attributed to the proteolytic degradation of tetragastrin within the intestinal lumen 
since, when injected after intra-ileal G-CA, intra-ileal tetragastrin did cause increased 
gastric acid secretion. Rather, it suggests that the barrier provided by the intestinal 
wall contributes more, in the former case, to the absence of a response. Thus, there 
appears to be a prima facie case that G-CA caused a long lasting permeability change 
which allowed tetragastrin to cross the mucosal barrier.
However, light microscopic (LM) analysis of the G-CA-perfused ileal wall (see Figs. 
3-22C and D) revealed little evidence of structural differences, when compared with 
LM analysis of the control mucosa, excised from a separate animal in which perfusion 
of the ileum was not carried out (see Figs. 3-22A and B). This suggests that a 
pathological change of the ileal mucosa is not involved, at least at the light 
microscopic level.
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Additional support for this view comes from the results obtained from our 
investigation of the response to jejunally-perfused G-CA (600pg kg'*), in which no 
measurable increase in gastric acid output was recorded. If the effect of G-CA occurs 
via a permeability increase, for example, at the side of the tight junctions between 
enterocytes, one might have expected, intuitively, that G-CA would also permeate 
across the jejunum. Thus, we are confident that, on the basis of the present results, 
G-CA has had no discernible effect on the permeability of this mucosa.
4.5.2 Potentiation of subthreshold absorption of tetragastrin
The control experiments which reported an absence of any increase in gastric acid 
secretion when tetragastrin was infused intra-ileally (Section 3.1.1) could not exclude 
the possibility that tetragastrin had, in fact, been absorbed but in amounts which were 
insufficient to stimulate gastric acid secretion.
The mechanism by which ileal tetragastrin, subsequent to administration of ileal G- 
CA, elicited an increase in gastric output may thus have arisen as a consequence of 
potentiation of this low level of intestinal absorption of tetragastrin by the continued 
presence of subthreshold doses of ileal G-CA in the circulation. However, this is 
unlikely since the increase in gastric acid levels evoked by the second intravenous 
injection of G-CA, administered subsequent to ileal G-CA, demonstrated no 
significant potentiation of either the peak or the cumulative response to the first i.v. 
injection of G-CA, as a first procedure (P^O.63 and P=0.51, respectively) (see 
Section 3.1.3(ii)).
4.5.3 Release of G-CA adsorbed by the ileal mucosa
The adsorption of drugs by the intestinal mucosa has been well documented (Barry 
and Braybrooks, 1975; Nimmerfall and Rosenthaler, 1980; Shurgers, De Blaey and 
Crommelin, 1985; Niibuchi, Aramaki and Tsuchiya, 1986). Accordingly, it is 
conceivable that, in the present study, the ileal injection of tetragastrin acted to release 
any mucosal G-CA, injected previously, which had been adsorbed by the mucosa of 
the ileum. This implies that it was the administration of a second infusion into the 
ileum, rather than what it contained, that led to the elevated gastric acid secretion. 
The increase in gastric acid levels above baseline would thus be explained if
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subsequent transportation of the residual G-CA across the ileal mucosa, via the bile 
salt active carrier system, into the circulation had occurred.
4.5 .4 Hepatic recirculation of G-CA
It is also possible that the elevation of gastric acid levels which were recorded in 
response to ileal tetragastrin, administered subsequent to ileal G-CA, is instead 
associated with the recycling of ileal G-CA via the enterohepatic circulation. In other 
words, the infusion of fluid into the ileum facilitated the rate at which G-CA, excreted 
into the duodenum, arrived at the ileum. The magnitude of such a process would, 
however, depend on the rate of excretion of hepatic G-CA which, in turn, would be 
dependent on the rate of uptake of G-CA by the hepatocytes. In addition, the process 
would depend on the rate of inactivation of G-CA within the hepatocytes. In the 
present study, the increase in gastric acid levels evoked by a second intravenous 
injection of G-CA, administered subsequent to ileal G-CA, demonstrated no 
significant potentiation of the peak or cumulative response to the first intravenous 
injection of G-CA, as a first procedure (P-0.63 and P=0.51, respectively) (see 
Section 3.1.3(ii)), which makes it unlikely that re-circulated G-CA played a role in 
this series of experiments.
Even if recycled G-CA, per se, were insufficient to account for the elevated gastric 
acid secretion arising when intra-ileal tetragastrin was infused, there may be another 
consequence, even if this process occurred at a subliminal level. If we surmise that 
ileally-administered tetragastrin does in fact manage to permeate the intestinal 
mucosa, but is cleared rapidly from the portal blood by the liver, this would lead to an 
absence of response, as seen in our control experiments (Section 3.1.1). This being 
the case, pre-injection of ileal G-CA, which may also be taken up by hepatocytes as 
well as circulating in the plasma, may result in the saturation of those sinusoidal 
membrane carrier proteins of the hepatocytes involved in hormonal clearance from the 
portal circulation. As a result, subsequently administered ileal tetragastrin may now 
be subjected to the diminished effects of hepatic first-pass metabolism, thereby 
enabling the entry of tetragastrin into the systemic circulation to produce elevation of 
gastric acid secretion above basal levels.
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4.5.5 Sparing of G-CA from proteolytic degradation by tetragastrin 
An alternative explanation for the observed increase in gastric acid levels following 
the injection of tetragastrin into the ileal lumen subsequent to the ileal administration 
of G-CA, is that the recirculation of G-CA through the liver and bile duct does occur, 
and that tetragastrin is unable to permeate the ileal mucosa. However, proteolytic 
degradation of this luminal tetragastrin may, thus, spare the proteolytic degradation of 
recirculated G-CA or subliminal residual amounts of G-CA However, it seems 
unlikely that this mechanism alone could account for the sizeable increase in gastric 
acid secretion which was measured following ileal administration of tetragastrin, 
compared with the smaller increase observed in response to ileal G-CA (Table 4-4). 
Nevertheless, there is the possibility that summation of this action with the flushing of 
adsorbed G-CA by injection of tetragastrin, may account for the increase in gastric 
acid secretion observed in this study.
4.6 Time course of responses to ileal tetragastrin and G-CA 
The time courses of the responses to ileal G-CA and ileal tetragastrin (when preceded 
by ileal G-CA) were very similar in that gastric acid levels remained elevated above 
baseline for an extended duration of between 90 and 130 mins. Slight variations were 
observed in the occurrence of the peak increase in gastric acid levels. In the case of 
ileal G-CA, the peak level arose between 60 and 105 mins after administration, 
whereas, with ileal tetragastrin (when preceded by ileal G-CA), a peak increase was 
recorded earlier at between 15 and 60 minutes following instillation.
The time course of the increase in gastric acid secretion (e.g. Figs. 3-8, 3-11 and 3- 
16) imparts rather little information regarding the mechanism behind the absorption of 
ileal G-CA. The absence of intestinal carriers specific to the transport of tetrapeptides 
(as reviewed by Ganapathy et al, 1994) indicates that the movement of tetragastrin 
across the ileal mucosa could occur only by diffijsion which would be driven by a 
concentration gradient. As shown by the absence of a response to intra-jejunal 
infusion of tetragastrin (and of G-CA), this route would seem to be of minimal 
importance. The transport of G-CA would thus seem to depend upon the operation 
of a facilitated transport mechanism, namely the bile salt transport protein. In this 
case, one perspective may be that operation of a facilitated transport system would be 
expected to remove G-CA from the ileum at a relatively fast rate, which would be at
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variance with the observed time course of the response. On the other hand, the ileal 
bile salt transport system is considered to operate maximally at a low concentration 
(IVrClintock and Shiau, 1983). Since we instilled a relatively large amount of G-CA 
into the ileum, it is conceivable that the transport of bile salts might have occurred at 
a low rate over an extended time period. Thus, no unequivocal inferences may be 
drawn from the time courses of the responses to intra-ileal infiisions.
4.7 Further studies
In order to seek answers to the unresolved issues raised by this study, several further 
lines of investigation may be undertaken.
4.7.1 Bile acid transport inhibitors
Bile acid reabsorption inhibitors (BARI) have been reported to inhibit specifically, and 
in a concentration dependent manner, the uptake of [^H]-taurocholate into rabbit ileal 
brush border membrane vesicles and in a rat ileum perfiision preparation, in situ 
(Wess, Kramer, Enhsen et al, 1994; Kramer, Wess, Baringhaus et al, 1995). 
Measurement of the gastric acid output in the presence of such inhibitors would allow 
us to state rather more conclusively whether the mechanism underlying ileal 
transmucosal transport of G-CA involves the bile salt transporters. For completion, 
the study would need to demonstrate a reversibility of any inhibitory effect, that is, 
after washing out the BARI, we would need to be able to show that absorption of 
ileally-infused G-CA was reinstated.
4.7.2 Increasing the length of the conjugated peptide
Reports have indicated that increasing the chain length of the peptide attached to the 
C-3 position of the steroid nucleus of cholic acid results in a diminished affinity for 
the ileal bile acid transporter (Kramer et al, 1994). Peptide-cholic acid conjugates 
with up to four amino acid residues in the peptide side chain were able to 
competitively inhibit the uptake of [^H]-taurocholate in a dose-dependent manner. 
However, coupling of eight amino acid residues with cholic acid resulted in a 
significantly reduced affinity for the ileal bile salt carrier, thus allowing greater 
absorption of [^H]-taurocholate. Moreover, although the conjugation of a 
heptapeptide renin inhibitor to cholic and taurocholic acid at the C-3 position
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demonstrated high levels of affinity for the bile salt transporter in Caco-2 cells, the 
conjugate was not transported by the ileal bile salt transporter in vivo (Kim et al, 
1993). This is of considerable importance, since peptides employed as therapeutic 
agents are often in excess of seven or eight amino acids; insulin, for example, is 
composed of 51 amino acids.
By conjugating cholic acid with a peptide chain that is comprised of an increased 
number of amino acid residues making up the carboxy terminal end of gastrin, for 
example, pentagastrin (G5) or heptadecapeptide gastrin (G17), we could repeat the 
experimental protocols carried out in the present study. This would allow us to 
determine the effect that peptide length has on the transport of peptide-cholic acid 
conjugates in the ileum.
4.7.3 Determination of the mechanismfsl involved in ileal tetragastrin-induced gastric 
acid secretion 
4.7.3(i) Permeability changes caused by G-CA
The pre-conditioning of the ileum by G-CA to allow the possible ileal permeation of 
subsequently infused tetragastrin requires further elucidation. It would thus be of 
interest to determine the degree to which permeation of other hormones are enhanced 
by the employment of a different in vivo bioassay. For example, secretin (l.v.) has 
been shown to be very potent in evoking a marked increase in the secretion of HCOg 
and protein in pancreatic juice of rats (Wheeler, Eardley, McNulty, Sutcliffe and 
Morrison, 1997). The ileal instillation of secretin, subsequent to ileal administration 
of G-CA, and the measurement of the resultant HCO3 and protein in pancreatic 
secretions, relative to control levels, would provide an indication of the degree to 
which permeability of the ileum to macromolecules is altered.
Additionally, histological analysis of the perfused ileum, comparative to the 
unperftised ileum, may be ftirther extended by the use of transmission electron 
microscopy to examine the integrity of the epithelium with specific attention paid to 
the integrity of the tight junctions between cells.
4.7.3(ii) Displacement o f adsorbed G~CA from ileal mucous layer
The possible involvement of adsorbed residual G-CA, displaced from the mucous
layer of the ileum by injection of 1 .0 ml tetragastrin solution into the ileal lumen, in the
178
Discussion
induction of increased levels of gastric acid secretion, may be resolved by replacing 
the ileal tetragastrin injection with ileal injection of the same volume of isotonic saline; 
a resultant increase in gastric acid levels would provide confirmation of this flushing 
effect.
Alternatively, determination of the presence of residual G-CA in the ileum may be 
achieved by assay of the luminal contents using a photometric method, specific for 
conjugated and unconjugated cholates, as described by Irvin, Johnston and Kopala 
(1944).
4.7.3(iii) Hepatic recycling o f G-CA
It would be of interest to ascertain whether the increase in gastric acid secretion 
presented over the 180 minutes following ileal injection of tetragastrin contains a 
component due to recycling of G-CA via the enterohepatic circulation. This may be 
determined by repetition of the experiments in rats in which the bile duct has been 
ligated or the flow of bile diverted to the exterior by a cannula, thereby excluding the 
possible re-entry of G-CA into the lumen of the ileum.
4.8 Conclusions
In the present study, we have demonstrated the facilitation of ileal absorption of 
tetragastrin through the coupling of tetragastrin with cholic acid at the C-24 position. 
The absorption of ileal G-CA is unlikely to be attributable to passive diffusion of the 
non-ionised, lipophilic form of molecules since the compound was estimated to be in a 
predominantly ionised form. For transport to occur at a substantial rate, this would 
imply that a facilitated transport mechanism was involved. Moreover, this was a 
response specific to the ileum, since no apparent intestinal transmucosal movement of 
G-CA was observed after instillation of G-CA into the jejunum. Although we must 
consider, as possible mechanisms, the role played by the M cells of the ileum, as well 
as initiation of a hormonal release mechanism, the most likely explanation for the 
permeation of the ileal wall is transport of the conjugate by the bile acid carrier 
system, which is present only in the ileum. If this is the case, the results of this study 
are very encouraging in terms of a successfiil approach to address the improvement of 
oral absorption of otherwise poorly absorbed macro-molecules.
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A ppendix
6.1 Ionisation states of intestinaUy-administered agents
In general, the unionised form of a weak acid or base will penetrate the intestinal wall 
at a faster rate than the corresponding ionised acid or base. The ratio of ionised and 
unionised form of a weak acid or weak base in a solution may be calculated using 
equation 6-1, if we know both the pH and the pKa values. When pH equals pKa, the 
compound is 50% ionised.
p H “ pKa +  iog [a ]
[h a ] (H A +  A")
equation 6-1
Determination of the state of ionisation of complex molecules, such as tetragastrin 
and the tetragastrin-cholic acid conjugate (in which the pKa values relating to the 
entire molecule are unknown) was made from a consideration of the ionisation of the 
carboxyl group (COOH, part of aspartate in both compounds) and the primary and 
secondary amine groups (NHi and NH, respectively). The pKa values for these 
(taken from Mahler and Cordes, 1969b) are listed in Table 6-1. The pH of the 
tetragastrin and tetragastrin-cholic acid conjugate solutions, as used in the 
experimental procedures, were measured prior to intestinal infusion, and are also 
presented in Table 6-1.
Table 6-1: pH values of intestinally administered solutions (iu 1.0ml isotonic 
saline), and the pKa values of the carboxyl and primary and secondary amine 
side groups of these compounds.
Compound Side groups pKa pH of solution
Tetragastrin COOH 4.6 3.8
NH2 7.9
NH 7.0
Tetragastrin-cholic acid COOH 4.6 4.7
conjugate NHz 7.9
NH 7.0
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6.1.1 Tetragastrin 
6 . l .l(i) Carboxyl group
COOH ^  COO" + H+
3.8 = 4.6 + log [COO]
[COOH]
0.8 = log [COOH]
[COO]
6.3 [COO ] = [COOH]
The carboxyl group of tetragastrin is approximately 14% ionised. 
6 .1. l(ii) Primary amine group
3.8 = 7.9 + log [NH2]
[NH3I  
4.1= log [NH3"]
[NH2]
12589 [NH2] = [NH3"]
The primary amine group of tetragastrin is approximately 100% ionised.
6 .1 . 1  (iii) Secondary amine group
^  NH +
3.8 = 7.0 + log [NH]
[NH2l
3.2 = log [NH2I  
[NH]
1584 [NH] = [NH2"]
The secondary amine group of tetragastrin is approximately 100% ionised.
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6.1.2 Tetragastrin-cholic acid conjugate 
6 .1 .2(i) Carboxyl group
COOH ^  COO" + H+
4.7 = 4.6 + log [COO']
[COOH]
0.1 = log [COO ]
[COOH]
1.3 [COOH] = [COO ]
The carboxyl group of tetragastrin-cholic acid conjugate is approximately 57% 
ionised.
6 . 1  2 (ii) Primary amine group
NH3 ^  NH2  + H
4.7 = 7.9 + log [NH2]
[NH3I
3.2 = log [NH3I  
[NH2]
1585 [NH2] -  [NH3 ]
The primary amine group of tetragastrin-cholic acid conjugate is approximately 1 0 0 % 
ionised.
6 .1 .2 (iii) Secondary amine group
^  NH +
4.7 = 7.0 + log [NH]
[NH2I
2.3 = log [NH;"]
[NH]
199 [NH] = [NH2*]
The secondary amine group of tetragastrin-cholic acid conjugate is approximately 
1 0 0 % ionised.
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You know, Tolstoy, like myself, wasn’t taken in by superstitions 
like science and medicine.
George Bernard Shaw
' ^ A S G W l  üN ivE R srrr IUBRAn? I
